Also O O
, O O
the O O
potential O O
for O O
hepatic O O
injury O O
should O O
be O O
considered O O
when O O
Rebif B-brand B-brand
is O O
used O O
in O O
combination O O
with O O
other O O
products O O
associated O O
with O O
hepatic O O
injury O O
, O O
or O O
when O O
new O O
agents O O
are O O
added O O
to O O
the O O
regimen O O
of O O
patients O O
already O O
on O O
Rebif B-brand B-brand
. O O

- O O
a O O
steroid B-group B-group
medicine I-group O
such O O
as O O
prednisone B-drug B-drug
( O O
Deltasone B-brand B-drug
, O O
Orasone B-brand B-brand
, O O
others O O
) O O
, O O
methylprednisolone B-drug B-drug
( O O
Medrol B-brand B-brand
, O O
others O O
) O O
, O O
prednisolone B-drug B-drug
( O O
Prelone B-brand B-brand
, O O
Pediapred B-brand B-brand
, O O
others O O
) O O
, O O
and O O
others O O
; O O

also O O
, O O
concurrent O O
use O O
of O O
this O O
medication O O
may O O
antagonise O O
the O O
anti-glaucoma O O
and O O
miotic O O
actions O O
of O O
ophthalmic O B-group
cholinesterase B-group I-group
inhibitors I-group I-group
. O O

If O O
any O O
signs O O
or O O
symptoms O O
occur O O
physicians O O
should O O
consider O O
discontinuation O O
of O O
either O O
one O O
or O O
both O O
agents O O
( O O
ZYVOX B-brand B-brand
or O O
concomitant O O
serotonergic B-group B-group
agents I-group I-group
) O O
. O O

This O O
time O O
window O O
is O O
different O O
than O O
for O O
other O O
oral O O
formulations O O
of O O
ciprofloxacin B-drug B-drug
, O O
which O O
are O O
usually O O
administered O O
2 O O
hours O O
before O O
or O O
6 O O
hours O O
after O O
antacids B-group B-group
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

No O O
pharmacokinetic O O
data O O
are O O
available O O
. O O

pregnancies O O
have O O
been O O
reported O O
. O O

On O O
the O O
basis O O
of O O
the O O
estimated O O
number O O
of O O
regular O O
users O O
of O O
intravenous O O
amphetamine B-drug B-drug
in O O
Ontario O O
, O O
the O O
mortality O O
rate O O
in O O
such O O
users O O
is O O
at O O
least O O
four O O
times O O
as O O
high O O
as O O
in O O
the O O
general O O
population O O
of O O
the O O
same O O
age O O
, O O
and O O
is O O
comparable O O
to O O
that O O
in O O
alcoholics O B-group
and O O
heroin B-drug_n B-drug
addicts O O
. O O

The O O
effects O O
of O O
L-CCG-1 B-drug_n B-drug_n
were O O
not O O
so O O
strong O O
. O O

A O O
400 O O
mg O O
once-daily O O
dose O O
was O O
not O O
studied O O
but O O
would O O
be O O
expected O O
to O O
increase O O
aliskiren B-drug B-drug
blood O O
levels O O
further O O
. O O

SSRIs B-group B-group
: O O
Weakness O O
hyperreflexia O O
, O O
and O O
incoordination O O
have O O
been O O
reported O O
rarely O O
when O O
5-HT1 B-group B-group
agonists I-group I-group
have O O
been O O
co-administered O O
with O O
SSRIs B-group B-group
( O O
e. O O
g O O
. O O

Because O O
moderate O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
diltiazem B-drug B-drug
) O O
result O O
in O O
2-fold O O
increase O O
in O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
, O O
concomitant O O
administration O O
should O O
also O O
be O O
approached O O
with O O
caution O O
. O O

Exemestane B-drug B-drug
is O O
extensively O O
metabolized O O
by O O
CYP O O
3A4 O O
, O O
but O O
coadministration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP O O
3A4 O O
, O O
has O O
no O O
significant O O
effect O O
on O O
exemestane B-drug B-drug
pharmacokinetics O O
. O O

Phenytoin B-drug B-drug
: O O
Altered O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
( O O
increased O O
and O O
decreased O O
) O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
concomitant O O
ciprofloxacin B-drug B-drug
. O O

Since O O
iloprost B-drug B-drug
inhibits O O
platelet O O
function O O
, O O
there O O
is O O
a O O
potential O O
for O O
increased O O
risk O O
of O O
bleeding O O
, O O
particularly O O
in O O
patients O O
maintained O O
on O O
anticoagulants B-group B-group
. O O

Therefore O O
, O O
caution O O
is O O
advised O O
if O O
the O O
concomitant O O
administration O O
of O O
loxapine B-drug B-drug
and O O
CNS-active O O
drugs O O
is O O
required O O
. O O

Consequently O O
, O O
drugs O O
with O O
a O O
low O O
therapeutic O O
margin O O
, O O
such O O
as O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
, O O
phenytoin B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
, O O
could O O
have O O
a O O
delayed O O
elimination O O
and O O
increases O O
in O O
their O O
serum O O
half-life O O
leading O O
to O O
a O O
toxic O O
level O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
using O O
these O O
drugs O O
together O O

Phenytoin B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenytoin B-drug B-drug
; O O

Anticoagulants B-group B-group
: O O
Flurbiprofen B-drug B-drug
like O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
has O O
been O O
shown O O
to O O
affect O O
bleeding O O
parameters O O
in O O
patients O O
receiving O O
anti-coagulants B-group B-group
, O O
and O O
serious O O
clinical O O
bleeding O O
has O O
been O O
reported O O
. O O

propranolol B-drug B-drug
to O O
healthy O O
volunteers O O
under O O
steady-state O O
conditions O O
had O O
no O O
relevant O O
effect O O
on O O
either O O
drug O O
s O O
bioavailability O O
, O O
AUC O O
and O O
Cmax O O
, O O
differences O O
were O O
20 O O
% O O
between O O
isradipine B-drug B-drug
given O O
singly O O
and O O
in O O
combination O O
with O O
propranolol B-drug B-drug
, O O
and O O
between O O
propranolol B-drug B-drug
given O O
singly O O
and O O
in O O
combination O O
with O O
isradipine B-drug B-drug
. O O

ocular O O
effects O O
; O O

The O O
concomitant O O
administration O O
of O O
bosentan B-drug B-drug
and O O
cyclosporine B-drug B-drug
A I-drug O
is O O
contraindicated O O
. O O

This O O
oxidation O O
, O O
which O O
is O O
catalyzed O O
by O O
xanthine O O
oxidase O O
, O O
inactivates O O
mercaptopurine B-drug B-drug
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug
: O O
Substrate O O
of O O
CYP3A4 O O
( O O
major O O
) O O
, O O
3A5-7 O O
( O O
minor O O
) O O
; O O

4 O O
. O O

The O O
mean O O
clearances O O
of O O
dofetilide B-drug B-drug
were O O
16 O O
% O O
and O O
15 O O
% O O
lower O O
in O O
patients O O
on O O
thiazide B-group B-group
diuretics I-group I-group
and O O
inhibitors O O
of O O
tubular O O
organic O O
cation O O
transport O O
, O O
respectively O O
. O O

In O O
addition O O
, O O
levetiracetam B-drug B-drug
does O O
not O O
affect O O
the O O
in O O
vitro O O
glucuronidation O O
of O O
valproic B-drug B-drug
acid I-drug I-drug
. O O

Specifically O O
, O O
they O O
have O O
focused O O
on O O
aspects O O
of O O
learning O O
and O O
memory O O
that O O
are O O
impaired O O
( O O
vs. O O
spared O O
) O O
by O O
lesions O O
of O O
the O O
hippocampal O O
formation O O
. O O

The O O
concentrations O O
of O O
SN38 B-drug_n B-drug_n
, O O
the O O
active O O
metabolite O O
of O O
irinotecan B-drug B-drug
, O O
were O O
on O O
average O O
33 O O
% O O
higher O O
in O O
patients O O
receiving O O
bolus-IFL O O
in O O
combination O O
with O O
AVASTIN B-brand B-brand
when O O
compared O O
with O O
bolus-IFL O O
alone O O
. O O

All O O
vasopressors B-group B-group
should O O
be O O
used O O
cautiously O O
in O O
patients O O
taking O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

If O O
an O O
alternative O O
treatment O O
is O O
unavailable O O
, O O
a O O
TARCEVA B-brand B-brand
dose O O
greater O O
than O O
150 O O
mg O O
should O O
be O O
considered O O
for O O
NSCLC O O
patients O O
, O O
and O O
greater O O
than O O
100 O O
mg O O
considered O O
for O O
pancreatic O O
cancer O O
patients O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

Check O O
serum O O
potassium O O
levels O O
at O O
frequent O O
intervals O O
; O O

Twenty-four O O
healthy O O
male O O
subjects O O
were O O
randomized O O
to O O
one O O
of O O
two O O
cohorts O O
. O O

Androgens B-group B-group
may O O
increase O O
sensitivity O O
to O O
oral O O
anticoagulahts O O
. O O

The O O
serum O O
concentration O O
of O O
phenytoin B-drug B-drug
increased O O
dramatically O O
from O O
16.6 O O
to O O
49.1 O O
microg/mL O O
when O O
fluvoxamine B-drug B-drug
was O O
coadministered O O
, O O
although O O
the O O
daily O O
dosage O O
of O O
phenytoin B-drug B-drug
and O O
other O O
drugs B-drug O
had O O
not O O
changed O O
. O O

Acetazolamide B-drug B-drug
may O O
increase O O
the O O
effects O O
of O O
other O O
folic B-group B-group
acid I-group I-group
antagonists I-group I-group
. O O

If O O
replacing O O
clonidine B-drug B-drug
by O O
beta-blocker B-group B-group
therapy O O
, O O
the O O
introduction O O
of O O
beta B-group B-group
blockers I-group I-group
should O O
be O O
delayed O O
for O O
several O O
days O O
after O O
clonidine B-drug B-drug
administration O O
has O O
stopped O O
. O O

Grapefruit O O
juice O O
Co-administration O O
of O O
felodipine B-drug B-drug
with O O
grapefruit O O
juice O O
resulted O O
in O O
more O O
than O O
2-fold O O
increase O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
but O O
no O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

Renal O O
clearance O O
measurements O O
of O O
PAH B-drug B-drug
can O O
not O O
be O O
made O O
with O O
any O O
significant O O
accuracy O O
in O O
patients O O
receiving O O
sulfonamides B-group B-group
, O O
procaine B-drug B-drug
, O O
or O O
thiazolesulfone B-drug B-drug
. O O

Co-administration O O
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
indinavir B-drug B-drug
, O O
erythromycin B-drug B-drug
) O O
may O O
increase O O
their O O
clearance O O
, O O
resulting O O
in O O
decreased O O
plasma O O
concentration O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
As O O
a O O
result O O
of O O
administration O O
of O O
Keflex B-brand B-brand
, O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Marked O O
symptomatic O O
orthostatic O O
hypotension O O
has O O
been O O
reported O O
when O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
organic O B-group
nitrates B-group I-group
were O O
used O O
in O O
combination O O
. O O

There O O
were O O
no O O
clinically O O
relevant O O
alterations O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

MAO B-group B-group
inhibitors I-group I-group
: O O
MAOI B-group B-group
antidepressants I-group I-group
, O O
as O O
well O O
as O O
a O O
metabolite O O
of O O
furazolidone B-drug B-drug
, O O
slow O O
amphetamine B-group B-drug
metabolism O O
. O O

A O O
host O O
of O O
other O O
medical O O
considerations O O
are O O
discussed O O
in O O
chapter O O
8 O O
, O O
including O O
persistent O O
ovarian O O
follicles O O
; O O

Aprepitant B-drug B-drug
increased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
by O O
25 O O
% O O
on O O
Day O O
4 O O
and O O
decreased O O
the O O
AUC O O
of O O
midazolam B-drug B-drug
by O O
19 O O
% O O
on O O
Day O O
8 O O
relative O O
to O O
the O O
dosing O O
of O O
Aprepitant B-drug B-drug
on O O
Days O O
1 O O
through O O
3 O O
. O O

1 O O
. O O

Drug O O
Interactions O O
: O O
a O O
. O O
Drugs O O
Enhancing O O
Heparin B-drug B-drug
Effect O O
: O O
Oral O O
anticoagulants B-group B-group
: O O
Heparin B-drug B-drug
sodium I-drug I-drug
may O O
prolong O O
the O O
one-stage O O
prothrombin O O
time O O
. O O

Seventeen O O
percent O O
of O O
CHOP-HAART O O
patients O O
developed O O
severe O O
autonomic O O
neurotoxicity O O
, O O
whereas O O
none O O
of O O
the O O
CHOP O O
patients O O
developed O O
neurotoxicity O O
( O O
P O O
= O O
0.002 O O
) O O
. O O

metabolic O O
interference O O
has O O
sometimes O O
been O O
observed O O
and O O
the O O
behaviour O O
of O O
the O O
biological O O
indicators O O
differs O O
from O O
what O O
would O O
be O O
expected O O
. O O

The O O
different O O
responses O O
in O O
locomotor O O
activity O O
induced O O
by O O
cocaine B-drug B-drug
suggest O O
that O O
genetic O O
factors O O
may O O
play O O
a O O
role O O
in O O
determining O O
the O O
magnitude O O
of O O
response O O
to O O
this O O
drug O O
. O O

Acetylcysteine B-drug B-drug
interference O O
with O O
urine O O
ketone O O
test O O
. O O

Patients O O
with O O
renal O O
insufficiency O O
or O O
renal O O
failure O O
may O O
be O O
at O O
risk O O
for O O
further O O
kidney O O
damage O O
as O O
well O O
as O O
complications O O
related O O
to O O
interactions O O
of O O
herbal O O
remedies O O
with O O
complex O O
renal O O
therapy O O
regimens O O
. O O

nitrosourea B-group B-group
AUC O O
, O O
with O O
the O O
extent O O
of O O
the O O
reduction O O
depending O O
on O O
the O O
minimum O O
effective O O
concentration O O
( O O
MEC O O
) O O
chosen O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
interferes O O
with O O
renal O O
tubular O O
secretion O O
of O O
ciprofloxacin B-drug B-drug
and O O
produces O O
an O O
increase O O
in O O
the O O
level O O
of O O
ciprofloxacin B-drug B-drug
in O O
serum O O
. O O

Cholinesterase B-group B-group
Inhibitors I-group I-group
: O O
Dipyridamole B-drug B-drug
may O O
counteract O O
the O O
anticholinesterase O O
effect O O
of O O
cholinesterase B-group B-group
inhibitors I-group I-group
, O O
thereby O O
potentially O O
aggravating O O
myasthenia O O
gravis O O
. O O

At O O
steady O O
state O O
, O O
VIOXX B-brand B-brand
50 O O
mg O O
once O O
daily O O
had O O
no O O
effect O O
on O O
the O O
anti-platelet O O
activity O O
of O O
low-dose O O
( O O
81 O O
mg O O
once O O
daily O O
) O O
aspirin B-brand B-brand
, O O
as O O
assessed O O
by O O
ex O O
vivo O O
platelet O O
aggregation O O
and O O
serum O O
TXB2 O O
generation O O
in O O
clotting O O
blood O O
. O O

Cardiovascular O O
: O O
Hypotension O O
( O O
0-9 O O
% O O
) O O
. O O

antihistamines B-group B-group
; O O

No O O
significant O O
drug-drug O O
pharmacokinetic O O
( O O
or O O
pharmacodynamic O O
) O O
interactions O O
have O O
been O O
found O O
in O O
interaction O O
studies O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
and O O
nifedipine B-drug B-drug
. O O

WelChol B-brand B-brand
decreased O O
the O O
Cmax O O
and O O
AUC O O
of O O
sustained-release O O
verapamil B-drug B-drug
( O O
Calan B-brand B-brand
SR I-brand O
) O O
by O O
approximately O O
31 O O
% O O
and O O
11 O O
% O O
, O O
respectively O O
. O O

Pharmacokinetic O O
profile O O
of O O
etodolac B-drug B-drug
in O O
special O O
populations O O
. O O

- O O
Lithium B-drug B-drug
: O O
Lithium B-drug B-drug
should O O
generally O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
( O O
such O O
as O O
bumetanide B-drug B-drug
) O O
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Alternatives O O
to O O
clarithromycin B-drug B-drug
, O O
such O O
as O O
azithromycin B-drug B-drug
, O O
should O O
be O O
considered O O
. O O

Administration O O
of O O
eplerenone B-drug B-drug
with O O
other O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
erythromycin B-drug B-drug
500 O O
mg O O
BID O O
, O O
verapamil B-drug B-drug
240 O O
mg O O
QD O O
, O O
saquinavir B-drug B-drug
1200 O O
mg O O
TID O O
, O O
fluconazole B-drug B-drug
200 O O
mg O O
QD O O
) O O
resulted O O
in O O
increases O O
in O O
Cmax O O
of O O
eplerenone B-drug B-drug
ranging O O
from O O
1.4- O O
to O O
1.6- O O
fold O O
and O O
AUC O O
from O O
2.0- O O
to O O
2.9- O O
fold O O
. O O

These O O
alterations O O
in O O
digoxin B-drug B-drug
pharmacokinetics O O
produced O O
by O O
amiodarone B-drug B-drug
explain O O
the O O
increase O O
in O O
serum O O
digoxin B-drug B-drug
level O O
that O O
has O O
been O O
observed O O
when O O
this O O
drug O O
combination O O
has O O
been O O
used O O
clinically O O
. O O

co-administration O O
of O O
phenobarbital B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

Carbamazepine B-drug B-drug
: O O
Steady-state O O
trough O O
plasma O O
carbamazepine B-drug B-drug
and O O
carbamazepine B-drug_n B-drug
10 I-drug_n O
, I-drug_n O
11 I-drug_n O
epoxide I-drug_n O
concentrations O O
were O O
not O O
affected O O
by O O
concomitant O O
gabapentin B-drug B-drug
( O O
400 O O
mg O O
TID O O
; O O

Restoration O O
of O O
female O O
fertility O O
to O O
values O O
similar O O
to O O
controls O O
was O O
evident O O
following O O
a O O
29-day O O
withdrawal O O
period O O
after O O
dosing O O
at O O
2 O O
mg/kg/day O O
( O O
twice O O
the O O
human O O
dose O O
based O O
on O O
BSA O O
) O O
. O O

Cardiac B-group B-group
glycosides I-group I-group
could O O
exaggerate O O
the O O
depression O O
of O O
AV O O
nodal O O
conduction O O
observed O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

The O O
harmonic O O
mean O O
elimination O O
half-life O O
was O O
45.7 O O
and O O
43.4 O O
hours O O
for O O
rofecoxib B-drug B-drug
+ O O
digoxin B-drug B-drug
and O O
placebo O O
+ O O
digoxin B-drug B-drug
treatments O O
, O O
respectively O O
. O O

Most O O
who O O
take O O
EPA B-drug B-drug
supplements O O
and O O
the O O
above O O
drugs O O
or O O
herbs O O
do O O
not O O
suffer O O
from O O
these O O
problems O O
and O O
if O O
they O O
occur O O
, O O
they O O
are O O
rare O O
. O O

Rifampin B-drug B-drug
: O O
Coadministration O O
of O O
rifampin B-drug B-drug
and O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
82 O O
% O O
decrease O O
in O O
nelfinavir B-drug B-drug
plasma O O
A.C O O
. O O

Animal O O
studies O O
also O O
suggest O O
an O O
increased O O
potential O O
for O O
seizures O O
when O O
these O O
two O O
drugs O O
are O O
given O O
concomitantly O O
. O O

and O O
overdose O O
. O O

Tadalafil B-drug B-drug
dose O O
should O O
not O O
exceed O O
a O O
maximum O O
of O O
10 O O
mg O O
in O O
a O O
72- O O
hour O O
period O O
in O O
patients O O
receiving O O
concomitant O O
indinavir B-drug B-drug
therapy O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
be O O
used O O
. O O

The O O
uptake O O
inhibitors O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
( O O
3 O O
mumol/liter O O
) O O
potentiated O O
the O O
positive O O
inotropic O O
effects O O
of O O
norepinephrine B-drug B-drug
in O O
nonfailing O O
myocardium O O
( O O
p O O
< O O
0.05 O O
) O O
but O O
not O O
in O O
functional O O
class O O
IV O O
myocardium O O
. O O

In O O
clinical O O
studies O O
performed O O
with O O
Fondaparinux B-drug B-drug
, O O
the O O
concomitant O O
use O O
of O O
oral O O
anticoagulants B-group B-group
( O O
warfarin B-drug B-drug
) O O
, O O
platelet B-group B-group
inhibitors I-group I-group
( O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
) O O
, O O
NSAIDs B-group B-group
( O O
piroxicam B-drug B-drug
) O O
, O O
and O O
digoxin B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics/pharmacodynamics O O
of O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
. O O

The O O
half-life O O
of O O
ketamine B-drug B-drug
in O O
plasma O O
and O O
brain O O
was O O
longer O O
in O O
the O O
presence O O
of O O
halothane B-drug B-drug
than O O
when O O
ketamine B-drug B-drug
was O O
given O O
alone O O
. O O

Tacrolimus B-drug O
: O O
Co-administration O O
of O O
tacrolimus B-drug B-drug
and O O
bosentan B-drug B-drug
has O O
not O O
been O O
studied O O
in O O
man O O
. O O

Animal O O
studies O O
indicate O O
that O O
dobutamine B-drug B-drug
may O O
be O O
ineffective O O
if O O
the O O
patient O O
has O O
recently O O
received O O
a O O
b-blocking B-group B-group
drug I-group I-group
. O O

Avoid O O
dong O O
quai O O
and O O
black O O
cohosh O O
( O O
have O O
estrogen O O
activity O O
) O O
. O O

Administration O O
of O O
reserpine B-drug B-drug
during O O
therapy O O
with O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
has O O
been O O
shown O O
to O O
produce O O
a O O
stimulating O O
effect O O
in O O
some O O
depressed O O
patients O O
. O O

Nonetheless O O
, O O
they O O
have O O
been O O
observed O O
with O O
macrolide B-group B-group
products I-group I-group
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
with O O
CRIXIVAN B-brand B-brand

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
other O O
cephalosporins B-group B-group
with O I-group
potent O I-group
diuretics B-group I-group
such O O
as O O
furosemide B-drug B-drug
. O O

Drug/Laboratory O O
Interactions O O
No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Campath B-brand B-brand
. O O

Drug O O
interaction O O
studies O O
were O O
performed O O
with O O
azithromycin B-drug B-drug
and O O
other O O
drugs O O
likely O O
to O O
be O O
co-administered O O
. O O

No O O
dosage O O
adjustment O O
of O O
either O O
drug O O
is O O
recommended O O
when O O
azithromycin B-drug B-drug
is O O
co O O
administered O O
with O O
any O O
of O O
the O O
above O O
agents O O
. O O

Naproxen B-drug B-drug
, O O
naproxen B-drug B-drug
sodium I-drug I-drug
and O O
other O O
NSAIDs B-group B-group
have O O
been O O
reported O O
to O O
reduce O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
in O O
an O O
animal O O
model O O
, O O
possibly O O
increasing O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Adrenergic B-group B-group
blockers I-group I-group
: O O
Adrenergic B-group B-group
blockers I-group I-group
are O O
inhibited O O
by O O
amphetamines B-group B-group
. O O

+109 O O
% O O

Warfarin B-drug B-drug
: O O
A O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
to O O
healthy O O
subjects O O
who O O
were O O
stabilized O O
on O O
chronic O O
warfarin B-drug B-drug
therapy O O
. O O

RESULTS O O
: O O
Bombesin B-drug_n B-brand
significantly O O
increased O O
the O O
incidence O O
of O O
intestinal O O
tumors O O
and O O
cancer O O
metastasis O O
to O O
the O O
peritoneum O O
. O O

The O O
gastrointestinal O O
absorption O O
of O O
digoxin B-drug B-drug
also O O
appears O O
to O O
be O O
inhibited O O
. O O

. O O

The O O
physician O O
should O O
be O O
cautious O O
when O O
administering O O
flurbiprofen B-drug B-drug
to O O
patients O O
taking O O
anticoagulants B-group B-group
. O O

Interactions O O
may O O
occur O O
with O O
the O O
following O O
: O O
adrenocorticoids O B-group
( O O
cortisone-like O B-group
medicine O O
) O O
, O O
anticoagulants B-group B-group
( O O
blood B-group B-group
thinners O I-group
) O O
, O O
carbamazepine B-drug B-drug
, O O
corticotropin B-drug B-drug
( O O
barbiturates B-group B-group
may O O
decrease O O
the O O
effects O O
of O O
these O O
medicines O O
) O O
, O O
central B-group B-group
nervous I-group I-group
system I-group I-group
( I-group I-group
CNS I-group I-group
) I-group I-group
depressants I-group I-group
( O O
using O O
these O O
medicines O O
with O O
barbiturates B-group B-group
may O O
result O O
in O O
increased O O
CNS O O
depressant O O
effects O O
) O O
, O O
divalproex B-drug B-drug
sodium I-drug I-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
( O O
using O O
these O O
medicines O O
with O O
barbiturates B-group B-group
may O O
change O O
the O O
amount O O
of O O
either O O
medicine O O
that O O
you O O
need O O
to O O
take O O
) O O
, O O
and O O
oral O O
contraceptives B-group B-group
containing O O
estrogens B-group B-group
( O O
barbiturates B-group B-group
may O O
decrease O O
the O O
effectiveness O O
of O O
these O O
oral O O
contraceptives B-group B-group
, O O
and O O
you O O
may O O
need O O
to O O
change O O
to O O
a O O
different O O
type O O
of O O
birth O O
control O O
) O O
. O O

Other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
( O O
e.g O O
. O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
opioids B-group B-group
and O O
general O O
anesthetics B-group B-group
) O O
have O O
additive O O
or O O
potentiating O O
effects O O
with O O
INAPSINE B-brand B-brand
. O O

Because O O
of O O
the O O
small O O
effect O O
on O O
half-life O O
, O O
the O O
coadministration O O
with O O
probenecid B-drug B-drug
to O O
extend O O
the O O
half-life O O
of O O
ertapenem B-drug B-drug
is O O
not O O
recommended O O
. O O

[ O O
The O O
effect O O
of O O
sandimmune B-brand B-drug_n
on O O
the O O
activity O O
of O O
mixed-function O O
mono-oxidases O O
in O O
the O O
liver O O
microsomes O O
] O O
The O O
effects O O
of O O
the O O
immunodepressant B-group O
-- O O
the O O
drug O O
sandimmune B-brand B-drug
-- O O
on O O
hepatic O O
microsomal O O
monooxygenase O O
activities O O
were O O
studied O O
. O O

In O O
large O O
, O O
well O O
controlled O O
trials O O
in O O
patients O O
with O O
schizophrenia O O
or O O
related O O
psychoses O O
, O O
olanzapine B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
was O O
significantly O O
superior O O
to O O
haloperidol B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
in O O
overall O O
improvements O O
in O O
psychopathology O O
rating O O
scales O O
and O O
in O O
the O O
treatment O O
of O O
depressive O O
and O O
negative O O
symptoms O O
, O O
and O O
was O O
comparable O O
in O O
effects O O
on O O
positive O O
psychotic O O
symptoms O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
the O O
metabolism O O
of O O
docetaxel B-drug B-drug
may O O
be O O
modified O O
by O O
the O O
concomitant O O
administration O O
of O O
compounds O O
that O O
induce O O
, O O
inhibit O O
, O O
or O O
are O O
metabolized O O
by O O
cytochrome O O
P450 O O
3A4 O O
, O O
such O O
as O O
cyclosporine B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
troleandomycin B-drug B-drug
. O O

Maximal O O
exercise O O
testing O O
, O O
a O O
maneuver O O
often O O
applied O O
to O O
cardiac O O
patients O O
, O O
does O O
not O O
significantly O O
alter O O
the O O
serum O O
digoxin B-drug B-drug
level O O
. O O

Potential O O
interactions O O
between O O
TAXOL B-brand B-brand
, O O
a O O
substrate O O
of O O
CYP3A4 O O
, O O
and O O
protease B-group B-group
inhibitors I-group I-group
( O O
ritonavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
and O O
nelfinavir B-drug B-drug
) O O
, O O
which O O
are O O
substrates O O
and/or O O
inhibitors O O
of O O
CYP3A4 O O
, O O
have O O
not O O
been O O
evaluated O O
in O O
clinical O O
trials O O
. O O

( O O
41 O O
) O O
but O O
returned O O
to O O
normal O O
levels O O
when O O
the O O
nerves O O
were O O
rewarmed O O
. O O

Animal O O
experience O O
indicates O O
that O O
clorazepate B-drug B-drug
dipotassium I-drug I-drug
prolongs O O
the O O
sleeping O O
time O O
after O O
hexobarbital B-drug B-drug
or O O
after O O
ethyl B-drug B-drug
alcohol I-drug I-drug
, O O
increases O O
the O O
inhibitory O O
effects O O
of O O
chlorpromazine B-drug B-drug
, O O
but O O
does O O
not O O
exhibit O O
monoamine O O
oxidase O O
inhibition O O
. O O

and O O
calcium B-group B-group
channel I-group I-group
antagonists I-group I-group
e.g. O O
, O O
verapamil B-drug B-drug
) O O
, O O
CYP1A2 O O
inducers O O
( O O
omeprazole B-drug B-drug
) O O
and O O
CYP1A2 O B-group
inhibitors O I-group
( O O
furafylline B-drug B-drug
and O O
clarithromycin B-drug B-drug
) O O
. O O

Digoxin B-drug B-drug
and O O
verapamil B-drug B-drug
use O O
may O O
be O O
rarely O O
associated O O
with O O
ventricular O O
fibrillation O O
when O O
combined O O
with O O
Adenocard B-brand B-brand
. O O

Nelfinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
increased O O
by O O
12 O O
% O O
, O O
15 O O
% O O
, O O
and O O
14 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

Phase O O
II O O
clinical O O
trial O O
data O O
, O O
where O O
IRESSA B-brand B-brand
and O O
vinorelbine B-drug B-drug
have O O
been O O
used O O
concomitantly O O
, O O
indicate O O
that O O
IRESSA B-brand B-brand
may O O
exacerbate O O
the O O
neutropenic O O
effect O O
of O O
vinorelbine B-drug B-drug
. O O

Weak O O
inhibitory O O
effects O O
toward O O
other O O
isoforms O O
( O O
CYP2C8 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
3A4 O O
) O O
were O O
found O O
, O O
but O O
Ki O O
values O O
were O O
in O O
excess O O
of O O
plasma O O
concentrations O O
achieved O O
following O O
dosing O O
. O O

- O O
Drugs O O
that O O
may O O
decrease O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
include O O
: O O
carbamazepine B-drug B-drug
, O O
chronic O O
alcohol B-drug B-drug
abuse O O
, O O
reserpine B-drug B-drug

The O O
majority O O
of O O
patients O O
in O O
RA O O
clinical O O
studies O O
received O O
one O O
or O O
more O O
of O O
the O O
following O O
concomitant O O
medications O O
with O O
ORENCIA B-brand B-brand
: O O
MTX B-drug B-drug
, O O
NSAIDs B-group B-group
, O O
corticosteroids B-group B-group
, O O
TNF B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
azathioprine B-drug B-drug
, O O
chloroquine B-drug B-drug
, O O
gold B-drug B-drug
, O O
hydroxychloroquine B-drug B-drug
, O O
leflunomide B-drug B-drug
, O O
sulfasalazine B-drug B-drug
, O O
and O O
anakinra B-drug B-drug
. O O

Indinavir B-drug B-drug
steady-state O O
Cmax O O
, O O
A.C. O O
and O O
Cmin O O
were O O
decreased O O
by O O
22 O O
% O O
, O O
38 O O
% O O
, O O
and O O
27 O O
% O O
, O O
respectively O O
, O O
by O O
concomitant O O
amprenavir B-drug B-drug
. O O

In O O
contrast O O
, O O
the O O
potency O O
of O O
norepinephrine B-drug B-drug
was O O
increased O O
in O O
failing O O
hearts O O
( O O
New O O
York O O
Heart O O
Association O O
functional O O
class O O
IV O O
) O O
in O O
relation O O
to O O
the O O
concentrations O O
producing O O
50 O O
% O O
of O O
the O O
maximal O O
effect O O
( O O
EC50 O O
) O O
. O O

No O O
clinically O O
significant O O
adverse O O
interactions O O
with O O
commonly O O
used O O
preanesthetic O B-group
drugs O I-group
, O O
or O O
drugs O O
used O O
during O O
anesthesia O O
( O O
muscle B-group B-group
relaxants I-group I-group
, O O
intravenous O O
agents O O
, O O
and O O
local O O
anesthetic B-group B-group
agents I-group I-group
) O O
were O O
reported O O
in O O
clinical O O
trials O O
. O O

Monitor O O
prothrombin O O
levels O O
and O O
adjust O O
anticoagulant B-group B-group
dosage O O
accordingly O O
. O O

Further O O
, O O
if O O
guanfacine B-drug B-drug
is O O
to O O
be O O
discontinued O O
in O O
such O O
patients O O
, O O
careful O O
tapering O O
of O O
the O O
dosage O O
may O O
be O O
necessary O O
in O O
order O O
to O O
avoid O O
rebound O O
phenomena O O
. O O

Activation O O
of O O
an O O
effector O O
immediate-early O O
gene O O
arc O O
by O O
methamphetamine B-drug B-drug
. O O

CYP450 O O
Metabolized O O
Drugs O O
Results O O
from O O
in O O
vitro O O
and O O
in O O
vivo O O
studies O O
suggest O O
that O O
enfuvirtide B-drug B-drug
is O O
unlikely O O
to O O
have O O
significant O O
drug O O
interactions O O
with O O
concomitantly O O
administered O O
drugs O O
metabolized O O
by O O
CYP450 O O
enzymes O O
. O O

The O O
antihypertensive O O
effects O O
of O O
methyldopa B-drug B-drug
, O O
mecamylamine B-drug B-drug
, O O
reserpine B-drug B-drug
, O O
and O O
veratrum B-drug B-group
alkaloids I-drug I-group
may O O
be O O
reduced O O
by O O
sympathomimetics B-group B-group
. O O

The O O
clinical O O
relevance O O
of O O
these O O
increases O O
is O O
not O O
known O O
. O O

Omeprazole B-drug B-drug
should O O
be O O
taken O O
as O O
directed O O
and O O
Proquin B-brand B-brand
XR I-brand I-brand
should O O
be O O
taken O O
with O O
a O O
main O O
meal O O
of O O
the O O
day O O
, O O
preferably O O
the O O
evening O O
meal.. O O

Certain O O
drugs O O
, O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
NSAIDs B-group B-group
) O O
, O O
salicylates B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
non-selective B-group B-group
beta-adrenergic-blocking I-group I-group
agents I-group I-group
may O O
potentiate O O
the O O
hypoglycemic O O
action O O
of O O
Starlix B-brand B-brand
and O O
other O O
oral O O
antidiabetic B-group B-group
drugs I-group I-group
. O O

Corticosteroids B-group B-group
: O O
Concomitant O O
administration O O
with O O
aspirin B-brand B-brand
may O O
increase O O
the O O
risk O O
of O O
gastrointestinal O O
ulceration O O
and O O
may O O
reduce O O
serum O O
salicylate O B-group
levels O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Concomitant O O
treatment O O
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
may O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
. O O

Valproate B-drug B-drug
500 O O
mg O O
twice O O
daily O O
did O O
not O O
modify O O
the O O
rate O O
or O O
extent O O
of O O
levetiracetam B-drug B-drug
absorption O O
or O O
its O O
plasma O O
clearance O O
or O O
urinary O O
excretion O O
. O O

However O O
, O O
in O O
a O O
follow-up O O
study O O
in O O
normal O O
subjects O O
, O O
single-dose O O
administration O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
and O O
propranolol B-drug B-drug
and O O
twice-a-day O O
administration O O
for O O
5 O O
days O O
of O O
both O O
agents O O
did O O
not O O
affect O O
the O O
extent O O
of O O
propranolol B-drug B-drug
absorption O O
, O O
but O O
had O O
a O O
small O O
yet O O
statistically O O
significant O O
effect O O
on O O
its O O
rate O O
of O O
absorption O O
; O O

Sexual O O
intercourse O O
with O O
a O O
steady O O
partner O O
causes O O
no O O
more O O
cardiovascular O O
risk O O
than O O
normal O O
daily O O
activities O O
such O O
as O O
ironing O B-drug
, O O
2 O O
kilometers O O
of O O
walking O O
without O O
climbing O O
, O O
paperhanging O O
, O O
playing O O
golf O O
or O O
gardening O O
. O O

Probenecid B-drug B-drug
may O O
decrease O O
renal O O
tubular O O
secretion O O
of O O
cephalosporins B-group B-group
when O O
used O O
concurrently O O
, O O
resulting O O
in O O
increased O O
and O O
more O O
prolonged O O
cephalosporin B-group B-group
blood O O
levels O O
. O O

Warfarin B-drug B-drug
: O O
In O O
subjects O O
receiving O O
warfarin B-drug B-drug
, O O
no O O
significant O O
change O O
in O O
clotting O O
time O O
was O O
observed O O
when O O
grepafloxacin B-drug B-drug
was O O
coadministered O O
. O O

Bismuth B-drug B-drug
: O O
Bismuth B-drug B-drug
subsalicylate I-drug I-drug
, O O
given O O
concomitantly O O
with O O
enoxacin B-drug B-drug
or O O
60 O O
minutes O O
following O O
enoxacin B-drug B-drug
administration O O
, O O
decreased O O
enoxacin B-drug B-drug
bioavailability O O
by O O
approximately O O
25 O O
% O O
. O O

hepatotoxic O O
drugs O O
; O O

For O O
the O O
calcium-entry B-group B-group
blocking I-group I-group
agents I-group I-group
now O O
available O O
in O O
the O O
United O O
States O O
( O O
verapamil B-drug B-drug
, O O
nifedipine B-drug B-drug
and O O
diltiazem B-drug B-drug
) O O
, O O
these O O
data O O
appeared O O
well O O
after O O
clinical O O
patterns O O
of O O
use O O
evolved O O
. O O

However O O
, O O
prudent O O
evaluation O O
of O O
individual O O
cases O O
is O O
warranted O O
in O O
the O O
clinical O O
setting O O
. O O

When O O
used O O
concurrently O O
with O O
such O O
drugs O O
, O O
the O O
dose O O
of O O
butorphanol B-drug B-drug
should O O
be O O
the O O
smallest O O
effective O O
dose O O
and O O
the O O
frequency O O
of O O
dosing O O
reduced O O
as O O
much O O
as O O
possible O O
when O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
potentiate O O
the O O
action O O
of O O
opioids B-group B-group
. O O

Most O O
events O O
were O O
reported O O
to O O
occur O O
when O O
contrast O O
media O O
was O O
given O O
within O O
4 O O
weeks O O
after O O
the O O
last O O
dose O O
of O O
interleukin-2 B-drug B-drug
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
fosfomycin B-drug B-drug
when O O
coadministered O O
with O O
MONUROL B-brand B-brand
. O O

C57BL/6N O O
demonstrated O O
large O O
numbers O O
of O O
two O O
of O O
the O O
three O O
types O O
of O O
liver O O
tumors O O
seen O O
in O O
livers O O
of O O
genetically O O
predisposed O O
mice O O
, O O
one O O
of O O
which O O
required O O
the O O
additional O O
stimulus O O
of O O
dietary O O
phenobarbital B-drug B-drug
for O O
growth O O
. O O

May O O
interact O O
with O O
thyroid O B-group
medication O I-group
( O O
e.g. O O
, O O
levothyroxine B-drug B-drug
) O O
, O O
iodine-containing B-drug B-drug
products O O
, O O
antacids B-group B-group
, O O
H2-antagonists B-group B-group
( O O
e.g. O O
, O O
famotidine B-drug B-drug
, O O
ranitidine B-drug B-drug
) O O
, O O
and O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
( O O
e.g. O O
, O O
lansoprazole B-drug B-drug
, O O
omeprazole B-drug B-drug
) O O
. O O

Photic O O
evoked O O
potentials O O
were O O
recorded O O
from O O
the O O
visual O O
cortex O O
of O O
chronically O O
implanted O O
albino O O
rats O O
. O O

SETTING O O
: O O
Clinical O O
research O O
center O O
. O O

Concomitant O O
medications O O
were O O
grouped O O
as O O
ACE B-group B-group
inhibitors I-group I-group
, O O
oral O O
anticoagulants B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
beta B-group B-group
blockers I-group I-group
, O O
cardiac B-group B-group
glycosides I-group I-group
, O O
inducers O O
of O O
CYP3A4 O O
, O O
substrates O O
and O O
inhibitors O O
of O O
CYP3A4 O O
, O O
substrates O O
and O O
inhibitors O O
of O O
P-glycoprotein O O
, O O
nitrates B-group B-group
, O O
sulphonylureas B-group B-group
, O O
loop B-group B-group
diuretics I-group I-group
, O O
potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
, O O
thiazide B-group B-group
diuretics I-group I-group
, O O
substrates O O
and O O
inhibitors O O
of O O
tubular O O
organic O O
cation O O
transport O O
, O O
and O O
QTc-prolonging O O
drugs O O
. O O

Recombinant O O
shuttle O O
vectors O O
containing O O
a O O
vanH O O
promoter-vanA O O
antisense O O
gene O O
cassette O O
fully O O
restored O O
vancomycin B-drug B-drug
susceptibility O O
through O O
a O O
combined O O
transcriptional O O
activator O O
binding O O
domain O O
decoy O O
and O O
inducible O O
vanA O O
antisense O O
RNA O O
effect O O
. O O

3 O O
. O O

A O O
single O O
tonic O O
convulsion O O
was O O
seen O O
in O O
each O O
of O O
2 O O
male O O
dogs O O
( O O
one O O
treated O O
at O O
10 O O
mg/kg/day O O
and O O
one O O
at O O
120 O O
mg/kg/day O O
) O O
in O O
a O O
2-year O O
study O O
. O O

+82 O O
% O O

Gemfibrozil B-drug B-drug
Other O O
fibrates B-group B-group
Niacin B-drug B-drug
( O O
nicotinic B-drug B-drug
acid I-drug I-drug
) O O
( O O
=1 O O
g/day O O
) O O

Angiomax B-brand B-brand
does O O
not O O
exhibit O O
binding O O
to O O
plasma O O
proteins O O
( O O
other O O
than O O
thrombin O O
) O O
or O O
red O O
blood O O
cells O O
. O O

therefore O O
, O O
doses O O
greater O O
than O O
the O O
normal O O
antiasthmatic O O
dose O O
of O O
beta-agonist B-group B-group
bronchodilator I-group I-group
drugs I-group I-group
may O O
be O O
required O O
. O O

Co-administration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
strong O O
inhibitor O O
of O O
CYP3A4 O O
, O O
increased O O
cinacalcet B-drug B-drug
exposure O O
following O O
a O O
single O O
90 O O
mg O O
dose O O
of O O
Sensipar B-brand B-brand
by O O
2.3 O O
fold O O
. O O

If O O
resumed O O
during O O
captopril B-drug B-drug
therapy O O
, O O
such O O
agents O O
should O O
be O O
administered O O
cautiously O O
, O O
and O O
perhaps O O
at O O
lower O O
dosage O O
. O O

allopurinol B-drug B-drug
; O O

Certain O O
antibiotic B-group B-group
, O O
cisplatin B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
diuretic B-group B-group
, O O
foscarnet B-drug B-drug
, O O
and O O
vaccines B-group B-group
. O O

With O O
some O O
agents O O
, O O
the O O
metabolism O O
may O O
be O O
induced O O
, O O
resulting O O
in O O
decreased O O
concentrations O O
. O O

Beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
lithium B-drug B-drug
salts O O
, O O
and O O
alcohol B-drug B-drug
may O O
either O O
potentiate O O
or O O
weaken O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
. O O

Antimicrobial O O
activity O O
of O O
Ganoderma B-drug_n O
lucidum I-drug_n O
extract I-drug_n O
alone O O
and O O
in O O
combination O O
with O O
some O O
antibiotics B-group B-group
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

Due O O
to O O
the O O
possibility O O
of O O
antagonism O O
in O O
vivo O O
, O O
particularly O O
when O O
bactericidal O O
activity O O
is O O
desired O O
, O O
this O O
drug O O
combination O O
should O O
be O O
avoided O O
. O O

If O O
this O O
is O O
not O O
possible O O
, O O
the O O
starting O O
dose O O
should O O
be O O
reduced O O
and O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
several O O
hours O O
following O O
an O O
initial O O
dose O O
and O O
until O O
blood O O
pressure O O
has O O
stabilized O O
( O O
see O O
DOSAGE O O
AND O O
ADMINISTRATION O O
. O O
) O O

Cyclosporin B-drug B-drug
: O O
Reports O O
indicate O O
that O O
cyclosporine B-drug B-drug
levels O O
may O O
be O O
increased O O
during O O
concomitant O O
treatment O O
with O O
allopurinol B-drug B-drug
sodium I-drug I-drug
for O O
injection O O
. O O

Adequate O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
considered O O
when O O
therapy O O
with O O
VIOXX B-brand B-brand
is O O
initiated O O
or O O
changed O O
in O O
patients O O
receiving O O
theophylline B-drug B-drug
. O O

If O O
midazolam B-drug B-drug
is O O
administered O O
parenterally O O
, O O
special O O
precaution O O
is O O
required O O
since O O
the O O
sedative O O
effect O O
may O O
be O O
prolonged O O
. O O

The O O
effect O O
of O O
Keppra B-brand B-brand
on O O
probenecid B-drug B-drug
was O O
not O O
studied O O
. O O

Lopinavir/ritonavir B-drug B-drug

It O O
is O O
structurally O O
distinct O O
from O O
the O O
other O O
currently O O
available O O
HMGCoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
( O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
, O O
and O O
pravastatin B-drug B-drug
) O O
, O O
leading O O
to O O
unique O O
biopharmaceutical O O
properties O O
relative O O
to O O
the O O
other O O
agents O O
of O O
this O O
class O O
. O O

Digoxin B-drug B-drug
: O O
In O O
patients O O
with O O
hypercholesterolemia O O
, O O
concomitant O O
administration O O
of O O
lovastatin B-drug B-drug
and O O
digoxin B-drug B-drug
resulted O O
in O O
no O O
effect O O
on O O
digoxin B-drug B-drug
plasma O O
concentrations O O
. O O

There O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
experiencing O O
increases O O
in O O
their O O
prothrombin O O
times O O
when O O
etidronate B-drug B-drug
was O O
added O O
to O O
warfarin B-drug B-drug
therapy O O
. O O

ulcerans O O
infection O O
. O O

isoflurane B-drug B-drug
; O O

INDOCIN B-brand B-brand
has O O
been O O
reported O O
to O O
decrease O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
and O O
to O O
potentiate O O
its O O
toxicity O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
20 O O
% O O
. O O

The O O
behavioral O O
changes O O
of O O
mice O O
induced O O
by O O
acute O O
and O O
repeated O O
i.p O O
. O O

An O O
intravenous O O
injection O O
of O O
perchlorate B-drug_n B-drug
given O O
later O O
also O O
produces O O
a O O
complete O O
and O O
immediately O O
beginning O O
depletion O O
of O O
pertechnetate B-drug B-drug
already O O
accumulated O O
in O O
the O O
thyroid O O
, O O
within O O
a O O
period O O
of O O
195 O O
min O O
after O O
99m-TcO-4-injection O B-drug
with O O
a O O
corresponding O O
increase O O
in O O
blood O O
levels O O
. O O

The O O
development O O
of O O
clinical O O
vancomycin-resistant O O
strains O O
of O O
enterococci O O
( O O
VRE O O
) O O
is O O
a O O
major O O
cause O O
for O O
concern O O
. O O

In O O
human O O
heart O O
failure O O
, O O
there O O
is O O
a O O
presynaptic O O
defect O O
in O O
the O O
sympathetic O O
nervous O O
system O O
, O O
leading O O
to O O
reduced O O
uptake-1 O O
activity O O
. O O

Administering O O
InsP B-drug_n B-drug_n
( I-drug_n O
3 I-drug_n O
) I-drug_n O
together O O
with O O
RR B-drug_n B-drug_n
( O O
100-500 O O
microM O O
) O O
inhibited O O
InsP O B-drug_n
( O I-drug_n
3 O I-drug_n
) O I-drug_n
-induced O O
responses O O
( O O
both O O
Ca O O
( O O
2+ O O
) O O
and O O
current O O
responses O O
) O O
in O O
a O O
dose-dependent O O
fashion O O
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
metabolized O O
by O O
one O O
( O O
or O O
more O O
) O O
of O O
these O O
enzymes O O
. O O

Seizure O O
, O O
associated O O
with O O
increased O O
lidocaine B-drug B-drug
concentrations O O
, O O
has O O
been O O
reported O O
with O O
concomitant O O
administration O O
of O O
intravenous O O
amiodarone B-drug B-drug
. O O

Evaluation O O
of O O
its O O
efficacy O O
and O O
toxicity O O
. O O

Azithromycin B-drug B-drug
did O O
not O O
affect O O
the O O
prothrombin O O
time O O
response O O
to O O
a O O
single O O
dose O O
of O O
warfarin B-drug B-drug
. O O

Preliminary O O
investigations O O
indicate O O
that O O
icodextrin B-drug B-drug
and O O
its O O
metabolites O O
interfere O O
with O O
enzymatic-based O O
amylase O O
assays O O
, O O
resulting O O
in O O
inaccurately O O
low O O
values O O
. O O

Drugs O O
That O O
Inhibit O O
CYP3A4 O O
CYP3A4 O O
is O O
a O O
minor O O
metabolic O O
pathway O O
for O O
the O O
elimination O O
of O O
zaleplon B-drug B-drug
because O O
the O O
sum O O
of O O
desethylzaleplon O B-drug
( O O
formed O O
via O O
CYP3A4 O O
in O O
vitro O O
) O O
and O O
its O O
metabolites O O
, O O
5-oxo-desethylzaleplon B-drug_n B-drug_n
and O O
5-oxo-desethylzaleplon B-drug_n B-drug_n
glucuronide I-drug_n I-drug_n
, O O
account O O
for O O
only O O
9 O O
% O O
of O O
the O O
urinary O O
recovery O O
of O O
a O O
zaleplon B-drug B-drug
dose O O
. O O

Blood O O
samples O O
also O O
were O O
taken O O
before O O
morning O O
doses O O
on O O
the O O
3rd O O
, O O
4th O O
, O O
and O O
5th O O
days O O
of O O
phases O O
1 O O
and O O
3 O O
. O O

Elevated O O
International O O
Normalized O O
Ratio O O
and O O
Potential O O
Bleeding O O
International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
elevations O O
and O O
infrequent O O
reports O O
of O O
bleeding O O
events O O
including O O
gastrointestinal O O
and O O
non-gastrointestinal O O
bleedings O O
have O O
been O O
reported O O
in O O
clinical O O
studies O O
, O O
some O O
associated O O
with O O
concomitant O O
warfarin B-drug B-drug
administration O O
. O O

Cimetidine B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
the O O
bioavailability O O
of O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

indomethacin B-drug B-drug
; O O

- O O
In O O
isolated O O
cases O O
, O O
a O O
pronounced O O
though O O
reversible O O
, O O
impairment O O
of O O
renal O O
function O O
( O O
accompanied O O
by O O
a O O
corresponding O O
increase O O
in O O
the O O
serum O O
creatinine O O
level O O
) O O
has O O
been O O
reported O O
in O O
organ O O
transplant O O
patients O O
receiving O O
immuno-suppressant B-group B-group
therapy O O
and O O
concomitant O O
bezafibrate B-drug B-drug
. O O

Methadonea O O

Patients O O
taking O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
and O O
hepatic O O
enzyme O O
inhibitors O O
concomitantly O O
should O O
be O O
closely O O
monitored O O
. O O

Observe O O
the O O
patient O O
for O O
possible O O
diminished O O
effect O O
of O O
steroid B-group B-group
and O O
increase O O
the O O
steroid B-group B-group
dosage O O
accordingly O O
. O O

This O O
defect O O
is O O
not O O
related O O
to O O
acute O O
insulin O B-drug
release O O
or O O
the O O
presence O O
of O O
glucose B-drug O
. O O

In O O
vitro O O
studies O O
have O O
demonstrated O O
that O O
efavirenz B-drug B-drug
inhibits O O
2C9 O O
, O O
2C19 O O
, O O
and O O
3A4 O O
isozymes O O
in O O
the O O
range O O
of O O
observed O O
efavirenz B-drug B-drug
plasma O O
concentrations O O
. O O

At O O
a O O
higher O O
dose O O
and O O
a O O
shorter O O
withdrawal O O
period O O
( O O
20 O O
mg/kg O O
, O O
daily O O
for O O
7 O O
days O O
followed O O
by O O
a O O
3-day O O
withdrawal O O
) O O
, O O
the O O
SST O O
mice O O
showed O O
behavioral O O
sensitization O O
similar O O
to O O
the O O
RBC O O
mice O O
, O O
but O O
the O O
LST O O
mice O O
did O O
not O O
develop O O
sensitization O O
. O O

the O O
fourth O O
group O O
served O O
as O O
control O O
and O O
received O O
an O O
equivalent O O
volume O O
of O O
an O O
isocaloric O O
solution O O
of O O
dextrose B-drug B-drug
. O O

When O O
the O O
dose O O
of O O
picrotoxin B-drug_n B-drug_n
is O O
minimized O O
to O O
0.5 O O
mg/kg O O
such O O
an O O
effect O O
is O O
not O O
observed O O
. O O

They O O
should O O
be O O
observed O O
closely O O
, O O
particularly O O
if O O
renal O O
function O O
is O O
impaired O O
. O O

In O O
addition O O
, O O
the O O
frequency O O
of O O
monitoring O O
serum O O
lithium B-drug B-drug
concentration O O
should O O
be O O
increased O O
at O O
the O O
outset O O
of O O
such O O
combination O O
drug O O
treatment O O
. O O

Dose-response O O
curves O O
( O O
derived O O
from O O
the O O
results O O
of O O
using O O
the O O
tablets O O
as O O
well O O
as O O
pure O O
powders O O
) O O
showed O O
that O O
tripelennamine B-drug B-drug
was O O
responsible O O
for O O
the O O
inhibitory O O
activity O O
, O O
which O O
was O O
partially O O
antagonized O O
by O O
pentazocine B-drug B-drug
. O O

When O O
CANCIDAS B-brand B-brand
is O O
co-administered O O
with O O
inducers O O
of O O
drug O O
clearance O O
, O O
such O O
as O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
or O O
carbamazepine B-drug B-drug
, O O
use O O
of O O
a O O
daily O O
dose O O
of O O
70 O O
mg O O
of O O
CANCIDAS B-brand B-brand
should O O
be O O
considered O O

Antidiabetics B-group B-group
: O O
Because O O
corticosteroids B-group B-group
may O O
increase O O
blood O O
glucose O O
concentrations O O
, O O
dosage O O
adjustments O O
of O O
antidiabetic B-group B-group
agents I-group I-group
may O O
be O O
required O O
. O O

Sulfapyridine B-drug B-drug
may O O
interact O O
with O O
any O O
of O O
the O O
following O O
: O O
- O O
Acetaminophen B-drug B-drug
( O O
e.g. O O
, O O
Tylenol B-brand B-brand
) O O
( O O
with O O
long-term O O
, O O
high-dose O O
use O O
) O O
or O O

Patients O O
receiving O O
beta-blockers B-group B-group
should O O
be O O
warned O O
of O O
this O O
potential O O
hazard O O
. O O

Diltiazem B-drug B-drug
is O O
both O O
a O O
substrate O O
and O O
an O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
3A4 O O
enzyme O O
system O O
. O O

Recommendations O O
were O O
to O O
avoid O O
administration O O
of O O
diffusible O O
anti-helminthic B-group O
treatment O O
during O O
the O O
cure O O
, O O
and O O
to O O
improve O O
the O O
general O O
conditions O O
of O O
patients O O
before O O
the O O
cure O O
of O O
melarsoprol B-drug B-drug
. O O

Estrogen-containing B-group B-group
therapies O O
should O O
not O O
be O O
used O O
with O O
ARIMIDEX B-brand B-brand
as O O
they O O
may O O
diminish O O
its O O
pharmacologic O O
action O O
. O O

If O O
CEFOTAN B-brand B-brand
and O O
an O O
aminoglycoside B-group B-group
are O O
used O O
concomitantly O O
, O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
, O O
because O O
nephrotoxicity O O
may O O
be O O
potentiated O O
. O O

Anticoagulants B-group B-group
: O O
Coagulation O O
parameters O O
should O O
be O O
tested O O
more O O
frequently O O
and O O
monitored O O
regularly O O
during O O
simultaneous O O
administration O O
of O O
high O O
doses O O
of O O
heparin B-drug B-drug
, O O
oral O O
anticoagulants B-group B-group
, O O
or O O
other O O
drugs O O
that O O
may O O
affect O O
the O O
blood O O
coagulation O O
system O O
or O O
the O O
thrombocyte O O
function O O
. O O

Amprenavir B-drug B-drug
significantly O O
increased O O
the O O
area O O
under O O
the O O
curve O O
at O O
steady O O
state O O
( O O
AUC O O
( O O
ss O O
) O O
) O O
of O O
rifabutin B-drug B-drug
by O O
2.93-fold O O
and O O
the O O
AUC O O
( O O
ss O O
) O O
of O O
25-O-desacetylrifabutin B-drug_n B-drug_n
by O O
13.3-fold O O
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

The O O
concomitant O O
administration O O
of O O
Exjade B-brand B-brand
and O O
aluminum-containing B-drug B-drug
antacid B-group B-group
preparations I-group I-group
has O O
not O O
been O O
formally O O
studied O O
. O O

Clinical O O
experience O O
in O O
the O O
concurrent O O
administration O O
of O O
ECT O O
and O O
antidepressant B-group B-group
drugs I-group I-group
is O O
limited O O
. O O

Pharmacokinetic O O
Interaction O O
between O O
amprenavir B-drug B-drug
and O O
rifabutin B-drug B-drug
or O O
rifampin B-drug B-drug
in O O
healthy O O
males O O
. O O

Therefore O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
biocytin O O
inclusion O O
on O O
opioid B-group O
responses O O
and O O
other O O
membrane O O
properties O O
during O O
whole-cell O O
, O O
tight O O
seal O O
recordings O O
of O O
these O O
neurons O O
. O O

Probenecid B-drug B-drug
: O O
May O O
decrease O O
renal O O
tubular O O
secretion O O
of O O
ampicillin B-drug B-drug
resulting O O
in O O
increased O O
blood O O
levels O O
and/or O O
ampicillin B-drug B-drug
toxicity O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
potentiate O O
the O O
cardiovascular O O
effects O O
of O O
adreneric O B-group
agents O I-group
. O O

4 O O
. O O

Many O O
drugs O O
used O O
in O O
dentistry O O
can O O
not O O
be O O
taken O O
concomitantly O O
with O O
these O O
medications O O
. O O

Fluvastatin B-drug B-drug
is O O
the O O
first O O
synthetic B-group O
3-hydroxy-3-methylglutaryl I-group O
coenzyme I-group O
A I-group O
( I-group O
HMGCoA I-group B-group
) I-group I-group
reductase I-group I-group
inhibitor I-group I-group
to O O
be O O
approved O O
for O O
clinical O O
use O O
, O O
and O O
has O O
been O O
studied O O
extensively O O
in O O
humans O O
since O O
1986 O O
. O O

Endogenous O O
respiration O O
was O O
unaffected O O
by O O
the O O
drug O O
at O O
a O O
concentration O O
as O O
high O O
as O O
100 O O
mug/ml O O
, O O
whereas O O
exogenous O O
respiration O O
was O O
markedly O O
sensitive O O
and O O
inhibited O O
to O O
an O O
extent O O
of O O
85 O O
% O O
. O O

Nonsteroidal B-group B-group
Anti-Inflammatory I-group I-group
Drugs I-group I-group
: O O
The O O
administration O O
of O O
diflunisal B-drug B-drug
to O O
normal O O
volunteers O O
receiving O O
indomethacin B-drug B-drug
decreased O O
the O O
renal O O
clearance O O
and O O
significantly O O
increased O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
. O O

Analgesic/anti-inflammatory B-group O
( O O
e.g. O O
, O O
acetaminophen B-drug B-drug
, O O
aspirin B-brand B-brand
, O O
codeine B-drug B-drug
and O O
codeine B-drug B-drug
combinations O O
, O O
ibuprofen B-drug B-drug
, O O
indomethacin B-drug B-drug
) O O
. O O

Drugs O O
which O O
induce O O
CYP3A4 O O
activity O O
( O O
eg O O
, O O
phenobarbital B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
rifabutin B-drug B-drug
) O O
would O O
be O O
expected O O
to O O
increase O O
the O O
clearance O O
of O O
efavirenz B-drug B-drug
resulting O O
in O O
lowered O O
plasma O O
concentrations O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
digoxin B-drug B-drug
increases O O
the O O
serum O O
digoxin B-drug B-drug
concentration O O
by O O
70 O O
% O O
after O O
one O O
day O O
. O O

Haloperidol B-drug B-drug
reduced O O
or O O
eliminated O O
the O O
increases O O
in O O
FI O O
responding O O
produced O O
by O O
intermediate O O
doses O O
of O O
either O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
in O O
pigeons O O
, O O
but O O
did O O
not O O
antagonize O O
the O O
decreases O O
in O O
FI O O
or O O
FR O O
responding O O
produced O O
by O O
high O O
doses O O
of O O
PCP O B-drug_n
or O O
either O O
stereoisomer O O
of O O
NANM B-drug_n B-drug_n
. O O

WelChol B-brand B-brand
has O O
been O O
studied O O
in O O
several O O
human O O
drug O O
interaction O O
studies O O
in O O
which O O
it O O
was O O
administered O O
with O O
a O O
meal O O
and O O
the O O
test O O
drug O O
. O O

Propoxyphene B-drug B-drug
: O O
In O O
cases O O
of O O
propoxyphene B-drug B-drug
overdosage O O
, O O
amphetamine B-group B-drug
CNS O O
stimulation O O
is O O
potentiated O O
and O O
fatal O O
convulsions O O
can O O
occur O O
. O O

No O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
for O O
COLAZAL B-brand B-brand
, O O
however O O
the O O
use O O
of O O
orally O O
administered O O
antibiotics B-group B-group
could O O
, O O
theoretically O O
, O O
interfere O O
with O O
the O O
release O O
of O O
mesalamine B-drug B-drug
in O O
the O O
colon O O
. O O

T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Local O O
and O O
some O O
general O O
anesthetics B-group B-group
, O O
antiarrhythmic B-group B-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
interfere O O
with O O
neuromuscular O O
transmission O O
should O O
be O O
used O O
cautiously O O
, O O
if O O
at O O
all O O
, O O
in O O
patients O O
with O O
myasthenia O O
gravis O O
; O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
not O O
clear O O
. O O

If O O
intravenous O O
pentamidine B-drug B-drug
is O O
required O O
to O O
treat O O
Pneumocystis O O
carinii O O
pneumonia O O
, O O
treatment O O
with O O
HIVID B-drug B-drug
should O O
be O O
interrupted O O
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
block O O
morphine-induced B-drug B-drug
and O O
nicotine-induced B-drug B-drug
dopamine O I-drug
release O O
in O O
the O O
nucleus O O
accumbens O O
; O O

Tetracyclines B-group B-group
: O O
Since O O
both O O
acitretin B-drug B-drug
and O O
tetracyclines B-group B-group
can O O
cause O O
increased O O
intracranial O O
pressure O O
, O O
their O O
combined O O
use O O
is O O
contraindicated O O
. O O

In O O
vitro O O
, O O
buspirone B-drug B-drug
may O O
displace O O
less O O
firmly O O
bound O O
drugs O O
like O O
digoxin B-drug B-drug
. O O

Death O O
in O O
amphetamine B-drug B-drug
users O O
: O O
causes O O
and O O
rates O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
reported O O
with O O
erythromycin B-drug B-drug
products O O
. O O

The O O
goal O O
of O O
enhancing O O
selective O O
tumor O O
cell O O
killing O O
relative O O
to O O
the O O
normal O O
cells O O
that O O
are O O
dose O O
limiting O O
may O O
be O O
achieved O O
either O O
by O O
overcoming O O
tumor O O
cell O O
resistance O O
or O O
by O O
protecting O O
normal O O
cells O O
. O O

this O O
phenomenon O O
was O O
not O O
observed O O
in O O
North O O
American O O
clinical O O
trials O O
. O O

Acetazolamide B-drug B-drug
reduces O O
urinary O O
excretion O O
of O O
quinidine B-drug B-drug
and O O
may O O
enhance O O
its O O
effect O O
. O O

Agents O O
that O O
may O O
enhance O O
the O O
risk O O
of O O
hemorrhage O O
should O O
be O O
discontinued O O
prior O O
to O O
initiation O O
of O O
Fondaparinux B-drug B-drug
therapy O O
. O O

The O O
absorption O O
of O O
lymecycline B-drug B-drug
may O O
be O O
affected O O
by O O
the O O
simultaneous O O
administration O O
of O O
indigestion O O
remedies O O
, O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
supplements O O
. O O

RESULTS O O
: O O
Sildenafil B-drug B-drug
has O O
demonstrated O O
effectiveness O O
in O O
men O O
with O O
erectile O O
dysfunction O O
associated O O
with O O
prostatectomy O O
, O O
radiation O O
therapy O O
, O O
diabetes O O
mellitus O O
, O O
certain O O
neurologic O O
disorders O O
, O O
and O O
drug O O
therapy O O
( O O
eg O O
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
[ O O
SSRIs B-group B-group
] O O
) O O
. O O

Beta-Blockers B-group B-group
: O O
In O O
controlled O O
clinical O O
studies O O
, O O
adrenergic B-group B-group
beta-receptor I-group I-group
blockers I-group I-group
have O O
been O O
frequently O O
administered O O
concomitantly O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
. O O

Metoprolol B-drug B-drug
- O O
Administration O O
of O O
20 O O
mg/day O O
LEXAPRO B-brand B-brand
for O O
21 O O
days O O
in O O
healthy O O
volunteers O O
resulted O O
in O O
a O O
50 O O
% O O
increase O O
in O O
Cmax O O
and O O
82 O O
% O O
increase O O
in O O
AUC O O
of O O
the O O
beta-adrenergic B-group B-group
blocker I-group I-group
metoprolol B-drug B-drug
( O O
given O O
in O O
a O O
single O O
dose O O
of O O
100 O O
mg O O
) O O
. O O

Histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
: O O
Histamine B-group B-group
H2-receptor I-group I-group
antagonists I-group I-group
appear O O
to O O
have O O
no O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
ciprofloxacin B-drug B-drug
. O O

( O O
200 O O
mg O O
Q12h O O
) O O

Usually O O
, O O
such O O
inactivation O O
of O O
the O O
aminoglycoside B-group B-group
is O O
clinically O O
significant O O
only O O
in O O
patients O O
with O O
severely O O
impaired O O
renal O O
function.. O O

Liver O O
Function O O
Tests O O
: O O
Elevations O O
of O O
AST O O
( O O
SGOT O O
) O O
, O O
ALT O O
( O O
SGPT O O
) O O
or O O
LDH O O
were O O
experienced O O
by O O
approximately O O
1 O O
in O O
3 O O
patients O O
treated O O
with O O
Soriatane B-brand B-drug
. O O

Phenytoin B-drug B-drug

Concomitant O O
administration O O
of O O
Robinul B-brand B-brand
Injection O O
and O O
potassium B-drug B-drug
chloride I-drug I-drug
in O O
a O O
wax O O
matrix O O
may O O
increase O O
the O O
severity O O
of O O
potassium O B-drug
chloride-induced O I-drug
gastrointestinal O O
lesions O O
as O O
a O O
result O O
of O O
a O O
slower O O
gastrointestinal O O
transit O O
time O O
. O O

There O O
are O O
no O O
significant O O
effects O O
on O O
cefdinir B-drug B-drug
pharmacokinetics O O
if O O
the O O
antacid B-group B-group
is O O
administered O O
2 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
cefdinir B-drug B-drug
. O O

Acarbose B-drug B-drug
has O O
been O O
shown O O
to O O
change O O
the O O
bioavailabillty O O
digoxin B-drug B-drug
when O O
they O O
are O O
co-administered O O
, O O
which O O
may O O
require O O
digoxin B-drug B-drug
dose O O
adjustment O O
. O O

In O O
such O O
cases O O
, O O
the O O
unbound O O
( O O
free O O
) O O
hormone O O
should O O
be O O
measured O O
. O O

- O O
Procainamide B-drug B-drug
( O O
e.g. O O
, O O
Pronestyl B-brand B-brand
) O O
or O O

4 O O
microg O O
mL O O
( O O
-1 O O
) O O
in O O
the O O
presence O O
of O O
galangin B-drug B-drug
( O O
12.5 O O
microg O O
mL O O
( O O
-1 O O
) O O
) O O
or O O
3,7-dihydroxyflavone O O
( O O
6.25 O O
microg O O
mL O O
( O O
-1 O O
) O O
) O O
. O O

Aspirin B-brand B-brand
: O O
CELEBREX B-brand B-brand
can O O
be O O
used O O
with O O
low O O
dose O O
aspirin B-brand B-brand
. O O

however O O
, O O
no O O
deleterious O O
interactions O O
were O O
seen O O
when O O
ROMAZICON B-brand B-brand
was O O
administered O O
after O O
narcotics B-group B-group
, O O
inhalational O B-group
anesthetics B-group I-group
, O O
muscle B-group B-group
relaxants I-group I-group
and O O
muscle O B-group
relaxant O I-group
antagonists O I-group
administered O O
in O O
conjunction O O
with O O
sedation O O
or O O
anesthesia O O
. O O

Opioid B-group B-group
analgesics I-group I-group
Decreased O O
antinociceptive O O
action O O

Both O O
digoxin B-drug B-drug
and O O
COREG B-brand B-brand
slow O O
AV O O
conduction O O
. O O

Patients O O
with O O
HACA O B-drug
titers O O
may O O
have O O
allergic O O
or O O
hypersensitivity O O
reactions O O
when O O
treated O O
with O O
other O O
diagnostic B-group O
or O O
therapeutic B-group O
monoclonal I-group O
antibodies I-group O
. O O

Acute O O
dosing O O
with O O
clozapine B-drug B-drug
failed O O
to O O
alter O O
the O O
behavioral O O
effects O O
of O O
PCP B-drug_n B-drug_n
in O O
either O O
procedure O O
even O O
when O O
tested O O
up O O
to O O
doses O O
that O O
produced O O
pharmacological O O
effects O O
alone O O
. O O

Pharmacodynamic O O
Interactions O O
: O O
The O O
CNS-depressant O O
action O O
of O O
the O O
benzodiazepine B-group B-group
class I-group I-group
of O O
drugs O O
may O O
be O O
potentiated O O
by O O
alcohol B-drug B-drug
, O O
narcotics B-group B-group
, O O
barbiturates B-group B-group
, O O
nonbarbiturate B-group B-group
hypnotics I-group I-group
, O O
antianxiety B-group B-group
agents I-group I-group
, O O
the O O
phenothiazines O B-group
, O O
thioxanthene O B-drug
and O O
butyrophenone B-group B-drug
classes I-group O
of I-group O
antipsychotic I-group B-group
agents I-group I-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
and O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
by O O
other O O
anticonvulsant B-group B-group
drugs I-group I-group
. O O

Massive O O
seizures O O
may O O
be O O
encountered O O
with O O
this O O
combination O O
. O O

This O O
article O O
reviews O O
the O O
impact O O
of O O
renal O O
disease O O
on O O
the O O
pharmacokinetics O O
of O O
cardiovascular O O
drugs O O
and O O
identifies O O
clinically O O
important O O
interactions O O
between O O
these O O
and O O
other O O
drugs O O
commonly O O
used O O
in O O
the O O
management O O
of O O
chronic O O
renal O O
disease O O
. O O

In O O
diabetic O O
patients O O
, O O
the O O
metabolic O O
effects O O
of O O
androgens B-group B-group
may O O
decrease O O
blood O O
glucose O O
and O O
therefore O O
, O O
insulin B-drug B-drug
requirements O O
. O O

Some O O
early O O
studies O O
indicated O O
that O O
EPA B-drug B-drug
supplements O O
might O O
have O O
detrimental O O
effects O O
in O O
those O O
groups O O
. O O

Exacerbation O O
or O O
the O O
initial O O
presentation O O
of O O
a O O
number O O
of O O
autoimmune O O
and O O
inflammatory O O
disorders O O
has O O
been O O
observed O O
following O O
concurrent O O
use O O
of O O
interferon-alfa B-drug B-drug
and O O
PROLEUKIN B-brand B-brand
, O O
including O O
crescentic O O
IgA O O
glomerulonephritis O O
, O O
oculo-bulbar O O
myasthenia O O
gravis O O
, O O
inflammatory O O
arthritis O O
, O O
thyroiditis O O
, O O
bullous O O
pemphigoid O O
, O O
and O O
Stevens-Johnson O O
syndrome O O
. O O

3 O O
. O O

In O O
female O O
rats O O
, O O
fulvestrant B-drug B-drug
administered O O
at O O
doses O O
0.01 O O
mg/kg/day O O
( O O
approximately O O
one-hundredth O O
of O O
the O O
human O O
recommended O O
dose O O
based O O
on O O
body O O
surface O O
area O O
[ O O
BSA O O
] O O
, O O
for O O
2 O O
weeks O O
prior O O
to O O
and O O
for O O
1 O O
week O O
following O O
mating O O
, O O
caused O O
a O O
reduction O O
in O O
fertility O O
and O O
embryonic O O
survival O O
. O O

indinavir I-drug I-drug
concentration O O

DOXIL B-brand B-brand
may O O
interact O O
with O O
drugs O O
known O O
to O O
interact O O
with O O
the O O
conventional O O
formulation O O
of O O
doxorubicin B-drug B-drug
HCl I-drug I-drug
. O O

Ethosuximide B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
ethosuximide B-drug B-drug
. O O

In O O
situations O O
in O O
which O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

This O O
interference O O
has O O
resulted O O
in O O
significant O O
increases O O
in O O
half-life O O
and O O
AUC O O
. O O

suppression O O
of O O
midcycle O O
gonadotropin O O
peaks O O
; O O

However O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
CELEBREX B-brand B-brand
with O O
warfarin B-drug B-drug
since O O
these O O
patients O O
are O O
at O O
increased O O
risk O O
of O O
bleeding O O
complications O O
. O O

Gentamicin B-drug B-drug
- O O
Methionine B-drug B-drug
may O O
protect O O
against O O
the O O
ototoxic O O
effects O O
of O O
gentamicin B-drug B-drug
. O O

Atracurium B-drug B-drug
was O O
again O O
given O O
by O O
infusion O O
to O O
maintain O O
40 O O
% O O
twitch O O
for O O
a O O
second O O
hour O O
, O O
then O O
2 O O
mg O O
gentamycin/kg B-drug B-drug
bwt O O
were O O
given O O
i.v O O
. O O

conversely O O
, O O
diethylpropion B-drug O
may O O
interfere O O
with O O
antihypertensive B-group B-group
drugs I-group I-group
( O O
i.e. O O
, O O
guanethidine B-drug B-drug
, O O
a-methyldopa B-drug B-drug
) O O
. O O

Co-treatment O O
with O O
the O O
potent O O
CYP3A4 O O
inhibitor O O
ketoconazole B-drug B-drug
increases O O
erlotinib B-drug B-drug
AUC O O
by O O
2/3 O O
. O O

Platelet B-group B-group
inhibitors I-group I-group
: O O
Drugs O O
such O O
as O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
dextran B-drug B-drug
, O O
phenylbutazone B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
dipyridamole B-drug B-drug
, O O
hydroxychloroquine B-drug B-drug
and O O
others O O
that O O
interfere O O
with O O
platelet-aggregation O O
reactions O O
( O O
the O O
main O O
hemostatic O O
defense O O
of O O
heparinized O O
patients O O
) O O
may O O
induce O O
bleeding O O
and O O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

It O O
is O O
not O O
known O O
whether O O
the O O
concurrent O O
use O O
of O O
these O O
agents O O
with O O
apraclonidine B-drug B-drug
can O O
lead O O
to O O
a O O
reduction O O
in O O
IOP O O
lowering O O
effect O O
. O O

The O O
approach O O
is O O
applicable O O
across O O
a O O
wide O O
variety O O
of O O
settings O O
commonly O O
associated O O
with O O
joint O O
action O O
data O O
, O O
including O O
continuous O O
and O O
discrete O O
responses O O
, O O
alternative O O
error O O
structures O O
, O O
and O O
nonzero O O
background O O
response O O
. O O

CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
cardiac O O
arrhythmias O O
. O O

Methotrexate B-drug B-drug
: O O
Ibuprofen B-drug B-drug
, O O
as O O
well O O
as O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
probably O O
reduces O O
the O O
tubular O O
secretion O O
of O O
methotrexate B-drug B-drug
based O O
on O O
in O O
vitro O O
studies O O
in O O
rabbit O O
kidney O O
slices O O
. O O

Inducers O O
of O O
CYP3A4 O O

Because O O
of O O
the O O
potential O O
for O O
additive O O
or O O
synergistic O O
depressant O O
effects O O
on O O
the O O
SA O O
and O O
AV O O
nodes O O
, O O
however O O
, O O
Adenocard B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
the O O
presence O O
of O O
these O O
agents O O
. O O

Food O O
: O O
Isoniazid B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
food O O
. O O

Postoperatively O O
, O O
45 O O
patients O O
were O O
randomly O O
assigned O O
in O O
a O O
double-blind O O
fashion O O
to O O
receive O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
4 O O
mg O O
) O O
or O O
placebo O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.15 O O
mg/kg O O
) O O
or O O
to O O
receive O O
oral O O
and O O
intravenous O O
placebo O O
. O O

No O O
information O O
available O O
. O O

An O O
increased O O
incidence O O
of O O
benign O O
ovarian O O
granulosa O O
cell O O
tumors O O
and O O
testicular O O
Leydig O O
cell O O
tumors O O
was O O
evident O O
, O O
in O O
females O O
dosed O O
at O O
10 O O
mg/rat/15 O O
days O O
and O O
males O O
dosed O O
at O O
15 O O
mg/rat/30 O O
days O O
, O O
respectively O O
. O O

Behavioral O O
responses O O
to O O
repeated O O
cocaine B-drug B-drug
exposure O O
in O O
mice O O
selectively O O
bred O O
for O O
differential O O
sensitivity O O
to O O
pentobarbital B-drug B-drug
. O O

Such O O
individuals O O
are O O
referred O O
to O O
as O O
poor O O
metabolizers O O
of O O
drugs O O
such O O
as O O
debrisoquin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
clozapine B-drug B-drug
. O O

Steady-state O O
plasma O O
felbamate B-drug B-drug
concentrations O O
were O O
found O O
to O O
be O O
29 O O
% O O
lower O O
than O O
the O O
mean O O
concentrations O O
of O O
a O O
group O O
of O O
newly O O
diagnosed O O
subjects O O
with O O
epilepsy O O
also O O
receiving O O
2400 O O
mg O O
of O O
felbamate B-drug B-drug
a O O
day O O
. O O

Cevimeline B-drug B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
individuals O O
known O O
or O O
suspected O O
to O O
be O O
deficient O O
in O O
CYP2D6 O O
activity O O
, O O
based O O
on O O
previous O O
experience O O
, O O
as O O
they O O
may O O
be O O
at O O
a O O
higher O O
risk O O
of O O
adverse O O
events O O
. O O

see O O
DOSAGE O O
AND O O
ADMINISTRATION O O
) O O
. O O

Dasatinib B-drug B-drug
and O O
its O O
metabolites O O
are O O
minimally O O
excreted O O
via O O
the O O
kidney O O
. O O

Other O O
CYP3A4 O O
inducers O O
include O O
, O O
but O O
are O O
not O O
limited O O
to O O
, O O
rifabutin B-drug B-drug
, O O
rifapentine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
and O O
St. O O
Johns O O
Wort O O
. O O

. O O

Co-medications O O
that O O
induce O O
CYP O O
3A4 O O
( O O
e.g. O O
, O O
rifampicin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
or O O
St. O O
John O O
s O O
wort O O
) O O
may O O
significantly O O
decrease O O
exposure O O
to O O
exemestane B-drug B-drug
. O O

Among O O
the O O
risk O O
factors O O
studied O O
, O O
two O O
appear O O
to O O
increase O O
the O O
risk O O
of O O
ARE O O
: O O
the O O
prescription O O
of O O
thiabendazole B-drug B-drug
to O O
treat O O
strongyloidiasis O O
during O O
the O O
melarsoprol B-drug B-drug
cure O O
and O O
the O O
bad O O
general O O
clinical O O
conditions O O
of O O
patients O O
. O O

The O O
effects O O
of O O
nonbenzodiazepine O B-group
agonists O I-group
at O O
benzodiazepine O B-group
receptors O O
, O O
such O O
as O O
zopiclone B-drug B-drug
, O O
triazolopyridazines O B-group
and O O
others O O
, O O
are O O
also O O
blocked O O
by O O
ROMAZICON B-brand B-brand
. O O

. O O

When O O
administered O O
with O O
food O O
or O O
milk O O
, O O
there O O
is O O
more O O
rapid O O
absorption O O
; O O

Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O

indinavir I-drug I-drug
concentration O O

= O O
decrease O O

No O O
change O O
in O O
dose O O
of O O
either O O
drug O O
is O O
recommended O O
. O O

INH B-drug O
( O O
Isoniazid B-drug B-drug
) O O
is O O
also O O
reported O O
to O O
affect O O
ketoconazole B-drug B-drug
concentrations O O
adversely O O
. O O

In O O
vitro O O
studies O O
demonstrated O O
that O O
the O O
plasma O O
protein O O
binding O O
of O O
des-ciclesonide B-drug B-drug
was O O
not O O
affected O O
by O O
warfarin B-drug B-drug
or O O
salicylic B-drug B-drug
acid I-drug I-drug
, O O
indicating O O
no O O
potential O O
for O O
protein O O
binding-based O O
drug O O
interactions O O
. O O

The O O
following O O
drug O O
interactions O O
have O O
been O O
identified O O
involving O O
NIZORAL B-brand B-brand
Tablets O O
and O O
other O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
: O O
Ketoconazole B-drug B-drug
tablets O O
inhibit O O
the O O
metabolism O O
of O O
terfenadine B-drug B-drug
, O O
resulting O O
in O O
an O O
increased O O
plasma O O
concentration O O
of O O
terfenadine B-drug B-drug
and O O
a O O
delay O O
in O O
the O O
elimination O O
of O O
its O O
acid O O
metabolite O O
. O O

Cmax O O
and O O
t1/2 O B-drug
were O O
increased O O
1.4-fold O O
and O O
1.3-fold O O
, O O
respectively O O
. O O

Pharmacokinetic O O
interactions O O
between O O
nisoldipine B-drug B-drug
and O O
beta-blockers B-group B-group
( O O
atenolol B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
were O O
variable O O
and O O
not O O
significant O O
. O O

Theophylline-related B-drug O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
when O O
theophylline B-drug B-drug
and O O
enoxacin B-drug B-drug
were O O
coadministered O O
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Example O O
inhibitors O B-group
include O O
azole B-group B-group
antifungals I-group I-group
, O O
ciprofloxacin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
diclofenac B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
imatinib B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
propofol B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
quinidine B-drug B-drug
, O O
and O O
verapamil B-drug B-drug
. O O

Effect O O
of O O
diazepam B-drug B-drug
and O O
midazolam B-drug B-drug
on O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
, O O
metamizol B-drug B-drug
and O O
indomethacin B-drug B-drug
in O O
mice O O
. O O

When O O
encountered O O
, O O
such O O
arrhythmias O O
may O O
respond O O
to O O
administration O O
of O O
a O O
beta-adrenergic B-group B-group
blocking I-group I-group
drug I-group I-group
. O O

The O O
clinical O O
significance O O
is O O
unknown O O
. O O

Cytochrome O O
P-450 O O
inducers O O
, O O
such O O
as O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
and O O
phenobarbital B-drug B-drug
, O O
induce O O
clonazepam B-drug B-drug
metabolism O O
, O O
causing O O
an O O
approximately O O
30 O O
% O O
decrease O O
in O O
plasma O O
clonazepam B-drug B-drug
levels O O
. O O

Binding O O
to O O
plasma O O
protein O O
is O O
not O O
significantly O O
altered O O
by O O
diazepam B-drug B-drug
, O O
diphenylhydantoin B-drug B-drug
, O O
or O O
phenylbutazone B-drug B-drug
. O O

Immunogenicity/Re-exposure O O
: O O
In O O
in O O
vitro O O
studies O O
, O O
Angiomax B-brand B-brand
exhibited O O
no O O
platelet O O
aggregation O O
response O O
against O O
sera O O
from O O
patients O O
with O O
a O O
history O O
of O O
HIT/HITTS O O
. O O

Concomitant O O
administration O O
of O O
other O O
sympathomimetic B-group B-group
agents I-group I-group
may O O
potentiate O O
the O O
undesirable O O
effects O O
of O O
FORADIL B-brand B-brand
. O O

Doxylamine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
epinephrine B-drug B-drug
. O O

Rare O O
instances O O
of O O
dyspnea O O
, O O
palpitation O O
, O O
chest O O
pain O O
, O O
syncope O O
. O O

Nevertheless O O
, O O
the O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
monitored O O
when O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
and O O
enoxacin B-drug B-drug
are O O
given O O
concomitantly O O
. O O

These O O
agents O O
should O O
not O O
be O O
taken O O
within O O
4 O O
hours O O
before O O
or O O
4 O O
hours O O
after O O
grepafloxacin B-drug B-drug
administration O O
. O O

Amiodarone B-drug B-drug
taken O O
concomitantly O O
with O O
quinidine B-drug B-drug
increases O O
quinidine B-drug B-drug
serum O O
concentration O O
by O O
33 O O
% O O
after O O
two O O
days O O
. O O

If O O
antacid B-group B-group
therapy O O
is O O
needed O O
, O O
the O O
antacid O B-group
dose O O
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
prior O O
to O O
or O O
2 O O
hours O O
after O O
the O O
dose O O
of O O
SPRYCEL B-brand B-brand
. O O

Although O O
17-hydroxy-corticosteroid O O
measurements O O
( O O
Porter-Silber O O
test O O
) O O
do O O
not O O
appear O O
to O O
be O O
artifactually O O
altered O O
, O O
it O O
is O O
suggested O O
that O O
therapy O O
with O O
naproxen B-drug B-drug
be O O
temporarily O O
discontinued O O
72 O O
hours O O
before O O
adrenal O O
function O O
tests O O
are O O
performed O O
if O O
the O O
Porter-Silber O O
test O O
is O O
to O O
be O O
used O O
. O O

Rifampin B-drug B-drug
, O O
an O O
inducer O O
of O O
drug O O
metabolism O O
, O O
decreased O O
the O O
concentrations O O
of O O
losartan B-drug B-drug
and O O
its O O
active O O
metabolite O O
. O O

Drugs O O
Whose O O
Absorption O O
Can O O
Be O O
Affected O O
by O O
the O O
Level O O
of O O
Acidity O O
in O O
the O O
Stomach O O
: O O
Drugs O O
such O O
as O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
prior O O
to O O
dosing O O
with O O
VIDEX B-brand B-brand
. O O

Vaccinations O O
with O O
attenuated O O
live O O
bacteria O O
should O O
therefore O O
be O O
completed O O
at O O
least O O
3 O O
days O O
before O O
the O O
first O O
dose O O
of O O
Mefloquine B-drug B-drug
. O O

Additional O O
reductions O O
in O O
blood O O
pressure O O
may O O
occur O O
when O O
FLOLAN B-brand B-brand
is O O
administered O O
with O O
diuretics B-group B-group
, O O
antihypertensive B-group B-group
agents I-group I-group
, O O
or O O
other O O
vasodilators B-group B-group
. O O

The O O
inhibitor O O
, O O
on O O
the O O
other O O
hand O O
, O O
promoted O O
significant O O
decrease O O
of O O
nucleolin/C23 O O
in O O
NIH-3T3 O O
cells O O
during O O
serum O O
deprivation O O
. O O

Candida O O
albicans O O
, O O
one O O
of O O
the O O
pathogenic O O
species O O
, O O
was O O
totally O O
inhibited O O
at O O
a O O
concentration O O
of O O
approximately O O
10 O O
mug/ml O O
. O O

certain O O
antibiotics B-group B-group
, O O
especially O O
the O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
; O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

The O O
AUC O O
of O O
eszopiclone B-drug B-drug
was O O
increased O O
2.2-fold O O
by O O
coadministration O O
of O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
400 O O
mg O O
daily O O
for O O
5 O O
days O O
. O O

Lopinavir I-drug B-drug

Particular O O
caution O O
is O O
necessary O O
when O O
using O O
ROMAZICON B-brand B-brand
in O O
cases O O
of O O
mixed O O
drug O O
overdosage O O
since O O
the O O
toxic O O
effects O O
( O O
such O O
as O O
convulsions O O
and O O
cardiac O O
dysrhythmias O O
) O O
of O O
other O O
drugs O O
taken O O
in O O
overdose O O
( O O
especially O O
cyclic B-group B-group
antidepressants I-group I-group
) O O
may O O
emerge O O
with O O
the O O
reversal O O
of O O
the O O
benzodiazepine B-group B-group
effect O O
by O O
flumazenil B-drug B-drug
. O O

The O O
second O O
response O O
is O O
due O O
to O O
a O O
release O O
of O O
norepinephrine O B-drug
from O O
nerves O O
and O O
was O O
potentiated O O
by O O
ouabain B-drug B-drug
through O O
the O O
increase O O
in O O
the O O
norepinephrine O O
release O O
, O O
whereas O O
the O O
first O O
response O O
was O O
not O O
due O O
to O O
the O O
norepinephrine O B-drug
release O O
but O O
presumably O O
to O O
a O O
direct O O
action O O
on O O
smooth O O
muscle O O
cell O O
and O O
was O O
inhibited O O
by O O
ouabain B-drug B-drug
. O O

Oral O O
contraceptives B-group B-group
and O O
other O O
hormonalmethods O O
of O O
birth O O
control O O
should O O
not O O
be O O
usedas O O
the O O
sole O O
method O O
of O O
contraception O O
inwomen O O
taking O O
nevirapine B-drug B-drug
, O O
since O O
nevirapinemay O O
lower O O
the O O
plasma O O
levels O O
of O O
thesemedications O O
. O O

Therefore O O
, O O
the O O
potential O O
for O O
such O O
drug O O
interactions O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
dorzolamide B-drug B-drug
. O O

Human I-drug O
growth I-drug O
hormone I-drug O
- O O
Concomitant O O
use O O
of O O
L-glutamine B-drug B-drug
and O O
human B-drug O
growth I-drug O
hormone I-drug O
may O O
enhance O O
nutrient O O
absorption O O
in O O
those O O
with O O
severe O O
short O O
bowel O O
syndrome O O
. O O

No O O
effects O O
on O O
plasma O O
concentrations O O
of O O
cimetidine B-drug B-drug
or O O
ketoconazole B-drug B-drug
were O O
observed O O
. O O

amphotericin B-drug B-drug
B I-drug I-drug
, O O
however O O
, O O
is O O
useful O O
in O O
therapy O O
of O O
human O O
fungal O O
infections O O
because O O
it O O
is O O
less O O
toxic O O
. O O

Administration O O
of O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
concomitantly O O
with O O
cyclosporine B-drug B-drug
has O O
been O O
associated O O
with O O
an O O
increase O O
in O O
cyclosporine-induced B-drug B-drug
toxicity O O
, O O
possibly O O
due O O
to O O
decreased O O
synthesis O O
of O O
renal O O
prostacyclin O O
. O O

No O O
studies O O
have O O
been O O
performed O O
with O O
other O O
NNRTIs B-group B-group
. O O

Nicotine B-drug B-drug
: O O
Nicotine B-drug B-drug
may O O
provoke O O
vasoconstriction O O
in O O
some O O
patients O O
, O O
predisposing O O
to O O
a O O
greater O O
ischemic O O
response O O
to O O
ergot B-drug B-group
therapy O O
. O O

8 O O
. O O

Because O O
of O O
the O O
broadening O O
indications O O
for O O
immunosuppressive B-group B-group
drugs I-group I-group
, O O
and O O
the O O
prolonged O O
survival O O
in O O
conditions O O
for O O
which O O
they O O
are O O
being O O
used O O
, O O
many O O
patients O O
on O O
immunosuppression O O
are O O
now O O
cared O O
for O O
in O O
the O O
community O O
or O O
seen O O
in O O
non-specialist O O
hospitals O O
, O O
usually O O
in O O
close O O
collaboration O O
with O O
a O O
specialist O O
. O O

A O O
causal O O
relationship O O
has O O
not O O
been O O
established O O

Therefore O O
, O O
there O O
is O O
a O O
potential O O
for O O
an O O
in O O
vivo O O
drug O O
interaction O O
with O O
drugs O O
that O O
are O O
metabolized O O
by O O
P450 O O
2D6 O O
. O O

Verapamil B-drug B-drug
: O O
Concomitant O O
use O O
of O O
verapamil B-drug B-drug
is O O
contraindicated O O
. O O

( O O
500 O O
mg O O
Q8h O O
) O O

Duloxetine B-drug B-drug
May O O
Have O O
a O O
Clinically O O
Important O O
Interaction O O
with O O
the O O
Following O O
Other O O
Drugs O O
: O O
Alcohol B-drug B-drug
: O O
When O O
Duloxetine B-drug B-drug
and O O
ethanol B-drug B-drug
were O O
administered O O
several O O
hours O O
apart O O
so O O
that O O
peak O O
concentrations O O
of O O
each O O
would O O
coincide O O
, O O
Duloxetine B-drug B-drug
did O O
not O O
increase O O
the O O
impairment O O
of O O
mental O O
and O O
motor O O
skills O O
caused O O
by O O
alcohol B-drug B-drug
. O O

On O O
the O O
basis O O
of O O
the O O
metabolism O O
of O O
bexarotene B-drug B-drug
by O O
cytochrome O O
P450 O O
3A4 O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
gemfibrozil B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
and O O
other O O
inhibitors O O
of O O
cytochrome O O
P450 O O
3A4 O O
would O O
be O O
expected O O
to O O
lead O O
to O O
an O O
increase O O
in O O
plasma O O
bexarotene B-drug B-drug
concentrations O O
. O O

- O O
Decreased O O
pregnanediol O B-drug
excretion O O

The O O
incidence O O
of O O
upper O O
gastrointestinal O O
events O O
in O O
patients O O
concomitantly O O
taking O O
aspirin B-brand B-brand
or O O
NSAIDs B-group B-group
was O O
similar O O
in O O
patients O O
taking O O
ibandronate B-drug B-drug
2.5 O O
mg O O
daily O O
( O O
21.7 O O
% O O
) O O
and O O
150 O O
mg O O
once O O
monthly O O
( O O
22.0 O O
% O O
) O O
. O O

Oral O O
Contraceptive B-group B-group
: O O
Based O O
on O O
AUC O O
and O O
half-life O O
, O O
multiple-dose O O
pharmacokinetic O O
profiles O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
following O O
administration O O
of O O
tablets O O
containing O O
2.5 O O
mg O O
of O O
norethindrone B-drug B-drug
acetate I-drug I-drug
and O O
50 O O
mcg O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
were O O
similar O O
with O O
and O O
without O O
coadministration O O
of O O
gabapentin B-drug B-drug
( O O
400 O O
mg O O
TID O O
; O O

Drugs O O
That O O
Are O O
Mainly O O
Metabolized O O
by O O
CYP3A4 O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
quinolone B-group B-group
use O O
. O O

Because O O
lithium B-drug B-drug
may O O
enhance O O
the O O
serotonergic O O
effects O O
of O O
escitalopram B-drug B-drug
, O O
caution O O
should O O
be O O
exercised O O
when O O
LEXAPRO B-brand B-brand
and O O
lithium B-drug B-drug
are O O
coadministered O O
. O O

Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
VIRACEPT B-brand B-brand
Antiarrhythmics B-group B-group
: O O
amiodarone B-drug B-drug
, O O
quinidine B-drug B-drug
Antihistamines B-group B-group
: O O
astemizole B-drug B-drug
, O O
terfenadine B-drug B-drug
Antimigraine O I-drug
: O O
ergot B-group B-group
derivatives I-group I-group
Antimycobacterial I-group I-group
agents I-group I-group
: O O
rifampin B-drug B-drug
Benzodiazepines B-group B-group
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug
GI O O
motility O O
agents O O
: O O
cisapride B-drug B-drug

Poor O O
metabolizers O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
TCAs B-group B-group
) O O
when O O
given O O
usual O O
doses O O
. O O

Cercarial O B-brand
encystment O O
at O O
concentrations O O
of O O
25000 O O
microg/l O O
or O O
higher O O
was O O
significantly O O
impaired O O
by O O
all O O
test O O
metals O O
; O O

Hyperpyrexia O O
has O O
been O O
reported O O
when O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
is O O
administered O O
with O O
anticholinergic B-drug B-group
agents O I-group
or O O
with O O
neuroleptic B-drug B-group
drugs O I-group
, O O
particularly O O
during O O
hot O O
weather O O
. O O

Some O O
clinicians O O
have O O
noted O O
that O O
these O O
reactions O O
resemble O O
the O O
immediate O O
side O O
effects O O
caused O O
by O O
interleukin-2 B-drug B-drug
administration O O
, O O
however O O
the O O
cause O O
of O O
contrast O O
reactions O O
after O O
interleukin-2 O B-drug
therapy O O
is O O
unknown O O
. O O

The O O
anxiogenic O O
effects O O
of O O
theophylline B-drug B-drug
were O O
reduced O O
by O O
pretreatment O O
with O O
CGS B-drug_n B-drug
21680 I-drug_n I-drug
, O O
an O O
A2-selective O O
agonist O O
, O O
but O O
not O O
by O O
N6-cyclopentyladenosine B-drug_n B-drug_n
( O O
CPA B-drug_n B-drug_n
) O O
, O O
an O O
A1-selective O B-group
agonist O I-group
. O O

CNS O O
vascular O O
lesions O O
, O O
characterized O O
by O O
perivascular O O
hemorrhages O O
, O O
edema O O
, O O
and O O
mononuclear O O
cell O O
infiltration O O
of O O
perivascular O O
spaces O O
, O O
have O O
been O O
observed O O
in O O
dogs O O
treated O O
with O O
other O O
members O O
of O O
this O O
class O O
. O O

Ketamine B-drug B-drug
is O O
clinically O O
compatible O O
with O O
the O O
commonly O O
used O O
general O O
and O O
local O O
anesthetic B-group B-group
agents I-group I-group
when O O
an O O
adequate O O
respiratory O O
exchange O O
is O O
maintained O O
. O O

Erythromycin B-drug B-drug

increased O O
plasminogen O O
antigen O O
and O O
activity O O
. O O

Although O O
there O O
was O O
no O O
clinical O O
evidence O O
in O O
the O O
vehicle-controlled O O
studies O O
of O O
drug O O
interactions O O
with O O
systemic O B-group
antiretroviral B-group I-group
agents I-group I-group
, O O
including O O
protease B-group B-group
inhibitors I-group I-group
, O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
and O O
azole B-group B-group
antifungals I-group I-group
, O O
the O O
effect O O
of O O
Panretin B-brand B-brand
gel O O
on O O
the O O
steady-state O O
concentrations O O
of O O
these O O
drugs O O
is O O
not O O
known O O
. O O

In O O
contrast O O
, O O
acute O O
toxicity O O
tests O O
showed O O
that O O
oral O O
CCNU B-drug B-drug
was O O
1.45 O O
times O O
less O O
toxic O O
to O O
normal O O
tissue O O
, O O
although O O
the O O
dose-limiting O O
organ O O
may O O
be O O
different O O
for O O
the O O
two O O
routes O O
. O O

Levodopa B-drug B-drug
and O O
Amantadine B-drug B-drug
: O O
Limited O O
clinical O O
data O O
suggest O O
a O O
higher O O
incidence O O
of O O
adverse O O
experiences O O
in O O
patients O O
receiving O O
bupropion B-drug B-drug
concurrently O O
with O O
either O O
levodopa B-drug B-drug
or O O
amantadine B-drug B-drug
. O O

In O O
patients O O
receiving O O
another O O
serotonin B-group B-group
reuptake I-group I-group
inhibitor I-group I-group
drug I-group I-group
in O O
combination O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOI B-group B-group
) O O
, O O
there O O
have O O
been O O
reports O O
of O O
serious O O
, O O
sometimes O O
fatal O O
, O O
reactions O O
including O O
hyperthermia O O
, O O
rigidity O O
, O O
myoclonus O O
, O O
autonomic O O
instability O O
with O O
possible O O
rapid O O
fluctuations O O
of O O
vital O O
signs O O
, O O
and O O
mental O O
status O O
changes O O
that O O
include O O
extreme O O
agitation O O
progressing O O
to O O
delirium O O
and O O
coma O O
. O O

In O O
addition O O
, O O
several O O
AED B-group B-group
s O O
that O O
are O O
cytochrome O O
P450 O O
inducers O O
can O O
decrease O O
plasma O O
concentrations O O
of O O
oxcarbazepine B-drug B-drug
and O O
MHD B-drug_n B-drug_n
. O O

Administer O O
LEVSIN B-brand B-brand
before O O
meals O O
; O O

No O O
studies O O
have O O
been O O
conducted O O
at O O
intermediate O O
doses O O
of O O
cimetidine B-drug B-drug
. O O

Inhibition O O
of O O
metabolism O O
may O O
produce O O
significant O O
increases O O
in O O
circulating O O
phenytoin B-drug B-drug
concentrations O O
and O O
enhance O O
the O O
risk O O
of O O
drug O O
toxicity O O
. O O

The O O
mechanism O O
for O O
this O O
interaction O O
is O O
not O O
known O O
. O O

In O O
ewes O O
given O O
40 O O
mg O O
of O O
phenobarbital B-drug B-drug
sodium/kg O I-drug
for O O
5 O O
days O O
intraperitoneally O O
( O O
IP O O
) O O
, O O
the O O
anticholinesterase O O
effect O O
of O O
4 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
was O O
significantly O O
reduced O O
and O O
signs O O
of O O
toxicity O O
were O O
not O O
present O O
. O O

There O O
also O O
was O O
no O O
effect O O
on O O
exposure O O
to O O
and O O
the O O
excretion O O
of O O
the O O
primary O O
metabolite O O
, O O
ucb O O
L057 O O
. O O

Chlorthalidone B-drug B-drug
may O O
add O O
to O O
or O O
potentiate O O
the O O
action O O
of O O
other O O
antihypertensive B-group B-group
drugs I-group I-group
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
. O O

OBJECTIVE O O
: O O
Our O O
objective O O
was O O
to O O
characterize O O
the O O
steady-state O O
pharmacokinetics O O
of O O
everolimus B-drug B-drug
and O O
cyclosporine B-drug B-drug
( O O
INN O O
, O O
ciclosporin B-drug B-drug
) O O
when O O
coadministered O O
in O O
de O O
novo O O
kidney O O
allograft O O
recipients O O
during O O
the O O
first O O
year O O
after O O
transplantation O O
. O O

Adrenocorticoids O B-group
: O O
Metabolic O O
clearance O O
of O O
adrenocorticoids O B-group
is O O
decreased O O
in O O
hypothyroid O O
patients O O
and O O
increased O O
in O O
hyperthyroid O O
patients O O
, O O
and O O
may O O
therefore O O
change O O
with O O
changing O O
thyroid O O
status O O
. O O

The O O
physician O O
should O O
be O O
notified O O
immediately O O
if O O
any O O
of O O
the O O
following O O
situations O O
occur O O
, O O
which O O
may O O
be O O
a O O
sign O O
of O O
seriously O O
worsening O O
asthma O O
: O O
Decreased O O
effectiveness O O
of O O
short-acting B-group O
, I-group O
inhaled I-group O
beta2-agonists I-group B-group
; O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

The O O
steady-state O O
Cmin O O
concentration O O
increased O O
to O O
17.8 O O
micrograms/mL O O
when O O
2400 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
for O O
one O O
week O O
. O O

Lithium B-drug B-drug
- O O
Coadministration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
10 O O
days O O
) O O
and O O
lithium B-drug B-drug
( O O
30 O O
mmol/day O O
for O O
5 O O
days O O
) O O
had O O
no O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
or O O
lithium B-drug B-drug
. O O

Avoid O O
the O O
use O O
of O O
preparations O O
such O O
as O O
decongestants B-group B-group
and O O
local O O
anesthetics B-group B-group
which O O
contain O O
any O O
sympathomimetic B-group B-group
amine I-group I-group
( O O
e.g. O O
, O O
epinephrine B-drug B-drug
, O O
norepinephrine B-drug B-drug
) O O
, O O
since O O
it O O
has O O
been O O
reported O O
that O O
tricyclic B-group B-group
antidepressants I-group I-group
can O O
potentiate O O
the O O
effects O O
of O O
catecholamines O B-group
. O O

The O O
para-aminobenzoic O O
acid O O
metabolite O O
of O O
chloroprocaine O B-drug
inhibits O O
the O O
action O O
of O O
sulfonamides B-group B-group
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
during O O
therapy O O
with O O
lithium B-drug B-drug
. O O

Use O O
with O O
caution O O
and O O
be O O
prepared O O
to O O
treat O O
hypertension O O
, O O
if O O
necessary O O
. O O

Gastrointestinal O B-group
agents O I-group
( O O
e.g. O O
, O O
antacids B-group B-group
) O O
. O O

- O O
Daunorubicin B-drug B-drug
( O O
e.g. O O
, O O
Cerubidine B-brand B-brand
) O O
or O O

Pediatric O O
Use O O
The O O
safety O O
and O O
effectiveness O O
of O O
PEGASYS B-brand B-brand
, O O
alone O O
or O O
in O O
combination O O
with O O
COPEGUS B-brand B-brand
in O O
patients O O
below O O
the O O
age O O
of O O
18 O O
years O O
have O O
not O O
been O O
established O O
. O O

Prolonged O O
menstrual O O
cycles O O
and/or O O
amenorrhea O O
were O O
observed O O
in O O
female O O
cynomolgus O O
monkeys O O
given O O
sc O O
injections O O
of O O
600 O O
m O O
g/kg/dose O O
( O O
7200 O O
m O O
g/m2/dose O O
) O O
of O O
PEGASYS B-brand B-brand
every O O
other O O
day O O
for O O
one O O
month O O
, O O
at O O
approximately O O
180 O O
times O O
the O O
recommended O O
weekly O O
human O O
dose O O
for O O
a O O
60 O O
kg O O
person O O
( O O
based O O
on O O
body O O
surface O O
area O O
) O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
using O O
these O O
drugs O O
together O O
. O O

Alternatives O O
to O O
rifampin B-drug B-drug
should O O
be O O
considered O O
during O O
the O O
course O O
of O O
PCP O B-drug_n
treatment O O
with O O
MEPRON B-brand B-brand
. O O

Component O O
P2 O O
, O O
however O O
, O O
was O O
increased O O
in O O
amplitude O O
. O O

In O O
utero O O
, O O
serum O O
levels O O
of O O
exposure O O
in O O
these O O
monkeys O O
were O O
23 O O
% O O
of O O
maternal O O
serum O O
levels O O
. O O

Patients O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
require O O
higher O O
doses O O
of O O
thyroid B-group B-group
hormone I-group I-group
. O O

Coadministration O O
of O O
LEXAPRO B-brand B-brand
and O O
metoprolol B-drug B-drug
had O O
no O O
clinically O O
significant O O
effects O O
on O O
blood O O
pressure O O
or O O
heart O O
rate O O
. O O

NaCMC B-drug_n B-drug_n
at O O
1 O O
% O O
( O O
m/v O O
) O O
in O O
the O O
presence O O
of O O
free O O
cysteine B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
the O O
R-value O O
of O O
NaFlu B-drug B-drug
compared O O
to O O
NaCMC B-drug_n B-drug_n
alone O O
. O O

It O O
is O O
recommended O O
that O O
these O O
tests O O
be O O
performed O O
prior O O
to O O
initiation O O
of O O
Soriatane B-brand B-brand
therapy O O
, O O
at O O
1- O O
to O O
2-week O O
intervals O O
until O O
stable O O
and O O
thereafter O O
at O O
intervals O O
as O O
clinically O O
indicated O O
. O O

24.9 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
4.5 O O
) O O
were O O
PICR O O
, O O
detected O O
in O O
11.7 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
2.5 O O
) O O
of O O
the O O
MAC O O
. O O

Data O O
beyond O O
10 O O
days O O
are O O
not O O
available O O
. O O

Each O O
month O O
of O O
therapy O O
, O O
the O O
patient O O
must O O
have O O
a O O
negative O O
result O O
from O O
a O O
urine O O
or O O
serum O O
pregnancy O O
test O O
. O O

When O O
intravenous O O
morphine B-drug B-drug
and O O
BREVIBLOC B-brand B-brand
were O O
concomitantly O O
administered O O
in O O
normal O O
subjects O O
, O O
no O O
effect O O
on O O
morphine B-drug B-drug
blood O O
levels O O
was O O
seen O O
, O O
but O O
BREVIBLOC B-brand B-brand
steady-state O O
blood O O
levels O O
were O O
increased O O
by O O
46 O O
% O O
in O O
the O O
presence O O
of O O
morphine B-drug B-drug
. O O

Because O O
of O O
the O O
pronounced O O
intersubject O O
variability O O
in O O
the O O
extent O O
of O O
the O O
sirolimus-diltiazem B-drug B-drug
interaction O O
, O O
whole O O
blood O O
sirolimus B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
treated O O
with O O
the O O
two O O
drugs O O
. O O

Effect O O

Therefore O O
, O O
patients O O
receiving O O
probenecid B-drug B-drug
will O O
have O O
erroneously O O
low O O
ERPF O O
and O O
Tm O O
PAH B-drug O
values O O
. O O

Drug-Drug O O
Interactions O O
: O O
No O O
clinically O O
significant O O
drug O O
interactions O O
have O O
been O O
found O O
with O O
theophylline B-drug B-drug
at O O
a O O
low O O
dose O O
, O O
azithromycin B-drug B-drug
, O O
pseudoephedrine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
or O O
erythromycin B-drug B-drug
. O O

Drug O O
and O O
Laboratory O O
Test O O
Interactions O O
1 O O
. O O

Drug O O
interactions O O
with O O
SUSTIVA B-brand B-brand
are O O
summarized O O
in O O
Table O O
5 O O
. O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Inhibitors O O
of O O
the O O
CYP3A4 O O
isoenzyme O O
could O O
increase O O
systemic O O
dofetilide B-drug B-drug
exposure O O
. O O

Furosemide B-drug B-drug
has O O
a O O
tendency O O
to O O
antagonize O O
the O O
skeletal O O
muscle O O
relaxing O O
effect O O
of O O
tubocurarine B-drug B-drug
and O O
may O O
potentiate O O
the O O
action O O
of O O
succinylcholine B-drug B-drug
. O O

The O O
concomitant O O
use O O
of O O
diflunisal B-drug B-drug
tablets O O
and O O
other O O
NSAIDs B-group B-group
is O O
not O O
recommended O O
due O O
to O O
the O O
increased O O
possibility O O
of O O
gastrointestinal O O
toxicity O O
, O O
with O O
little O O
or O O
no O O
increase O O
in O O
efficacy O O
. O O

Therefore O O
, O O
a O O
slower O O
onset O O
can O O
be O O
anticipated O O
if O O
STADOL B-brand B-brand
NS I-brand I-brand
is O O
administered O O
concomitantly O O
with O O
, O O
or O O
immediately O O
following O O
, O O
a O O
nasal B-group B-group
vasoconstrictor I-group I-group
. O O

Smokers O O
have O O
an O O
increased O O
clearance O O
of O O
benzodiazepines B-group B-group
as O O
compared O O
to O O
nonsmokers O O
; O O

In O O
post-marketing O O
experience O O
there O O
have O O
been O O
reports O O
of O O
increases O O
in O O
plasma O O
lithium B-drug B-drug
levels O O
. O O

periodic O O
monitoring O O
of O O
anticonvulsant B-group B-group
plasma O O
levels O O
should O O
be O O
conducted O O
. O O

Patients O O
receiving O O
azathioprine B-drug B-drug
and O O
allopurinol B-drug B-drug
concomitantly O O
should O O
have O O
a O O
dose O O
reduction O O
of O O
azathioprine B-drug B-drug
, O O
to O O
approximately O O
1/3 O O
to O O
1/4 O O
the O O
usual O O
dose O O
. O O

These O O
stimulants O O
are O O
commonly O O
found O O
in O O
coffee O O
and O O
tea O B-drug
, O O
respectively O O
. O O

The O O
pharmacodynamic O O
effects O O
can O O
be O O
explained O O
by O O
a O O
combination O O
of O O
the O O
increase O O
in O O
dofetilide B-drug B-drug
exposure O O
and O O
the O O
reductions O O
in O O
serum O O
potassium O O
. O O

In O O
about O O
30 O O
% O O
of O O
patients O O
, O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
had O O
to O O
be O O
reduced O O
in O O
order O O
to O O
maintain O O
cyclosporine B-drug B-drug
concentrations O O
within O O
the O O
therapeutic O O
range O O
, O O
while O O
in O O
the O O
remainder O O
no O O
adjustment O O
was O O
needed O O
. O O

The O O
pharmacokinetics O O
of O O
fluvastatin B-drug B-drug
have O O
also O O
been O O
assessed O O
in O O
various O O
demographic O O
groups O O
. O O

Potential O O
drug O O
interactions O O
between O O
Mentax B-brand B-brand
( O O
butenafine B-drug B-drug
HCl I-drug I-drug
cream O O
) O O
Cream O O
, O O
1 O O
% O O
, O O
and O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

( O O
Thiazides B-group B-group
may O O
decrease O O
arterial O O
responsiveness O O
to O O
norepinephrine B-drug B-drug
. O O

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
with O O
aminoglycoside B-group B-group
antibiotics I-group I-group
or O O
potent O O
diuretics B-group B-group
such O O
as O O
furosemide B-drug B-drug
. O O

. O O

Lithium-A B-drug O
drug O O
interaction O O
study O O
of O O
eplerenone B-drug B-drug
with O O
lithium B-drug B-drug
has O O
not O O
been O O
conducted O O
. O O

The O O
acid-catalyzed O O
ethanol-drug B-drug O
reaction O O
is O O
a O O
relatively O O
unexplored O O
area O O
and O O
may O O
alter O O
the O O
pharmacological O O
action O O
of O O
some O O
drugs O O
. O O

Immunosuppressants B-group B-group

Intestinal B-group O
adsorbents I-group O
( O O
e. O O
g. O O
, O O
charcoal B-drug B-drug
) O O
and O O
digestive B-group O
enzyme I-group O
preparations I-group O
containing O O
carbohydrate-splitting O O
enzymes O O
( O O
e. O O
g. O O
, O O
amylase B-drug O
, O O
pancreatin B-drug O
) O O
may O O
reduce O O
the O O
effect O O
of O O
Acarbose B-drug B-drug
and O O
should O O
not O O
be O O
taken O O
concomitantly O O
. O O

The O O
augmentation O O
persisted O O
even O O
after O O
carbachol B-drug B-drug
was O O
washed O O
out O O
and O O
was O O
resistant O O
to O O
chelated O O
extracellular O O
Ca O O
( O O
2+ O O
) O O
and O O
to O O
inhibitors O O
of O O
either O O
protein O O
kinase O O
C O O
or O O
calmodulin O B-drug
kinase O I-drug
II O I-drug
. O O

Much O O
higher O O
changes O O
were O O
observed O O
in O O
liver O O
, O O
increasing O O
from O O
a O O
level O O
of O O
60 O O
% O O
at O O
4 O O
h O O
up O O
to O O
nearly O O
4 O O
times O O
the O O
control O O
at O O
24 O O
h O O
for O O
single O O
dose O O
. O O

BACKGROUND O O
: O O
The O O
effects O O
of O O
combined O O
administration O O
of O O
bombesin B-drug_n B-drug_n
and O O
verapamil B-drug B-drug
hydrochloride I-drug I-drug
( O O
verapamil B-drug B-drug
) O O
, O O
a O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
, O O
on O O
the O O
incidence O O
of O O
peritoneal O O
metastasis O O
of O O
intestinal O O
adenocarcinomas O O
induced O O
by O O
azoxymethane B-drug_n B-drug_n
( O O
AOM B-drug_n B-drug_n
) O O
and O O
the O O
labeling O O
index O O
of O O
intestinal O O
cancers O O
were O O
investigated O O
in O O
male O O
Wistar O O
rats O O
. O O

Exjade B-brand B-brand
tablets O O
for O O
oral O O
suspension O O
can O O
be O O
dispersed O O
in O O
water O O
, O O
orange O O
juice O O
, O O
or O O
apple O O
juice O O
. O O

Since O O
apraclonidine B-drug B-drug
may O O
reduce O O
pulse O O
and O O
blood O O
pressure O O
, O O
caution O O
in O O
using O O
drugs O O
such O O
as O O
beta-blockers B-group B-group
( O O
ophthalmic O O
and O O
systemic O O
) O O
, O O
antihypertensives B-group B-group
, O O
and O O
cardiac B-group B-group
glycosides I-group I-group
is O O
advised O O
. O O

The O O
administration O O
of O O
lower O O
doses O O
of O O
Vardenafil B-drug B-drug
with O O
alpha-blockers B-group B-group
has O O
not O O
been O O
completely O O
evaluated O O
to O O
determine O O
if O O
they O O
can O O
be O O
safely O O
administered O O
together O O
. O O

Ascorbic B-drug B-drug
acid I-drug I-drug
: O O
Doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
( O O
vitamin B-drug B-drug
C I-drug I-drug
) O O
1 O O
g/day O O
have O O
been O O
reported O O
to O O
increase O O
plasma O O
concentration O O
of O O
synthetic B-group B-group
estrogens I-group I-group
by O O
~47 O O
% O O
, O O
possibly O O
by O O
inhibiting O O
conjugation O O
; O O

In O O
patients O O
with O O
impaired O O
cardiac O O
function O O
, O O
simultaneous O O
use O O
should O O
be O O
avoided O O
altogether O O
. O O

Investigations O O
into O O
the O O
effect O O
of O O
acitretin B-drug B-drug
on O O
the O O
protein O O
binding O O
of O O
anticoagulants B-group B-group
of I-group O
the I-group O
coumarin I-group B-group
type I-group I-group
( O O
warfarin B-drug B-drug
) O O
revealed O O
no O O
interaction O O
. O O

In O O
order O O
to O O
avoid O O
lithium B-drug B-drug
intoxication O O
, O O
lithium B-drug B-drug
plasma O O
levels O O
should O O
be O O
monitored O O
closely O O
. O O

2 O O
. O O

THE O O
DOSAGE O O
OF O O
THE O O
ANTICOAGULANTS B-group B-group
SHOULD O O
BE O O
REDUCED O O
TO O O
MAINTAIN O O
THE O O
PROTHROMBIN O O
TIME/INR O O
AT O O
THE O O
DESIRED O O
LEVEL O O
TO O O
PREVENT O O
BLEEDING O O
COMPLICATIONS O O
. O O

The O O
literature O O
provides O O
considerable O O
evidence O O
indicating O O
that O O
several O O
, O O
but O O
not O O
all O O
antihistaminics B-group B-group
, O O
are O O
indeed O O
analgesic B-group B-group
agents I-group I-group
and O O
some O O
are O O
analgesic B-group B-group
adjuvants I-group I-group
as O O
well O O
. O O

Two O O
of O O
16 O O
subjects O O
dosed O O
simultaneously O O
with O O
Vardenafil B-drug B-drug
10 O O
mg O O
and O O
tamsulosin B-drug B-drug
0.4 O O
mg O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

Thirty O O
male O O
rats O O
of O O
the O O
Fischer-344 O O
strain O O
were O O
divided O O
into O O
three O O
equal O O
groups O O
and O O
were O O
given O O
injections O O
of O O
trimethyl B-drug_n B-drug
lead I-drug_n I-drug
( O O
TML B-drug_n B-drug_n
) O O
( O O
8.0 O O
or O O
17.0 O O
mg/kg/ml O O
SC O O
) O O
or O O
the O O
saline O O
vehicle O O
. O O

Antacids B-group B-group
and O O
sucralfate B-drug B-drug
: O O
Sucralfate B-drug B-drug
and O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
, O O
as O O
well O O
as O O
formulations O O
containing O O
divalent O O
and O O
trivalent O O
cations O O
such O O
as O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
, O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
can O O
form O O
chelation O O
complexes O O
with O O
lomefloxacin B-drug B-drug
and O O
interfere O O
with O O
its O O
bioavailability O O
. O O

Flecainide B-drug B-drug
is O O
not O O
extensively O O
bound O O
to O O
plasma O O
proteins O O
. O O

In O O
well-controlled O O
patients O O
undergoing O O
concurrent O O
therapy O O
with O O
cimetidine B-drug B-drug
, O O
a O O
decrease O O
in O O
the O O
steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
occur O O
when O O
cime-tidine O B-drug
therapy O O
is O O
discontinued O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

Other O O
: O O
Concomitant O O
alcohol B-drug B-drug
or O O
hot O O
drinks O O
may O O
increase O O
the O O
side O O
effects O O
of O O
flushing O O
and O O
pruritus O O
and O O
should O O
be O O
avoided O O
at O O
the O O
time O O
of O O
drug O O
ingestion O O
. O O

Furosemide B-drug B-drug
: O O
TORADOL B-brand B-brand
IV/IM O O
reduced O O
the O O
diuretic B-group B-group
response O O
to O O
furosemide B-drug B-drug
in O O
normovolemic O B-drug
healthy O O
subjects O O
by O O
approximately O O
20 O O
% O O
( O O
mean O O
sodium O O
and O O
urinary O O
output O O
decreased O O
17 O O
% O O
) O O
. O O

After O O
the O O
coadministration O O
of O O
200 O O
mg O O
oral O O
ketoconazole B-drug B-drug
twice O O
daily O O
and O O
one O O
20 O O
mg O O
dose O O
of O O
loratadine B-drug B-drug
to O O
11 O O
subjects O O
, O O
the O O
AUC O O
and O O
Cmax O O
of O O
loratadine B-drug B-drug
averaged O O
302 O O
% O O
( O O
142 O O
S.D O O
. O O
) O O
and O O
251 O O
% O O
( O O
68 O O
S.D O O
. O O
) O O
, O O
respectively O O
, O O
of O O
those O O
obtained O O
after O O
co-treatment O O
with O O
placebo O O
. O O

Warfarin B-drug B-drug
: O O
Atorvastatin B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
on O O
prothrombin O O
time O O
when O O
administered O O
to O O
patients O O
receiving O O
chronic O O
warfarin B-drug B-drug
treatment O O
. O O

The O O
combination O O
is O O
well O O
tolerated O O
. O O

Acetazolamide B-drug B-drug
decreases O O
urinary O O
excretion O O
of O O
amphetamine B-drug B-drug
and O O
may O O
enhance O O
the O O
magnitude O O
and O O
duration O O
of O O
their O O
effect O O
. O O

Theoretically O O
, O O
fenoprofen B-drug B-drug
could O O
likewise O O
be O O
displaced O O
. O O

Oral O O
Contraceptives B-group B-group

It O O
is O O
concluded O O
that O O
ketamine B-drug B-drug
is O O
not O O
a O O
short-acting O O
drug O O
and O O
that O O
concomitant O O
use O O
with O O
halothane B-drug B-drug
would O O
be O O
expected O O
to O O
prolong O O
further O O
the O O
duration O O
of O O
its O O
action O O
on O O
the O O
central O O
nervous O O
system O O
. O O

therefore O O
it O O
is O O
not O O
expected O O
to O O
affect O O
the O O
plasma O O
concentrations O O
of O O
other O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
. O O

However O O
, O O
since O O
aspirin B-brand B-brand
, O O
NSAIDs B-group B-group
, O O
and O O
bisphosphonates B-group B-group
are O O
all O O
associated O O
with O O
gastrointestinal O O
irritation O O
, O O
caution O O
should O O
be O O
exercised O O
in O O
the O O
concomitant O O
use O O
of O O
aspirin B-brand B-brand
or O O
NSAIDs B-group B-group
with O O
Ibandronate B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

No O O
clinically O O
significant O O
effect O O
of O O
famotidine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
or O O
lithium B-drug B-drug
was O O
seen O O
on O O
the O O
pharmacokinetics O O
of O O
aripiprazole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
: O O
Drug- O O
Drug O O
Interactions O O
) O O
. O O

Carbamazepine B-drug B-drug
: O O
Coadministration O O
of O O
carbamazepine B-drug B-drug
( O O
200 O O
mg O O
BID O O
) O O
, O O
a O O
potent O O
CYP3A4 O O
inducer O O
, O O
with O O
aripiprazole B-drug B-drug
( O O
30 O O
mg O O
QD O O
) O O
resulted O O
in O O
an O O
approximate O O
70 O O
% O O
decrease O O
in O O
Cmax O O
and O O
AUC O O
values O O
of O O
both O O
aripiprazole B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
dehydro-aripiprazole B-drug_n B-drug_n
. O O

Certain O O
antibiotics B-group B-group
, O O
especially O O
neomycin B-drug B-drug
, O O
streptomycin B-drug B-drug
and O O
kanamycin B-drug B-drug
, O O
have O O
a O O
mild O O
but O O
definite O O
nondepolarizing O O
blocking O O
action O O
which O O
may O O
accentuate O O
neuromuscular O O
block O O
. O O

Loratadine B-drug B-drug
Descarboethoxyloratadine I-drug I-drug

. O O

Drug/Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
APOKYN B-brand B-brand
and O O
laboratory O O
tests O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

In O O
one O O
study O O
, O O
following O O
chronic O O
administration O O
of O O
bupropion B-drug B-drug
, O O
100 O O
mg O O
3 O O
times O O
daily O O
to O O
8 O O
healthy O O
male O O
volunteers O O
for O O
14 O O
days O O
, O O
there O O
was O O
no O O
evidence O O
of O O
induction O O
of O O
its O O
own O O
metabolism O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
with O O
Cetrotide B-brand B-drug
. O O

Since O O
hydroxyurea B-drug B-drug
may O O
raise O O
the O O
serum O O
uric O O
acid O O
level O O
, O O
dosage O O
adjustment O O
of O O
uricosuric B-group O
medication I-group O
may O O
be O O
necessary O O

Physiological O O
changes O O
resulting O O
from O O
smoking O O
cessation O O
, O O
with O O
or O O
without O O
nicotine B-drug B-drug
replacement O O
, O O
may O O
alter O O
the O O
pharmacokinetics O O
of O O
certain O O
concomitant O O
medications O O
, O O
such O O
as O O
tricyclic B-group B-group
antidepressants I-group I-group
and O O
theophylline B-drug B-drug
. O O

The O O
effect O O
of O O
administering O O
different O O
botulinum B-group B-group
neurotoxin I-group I-group
serotypes O O
at O O
the O O
same O O
time O O
or O O
within O O
less O O
than O O
4 O O
months O O
of O O
each O O
other O O
is O O
unknown O O
. O O

Established O O
Drug O O
Interactions O O

Non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group

Lithium B-drug B-drug
toxicity O O
was O O
usually O O
reversible O O
upon O O
discontinuation O O
of O O
lithium B-drug B-drug
and O O
the O O
ACE B-group B-group
inhibitor I-group I-group
. O O

The O O
in O O
vitro O O
anti-cryptosporidial O O
activity O O
of O O
buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
alone O O
and O O
in O O
combination O O
with O O
azithromycin B-drug B-drug
and O O
minocycline B-drug B-drug
was O O
investigated O O
. O O

Although O O
this O O
effect O O
was O O
noted O O
even O O
when O O
cholestyramine B-drug B-drug
was O O
given O O
4 O O
hours O O
prior O O
to O O
fluvastatin B-drug B-drug
, O O
this O O
regimen O O
did O O
not O O
result O O
in O O
diminished O O
efficacy O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Cephalosporins B-group B-group
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

Perioperative O O
administration O O
of O O
drugs O O
affecting O O
hepatic O O
blood O O
flow O O
or O O
enzyme O O
function O O
may O O
reduce O O
plasma O O
clearance O O
and O O
prolong O O
recovery O O
. O O

CONCLUSIONS O O
: O O
Macrolide B-group B-group
antibiotics I-group I-group
inhibit O O
the O O
metabolism O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
that O O
are O O
metabolized O O
by O O
CYP3A4 O O
( O O
i.e. O O
, O O
atorvastatin B-drug B-drug
, O O
cerivastatin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
simvastatin B-drug B-drug
) O O
. O O

CNS O O
depression O O
producing O O
medications O O
- O O
concurrent O O
use O O
may O O
potentiate O O
the O O
effects O O
of O O
either O O
these O O
medications O O
or O O
diphenidol B-drug B-drug
; O O

Nicardipine B-drug B-drug
HCl I-drug I-drug
usually O O
does O O
not O O
alter O O
the O O
plasma O O
levels O O
of O O
digoxin B-drug B-drug
, O O
however O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
evaluated O O
after O O
concomitant O O
therapy O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
is O O
initiated O O
. O O

Sirolimus B-drug B-drug
works O O
differently O O
from O O
the O O
immunosuppressants B-group B-group
currently O O
available O O
, O O
and O O
except O O
for O O
increased O O
lipid O O
levels O O
, O O
the O O
adverse O O
reaction O O
profile O O
of O O
sirolimus B-drug B-drug
does O O
not O O
appear O O
to O O
overlap O O
to O O
any O O
great O O
extent O O
with O O
that O O
associated O O
with O O
cyclosporine B-drug B-drug
or O O
tacrolimus B-drug B-drug
. O O

When O O
carbamazepine B-drug B-drug
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
reduced O O
. O O

A O O
common O O
phenotypic O O
subset O O
of O O
the O O
serotype O O
O11 O O
strains O O
from O O
drug O O
addicts O O
was O O
especially O O
resistant O O
to O O
the O O
inhibitory O O
effects O O
. O O

Because O O
there O O
are O O
no O O
data O O
on O O
the O O
compatibility O O
of O O
NovoLog B-brand B-brand
and O O
crystalline O O
zinc B-drug B-drug
insulin I-drug I-drug
preparations O O
, O O
NovoLog B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
these O O
preparations O O
. O O

In O O
this O O
paper O O
lists O O
of O O
multiple O O
exposure O O
in O O
which O O
the O O
doses O O
of O O
the O O
substances O O
, O O
the O O
types O O
of O O
interferences O O
and O O
the O O
behaviour O O
of O O
the O O
biological O O
levels O O
have O O
been O O
drawn O O
up O O
and O O
proposed O O
as O O
a O O
tool O O
for O O
easy O O
consultation O O
. O O

Administration O O
of O O
WELLBUTRIN B-brand B-brand
Tablets O O
to O O
patients O O
receiving O O
either O O
levodopa B-drug B-drug
or O O
amantadine B-drug B-drug
concurrently O O
should O O
be O O
undertaken O O
with O O
caution O O
, O O
using O O
small O O
initial O O
doses O O
and O O
small O O
gradual O O
dose O O
increases O O
. O O

consideration O O
should O O
be O O
given O O
to O O
possible O O
CNS O O
and O O
other O O
effects O O
of O O
alcohol B-drug B-drug
. O O

Agents O O
Causing O O
Renin O O
Release O O
: O O
The O O
antihypertensive O O
effect O O
of O O
enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
is O O
augmented O O
by O O
antihypertensive B-group B-group
agents I-group I-group
that O O
cause O O
renin O O
release O O
( O O
e.g. O O
, O O
diuretics B-group B-group
) O O
. O O

Serum O O
lithium B-drug B-drug
levels O O
should O O
be O O
monitored O O
frequently O O
if O O
INSPRA B-brand B-brand
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

Increased O O
hepatotoxicity O O
of O O
acetaminophen B-drug B-drug
by O O
concomitant O O
administration O O
of O O
caffeine B-drug B-drug
in O O
the O O
rat O O
. O O

Digoxin B-drug B-drug
: O O
Supraventricular O O
arrhythmias O O
may O O
mask O O
the O O
cardiotoxicity O O
associated O O
with O O
excessive O O
digoxin B-drug B-drug
levels O O
. O O

Since O O
falsely O O
elevated O O
glucose O O
levels O O
have O O
been O O
observed O O
with O O
blood O O
glucose O O
monitoring O O
devices O O
and O O
test O O
strips O O
that O O
use O O
glucose O O
dehydrogenase O O
pyrroloquinolinequinone O B-drug_n
( O O
GDH O O
PQQ O O
) O O
-based O O
methods O O
, O O
GDH O O
PQQ-based O O
methods O O
should O O
not O O
be O O
used O O
to O O
measure O O
glucose O O
levels O O
in O O
patients O O
administered O O
EXTRANEAL.. B-brand B-brand

Both O O
the O O
magnitude O O
and O O
duration O O
of O O
central O O
nervous O O
system O O
and O O
cardiovascular O O
effects O O
may O O
be O O
enhanced O O
when O O
ALFENTA B-brand B-brand
is O O
administered O O
in O O
combination O O
with O O
other O O
CNS B-group B-group
depressants I-group I-group
such O O
as O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
opioids B-group B-group
, O O
or O O
inhalation O O
general O O
anesthetics B-group B-group
. O O

However O O
, O O
co O O
administration O O
of O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
with O O
either O O
ketoconazole B-drug B-drug
or O O
erythromycin B-drug B-drug
led O O
to O O
increased O O
plasma O O
concentrations O O
of O O
fexofenadine B-drug B-drug
. O O

A O O
single O O
dose O O
of O O
pravastatin B-drug B-drug
had O O
no O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
fenofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
. O O

The O O
drug O O
interaction O O
studies O O
with O O
valdecoxib B-drug B-drug
were O O
performed O O
both O O
with O O
valdecoxib B-drug B-drug
and O O
a O O
rapidly O O
hydrolyzed O O
intravenous O O
prodrug O O
form O O
. O O

Usually O O
, O O
severe O O
abdominal O O
symptoms O O
appear O O
before O O
there O O
is O O
such O O
a O O
fall O O
in O O
the O O
blood O O
pressure O O
. O O

Determinations O O
of O O
serum O O
digoxin B-drug B-drug
levels O O
utilizing O O
commercially O O
available O O
kits O O
with O O
an O O
125I-labelled O O
antigen O O
were O O
precise O O
and O O
not O O
materially O O
different O O
from O O
results O O
obtained O O
with O O
a O O
3H-labelled O O
antigen O O
. O O

At O O
least O O
3 O O
weeks O O
should O O
elapse O O
between O O
discontinuation O O
of O O
dexfenfluramine B-drug B-drug
and O O
initiation O O
of O O
treatment O O
with O O
a O O
MAO B-group B-group
inhibitor I-group I-group
. O O

The O O
lower O O
rate O O
of O O
absorption O O
in O O
the O O
groups O O
receiving O O
446 O O
mg O O
Fe B-drug B-drug
instead O O
of O O
48 O O
mg O O
of O O
Fe B-drug B-drug
per O O
kg O O
diet O O
resulted O O
in O O
a O O
decreased O O
renal O O
excretion O O
of O O
cobalt B-drug B-drug
. O O

Etofibrate B-drug B-drug
elicited O O
62 O O
% O O
enhancement O O
of O O
post-heparin B-drug O
lipolytic O O
activity O O
and O O
100 O O
% O O
increase O O
of O O
3H-triglyceride O B-drug_n
fractional O O
clearance O O
rate O O
compared O O
with O O
placebo O O
treatment O O
. O O

Recovery O O
from O O
50 O O
% O O
twitch O O
to O O
75 O O
% O O
fade O O
recovery O O
took O O
13.8 O O
+/- O O
0.8 O O
min O O
for O O
atracurium B-drug B-drug
alone O O
and O O
13.7 O O
+/- O O
1.2 O O
min O O
for O O
atracurium B-drug B-drug
plus O O
gentamycin B-drug B-drug
. O O

This O O
increase O O
is O O
due O O
to O O
the O O
inhibition O O
of O O
celecoxib B-drug B-drug
metabolism O O
via O O
P450 O O
2C9 O O
by O O
fluconazole B-drug B-drug
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
- O O
Pharmacokinetics O O
: O O
Metabolism O O
) O O
. O O

Non-pegylated B-drug B-drug
interferon I-drug I-drug
alfa-2a I-drug I-drug
treatment O O
of O O
pregnant O O
Rhesus O O
monkeys O O
at O O
approximately O O
20 O O
to O O
500 O O
times O O
the O O
human O O
weekly O O
dose O O
resulted O O
in O O
a O O
statistically O O
significant O O
increase O O
in O O
abortions O O
. O O

In O O
monkeys O O
, O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
but O O
not O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
or O O
PCP B-drug_n B-drug_n
, O O
were O O
antagonized O O
by O O
naloxone B-drug B-drug
; O O

In O O
monkeys O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
was O O
about O O
10 O O
times O O
more O O
potent O O
than O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
in O O
decreasing O O
responding O O
, O O
whereas O O
in O O
pigeons O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
was O O
about O O
equipotent O O
with O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
. O O

Increased O O
toxicity O O
( O O
CNS O O
depression O O
) O O
: O O
CNS B-group B-group
depressants I-group I-group
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
phenothiazines B-group B-group
. O O

Transient O O
delirium O O
has O O
been O O
reported O O
in O O
patients O O
who O O
were O O
treated O O
with O O
one O O
gram O O
of O O
ethchlorvynol B-drug B-drug
and O O
75 O O
- O O
150 O O
mg O O
of O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
. O O

In O O
such O O
patients O O
, O O
the O O
mean O O
area O O
under O O
the O O
felodipine B-drug B-drug
plasma O O
concentration-time O O
curve O O
was O O
also O O
reduced O O
to O O
approximately O O
6 O O
% O O
of O O
that O O
observed O O
in O O
healthy O O
volunteers O O
. O O

Several O O
clinically O O
important O O
interactions O O
have O O
previously O O
been O O
reported O O
for O O
other O O
immunosuppressive B-group B-group
drugs I-group I-group
that O O
are O O
metabolized O O
by O O
the O O
same O O
enzyme O O
and O O
for O O
calcium B-group B-group
antagonists I-group I-group
. O O

Clarithromycin B-drug B-drug

Alteration O O
of O O
pH O O
may O O
affect O O
absorption O O
of O O
certain O O
drugs O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
) O O
. O O

Both O O
the O O
toxicity O O
of O O
filipin B-drug_n B-drug_n
and O O
the O O
therapeutic O O
value O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
can O O
be O O
rationalized O O
at O O
the O O
cellular O O
and O O
molecular O O
level O O
by O O
the O O
following O O
observations O O
: O O
( O O
i O O
) O O
these O O
polyene B-group B-group
antibiotics I-group I-group
showed O O
differential O O
effects O O
on O O
cells O O
; O O

Multivitamins B-group B-group
, O O
or O O
other O O
products O O
containing O O
iron B-drug B-drug
or O O
zinc B-drug B-drug
, O O
antacids B-group B-group
or O O
sucralfate B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
, O O
or O O
within O O
2 O O
hours O O
of O O
, O O
the O O
administration O O
of O O
norfloxacin B-drug B-drug
, O O
because O O
they O O
may O O
interfere O O
with O O
absorption O O
resulting O O
in O O
lower O O
serum O O
and O O
urine O O
levels O O
of O O
norfloxacin B-drug B-drug
. O O

In O O
addition O O
, O O
under O O
the O O
influence O O
of O O
sympatholytic O B-group
medicinal O O
products O O
such O O
as O O
beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
and O O
reserpine B-drug B-drug
, O O
the O O
signs O O
of O O
hypoglycemia O O
may O O
be O O
reduced O O
or O O
absent O O
. O O

Valproic B-drug B-drug
acid I-drug I-drug

May O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
CRIXIVAN B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease B-group B-group
inhibitors I-group I-group
or O O
other O O
coadministered O O
antiretroviral B-group B-group
agents I-group I-group
. O O

The O O
risk O O
of O O
myopathy O O
during O O
treatment O O
with O O
drugs O O
of O O
this O O
class O O
is O O
increased O O
with O O
concurrent O O
administration O O
of O O
cyclosporine B-drug B-drug
, O O
fibric B-group B-group
acid I-group I-group
derivatives I-group I-group
, O O
niacin B-drug B-drug
( O O
nicotinic B-drug B-drug
acid I-drug I-drug
) O O
, O O
erythromycin B-drug B-drug
, O O
azole B-group B-group
antifungals I-group I-group
. O O

In O O
this O O
formal O O
interaction O O
study O O
, O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
were O O
each O O
found O O
to O O
have O O
negative O O
inotropic O O
effects O O
; O O

This O O
slowing O O
potentiates O O
amphetamines B-group B-group
, O O
increasing O O
their O O
effect O O
on O O
the O O
release O O
of O O
norepinephrine O B-drug
and O O
other O O
monoamines O O
from O O
adrenergic O O
nerve O O
endings O O
; O O

Physiological O O
oral O O
magnesium B-drug B-drug
supplementation O O
( O O
5 O O
mg/kg/day O O
) O O
is O O
easy O O
and O O
can O O
be O O
carried O O
out O O
in O O
the O O
diet O O
or O O
with O O
magnesium B-drug B-drug
salts O O
, O O
with O O
practically O O
only O O
one O O
contra-indication O O
: O O
overt O O
renal O O
failure O O
. O O

Rifampin B-drug B-drug

Influence O O
of O O
AED B-group B-group
On O O
MHD B-drug_n B-drug_n
Concentration O O
( O O
Mean O O
change O O
, O O
90 O O
% O O
Confidence O O
Interval O O
) O O

- O O
Drugs O O
with O O
nephrotoxic O O
potential O O
: O O
There O O
has O O
been O O
no O O
experience O O
on O O
the O O
concurrent O O
use O O
of O O
bumetanide B-drug B-drug
with O O
drugs O O
known O O
to O O
have O O
a O O
nephrotoxic O O
potential O O
. O O

In O O
this O O
setting O O
, O O
cardioselective B-group B-group
beta-blockers I-group I-group
could O O
be O O
considered O O
, O O
although O O
they O O
should O O
be O O
administered O O
with O O
caution O O
. O O

Before O O
taking O O
glimepiride B-drug B-drug
, O O
tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
medicines O O
: O O
- O O
aspirin B-brand B-brand
or O O
another O O
salicylate B-group B-group
such O O
as O O
magnesium/choline B-drug B-drug
salicylate I-drug B-group
( O O
Trilisate B-brand B-brand
) O O
, O O
salsalate B-drug B-group
( O O
Disalcid B-brand B-brand
, O O
others O O
) O O
, O O
choline B-drug B-drug
salicylate I-drug I-drug
( O O
Arthropan B-drug B-brand
) O O
, O O
magnesium B-drug B-drug
salicylate I-drug I-drug
( O O
Magan B-brand B-drug
) O O
, O O
or O O
bismuth B-drug B-drug
subsalicylate I-drug I-drug
( O O
Pepto-Bismol B-brand B-drug
) O O
; O O

It O O
is O O
postulated O O
that O O
some O O
of O O
the O O
observed O O
training-induced O O
neurobiological O O
alterations O O
might O O
reflect O O
the O O
interaction O O
between O O
two O O
( O O
or O O
more O O
) O O
competing O O
memory O O
systems O O
at O O
the O O
hippocampal O O
level O O
. O O

These O O
effects O O
have O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
by O O
the O O
NSAID B-group B-group
. O O

Many O O
people O O
use O O
both O O
alcohol B-drug B-drug
and O O
nicotine B-drug B-drug
( O O
i.e. O O
, O O
cigarettes O O
and O O
other O O
tobacco O O
products O O
) O O
. O O

In O O
addition O O
, O O
reduced O O
kidney O O
and O O
liver O O
function O O
secondary O O
to O O
PROLEUKIN B-brand B-brand
treatment O O
may O O
delay O O
elimination O O
of O O
concomitant O O
medications O O
and O O
increase O O
the O O
risk O O
of O O
adverse O O
events O O
from O O
those O O
drugs O O
. O O

Drugs O O
That O O
Induce O O
CYP3A4 O O
Rifampin B-drug B-drug
: O O
CYP3A4 O B-drug
is O O
ordinarily O O
a O O
minor O O
metabolizing O O
enzyme O O
of O O
zaleplon B-drug B-drug
. O O

Atovaquone B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
protein O O
( O O
99.9 O O
% O O
) O O
. O O

and O O
Videx B-brand B-brand
, O O
( O O
Didanosine B-drug B-drug
) O O
, O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
may O O
substantially O O
interfere O O
with O O
the O O
absorption O O
of O O
quinolones B-group B-group
, O O
resulting O O
in O O
systemic O O
levels O O
considerably O O
lower O O
than O O
desired O O
. O O

No O O
specific O O
pharmacokinetic O O
or O O
other O O
formal O O
drug O O
interaction O O
studies O O
were O O
conducted O O
. O O

Methylprednisolone B-drug B-drug

Vaccines B-group B-group
neurological O O
complications O O
and O O
lack O O
of O O
antibody O O
response O O
. O O

Because O O
of O O
reports O O
of O O
prolongation O O
of O O
the O O
prothrombin O O
time O O
beyond O O
the O O
therapeutic O O
range O O
in O O
patients O O
taking O O
concurrent O O
levamisole B-drug B-drug
and O O
warfarin B-drug B-drug
sodium I-drug I-drug
, O O
it O O
is O O
suggested O O
that O O
the O O
prothrombin O O
time O O
be O O
monitored O O
carefully O O
, O O
and O O
the O O
dose O O
of O O
warfarin B-drug B-drug
sodium I-drug I-drug
or O O
other O O
coumarin-like B-group B-group
drugs O I-group
should O O
be O O
adjusted O O
accordingly O O
, O O
in O O
patients O O
taking O O
both O O
drugs O O
. O O

Therefore O O
, O O
it O O
can O O
prolong O O
bleeding O O
time O O
by O O
approximately O O
3 O O
to O O
4 O O
minutes O O
from O O
baseline O O
values O O
. O O

Time O O
to O O
reach O O
Cmax O O
is O O
also O O
prolonged O O
by O O
1 O O
hour O O
. O O

There O O
may O O
remain O O
some O O
indications O O
of O O
the O O
laxative O B-group
and O O
antacid O B-group
properties O O
of O O
non O O
soluble O O
magnesium B-drug B-drug
, O O
particularly O O
during O O
intermittent O O
haemodialysis O O
. O O

Increased O O
plasma O O
levels O O
of O O
diazepam B-drug B-drug
were O O
observed O O
12 O O
hours O O
after O O
dosing O O
and O O
onwards O O
. O O

Because O O
of O O
possible O O
clinical O O
significance O O
, O O
these O O
two O O
drugs O O
should O O
not O O
be O O
administered O O
concurrently O O
. O O

increased O O
thyroid O O
binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
, O O
as O O
measured O O
by O O
PBI O O
, O O
T4 O O
by O O
column O O
, O O
or O O
T4 O O
by O O
radioimmunoassay O O
. O O

Whether O O
an O O
alteration O O
in O O
norepinephrine B-drug B-drug
uptake-1 O O
occurs O O
is O O
still O O
unresolved O O
. O O

The O O
possibility O O
of O O
altered O O
safety O O
and O O
efficacy O O
should O O
be O O
considered O O
when O O
Ponstel B-brand B-brand
is O O
used O O
concomitantly O O
with O O
these O O
drugs O O
. O O

Interactions O O
for O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
( O O
Vitamin B-drug B-drug
D2 I-drug I-drug
, O O
Vitamin B-drug B-drug
D3 I-drug I-drug
, O O
Calcitriol B-drug B-drug
, O O
and O O
Calcidiol B-drug B-drug
) O O
: O O
Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
has O O
been O O
reported O O
to O O
reduce O O
intestinal O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
; O O

Reported O O
examples O O
of O O
this O O
interaction O O
include O O
the O O
following O O
: O O
Immunosuppressives B-drug B-group
: O O
Cyclosporine B-drug B-drug
( O O
CYP3A4 B-drug B-drug
substrate O O
) O O
administered O O
in O O
combination O O
with O O
oral O O
amiodarone B-drug B-drug
has O O
been O O
reported O O
to O O
produce O O
persistently O O
elevated O O
plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
resulting O O
in O O
elevated O O
creatinine O O
, O O
despite O O
reduction O O
in O O
dose O O
of O O
cyclosporine B-drug B-drug
. O O

In O O
addition O O
, O O
results O O
from O O
regression O O
analyses O O
of O O
patient O O
pharmacokinetic O O
data O O
suggest O O
that O O
co-administration O O
of O O
other O O
inducers O O
of O O
drug O O
clearance O O
( O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
or O O
carbamazepine B-drug B-drug
) O O
with O O
CANCIDAS B-brand B-brand
may O O
result O O
in O O
clinically O O
meaningful O O
reductions O O
in O O
caspofungin B-drug B-drug
concentrations O O
. O O

Concomitant O O
administration O O
of O O
drugs O O
known O O
to O O
inhibit O O
the O O
activity O O
of O O
cytochrome O O
P450 O O
isozymes O O
may O O
increase O O
the O O
plasma O O
levels O O
of O O
clozapine B-drug B-drug
. O O

Insulin O B-drug
parameters O O
were O O
not O O
affected O O
. O O

Specific O O
and O O
aspecific O O
treatments O O
of O O
magnesium B-drug B-drug
depletion O O
are O O
tricky O O
using O O
for O O
example O O
magnesium B-group B-drug
sparing I-group O
diuretics I-group B-group
, O O
pharmacological O O
doses O O
of O O
vitamin B-drug B-drug
B6 I-drug I-drug
, O O
physiological O O
doses O O
of O O
vitamin B-group B-group
D I-group I-group
and O O
of O O
selenium B-drug B-drug
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

The O O
effects O O
of O O
Mefloquineuine O B-drug
on O O
the O O
compromised O O
cardiovascular O O
system O O
have O O
not O O
been O O
evaluated O O
. O O

The O O
clinical O O
relevance O O
of O O
this O O
difference O O
is O O
unknown O O
. O O

Caution O O
is O O
therefore O O
advised O O
in O O
the O O
coadministration O O
of O O
ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
with O O
other O O
anticholinergic-containing B-group B-group
drugs O I-group
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
injection O O
and O O
potassium-depleting O B-group
agents O I-group
: O O
When O O
corticosteroids B-group B-group
are O O
administered O O
concomitantly O O
with O O
potassium-depleting O B-group
agents O I-group
( O O
e.g. O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
diuretics B-group B-group
) O O
, O O
patients O O
should O O
be O O
observed O O
closely O O
for O O
development O O
of O O
hypokalemia O O
. O O

No O O
clinically O O
relevant O O
pharmacokinetic O O
interactions O O
between O O
anagrelide B-drug B-drug
and O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
were O O
observed O O
. O O

SETTING O O
: O O
Rural O O
primary O O
care O O
centre O O
. O O

Cyclosporine B-drug B-drug
: O O
Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
cyclosporine B-drug B-drug
with O O
other O O
members O O
of O O
the O O
quinolone B-group B-group
class I-group I-group
. O O

Wait O O
2 O O
weeks O O
after O O
stopping O O
an O O
MAO B-group B-group
inhibitor I-group I-group
before O O
starting O O
escitalopram B-drug B-drug
. O O

Tolbutamide B-drug B-drug
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
decreased O O
the O O
AUC O O
of O O
tolbutamide B-drug B-drug
( O O
a O O
CYP2C9 O O
substrate O O
) O O
by O O
23 O O
% O O
on O O
Day O O
4 O O
, O O
28 O O
% O O
on O O
Day O O
8 O O
, O O
and O O
15 O O
% O O
on O O
Day O O
15 O O
, O O
when O O
a O O
single O O
dose O O
of O O
tolbutamide B-drug B-drug
500 O O
mg O O
was O O
admini O O
, O O
stered O O
orally O O
prior O O
to O O
the O O
administration O O
of O O
the O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
and O O
on O O
Days O O
4,8 O O
, O O
and O O
15 O O
. O O

increased O O
factors O O
II O O
, O O
VII O O
antigen O O
, O O
VIII O O
antigen O O
, O O
VIII O O
coagulant O O
activity O O
, O O
IX O O
, O O
X O O
, O O
XII O O
, O O
VII-X O O
complex O O
, O O
II-VII-X O O
complex O O
, O O
and O O
beta-thromboglobulin O O
; O O

There O O
is O O
one O O
report O O
of O O
cardiopulmonary O O
arrest O O
, O O
with O O
full O O
recovery O O
, O O
in O O
a O O
patient O O
who O O
was O O
taking O O
a O O
beta B-group B-group
blocker I-group I-group
( O O
propranolol B-drug B-drug
) O O
. O O

Such O O
agents O O
must O O
be O O
discontinued O O
at O O
least O O
seven O O
days O O
prior O O
to O O
starting O O
therapy O O
with O O
VISTIDE B-brand B-brand
. O O

Ephedrine B-drug B-drug
: O O
Ephedrine B-drug B-drug
may O O
enhance O O
the O O
metabolic O O
clearance O O
of O O
corticosteroids B-group B-group
, O O
resulting O O
in O O
decreased O O
blood O O
levels O O
and O O
lessened O O
physiologic O O
activity O O
, O O
thus O O
requiring O O
an O O
increase O O
in O O
corticosteroid B-group B-group
dosage O O
. O O

- O O
Anabolic B-group B-group
steroids I-group I-group
( O O
nandrolone B-drug B-drug
[ O O
e.g. O O
, O O
Anabolin B-brand B-brand
] O O
, O O
oxandrolone B-drug B-drug
[ O O
e.g. O O
, O O
Anavar B-brand B-brand
] O O
, O O
oxymetholone B-drug B-drug
[ O O
e.g. O O
, O O
Anadrol B-brand B-brand
] O O
, O O
stanozolol B-drug B-drug
[ O O
e.g. O O
, O O
Winstrol B-brand B-brand
] O O
) O O
or O O

When O O
given O O
concomitantly O O
with O O
felodipine B-drug B-drug
, O O
the O O
tacrolimus B-drug B-drug
blood O O
concentration O O
should O O
be O O
followed O O
and O O
the O O
tacrolimus O B-drug
dose O O
may O O
need O O
to O O
be O O
adjusted O O
. O O

Increased O O
anticoagulation O O
effects O O
due O O
to O O
a O O
drug O O
interaction O O
with O O
erythromycin B-drug B-drug
may O O
be O O
more O O
pronounced O O
in O O
the O O
elderly O O
. O O

A O O
specific O O
treatment O O
for O O
extravasation O O
reactions O O
is O O
unknown O O
at O O
this O O
time O O
. O O

An O O
interval O O
of O O
at O O
least O O
two O O
hours O O
between O O
intake O O
of O O
this O O
agent O O
and O O
chloroquine B-drug B-drug
should O O
be O O
observed O O
. O O

Amphetamines B-group B-group
may O O
decrease O O
the O O
hypotensive O O
effect O O
of O O
antihypertensives B-group B-group
. O O

Although O O
one O O
study O O
tentatively O O
supports O O
the O O
hypothesis O O
that O O
such O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
may O O
be O O
efficacious O O
, O O
a O O
second O O
study O O
by O O
the O O
same O O
group O O
did O O
not O O
confirm O O
the O O
significant O O
findings O O
, O O
and O O
no O O
clear O O
, O O
reproducible O O
pattern O O
of O O
efficacy O O
has O O
emerged O O
from O O
the O O
review O O
of O O
all O O
the O O
evidence O O
. O O

This O O
has O O
been O O
observed O O
with O O
Benedict O O
s O O
and O O
Fehling O O
s O O
solutions O O
and O O
also O O
with O O
Clinitest O O
tablets O O
. O O

Therefore O O
, O O
dose O O
adjustments O O
of O O
concomitant O O
medications O O
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2D6 O O
and O O
have O O
a O O
narrow O O
therapeutic O O
index O O
( O O
e.g. O O
, O O
flecainide B-drug B-drug
, O O
vinblastine B-drug B-drug
, O O
thioridazine B-drug B-drug
and O O
most O O
tricyclic B-group B-group
antidepressants I-group I-group
) O O
may O O
be O O
required O O
. O O

Plasma O O
concentrations O O
of O O
quinolone B-group B-group
antibiotics I-group I-group
are O O
decreased O O
when O O
administered O O
with O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
. O O

However O O
, O O
patients O O
receiving O O
infusions O O
of O O
FLOLAN B-brand B-brand
in O O
clinical O O
trials O O
were O O
maintained O O
on O O
anticoagulants B-group B-group
without O O
evidence O O
of O O
increased O O
bleeding O O
. O O

Monitoring O O
of O O
cyclosporine B-drug B-drug
levels O O
and O O
possible O O
adjustment O O
of O O
cyclosporine B-drug B-drug
dosage O O
should O O
be O O
considered O O
when O O
these O O
drugs O O
are O O
co-administered O O
. O O

Since O O
amiodarone B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 B-drug O
, O O
there O O
is O O
the O O
potential O O
that O O
the O O
use O O
of O O
St. O O
John O O
s O O
Wort O O
in O O
patients O O
receiving O O
amiodarone B-drug B-drug
could O O
result O O
in O O
reduced O O
amiodarone B-drug B-drug
levels O O
. O O

However O O
, O O
decreases O O
in O O
exposure O O
were O O
as O O
much O O
as O O
56 O O
% O O
and O O
66 O O
% O O
, O O
respectively O O
, O O
in O O
individual O O
subjects O O
. O O

Drug O O
Class O O

High O O
concentrations O O
of O O
cefoxitin B-drug B-drug
in O O
the O O
urine O O
may O O
interfere O O
with O O
measurement O O
of O O
urinary O O
17-hydroxy-corticosteroids O O
by O O
the O O
Porter-Silber O O
reaction O O
, O O
and O O
produce O O
false O O
increases O O
of O O
modest O O
degree O O
in O O
the O O
levels O O
reported O O
. O O

Based O O
on O O
total O O
ertapenem B-drug B-drug
concentrations O O
, O O
probenecid B-drug B-drug
increased O O
the O O
AUC O O
by O O
25 O O
% O O
and O O
reduced O O
the O O
plasma O O
and O O
renal O O
clearances O O
by O O
20 O O
% O O
and O O
35 O O
% O O
, O O
respectively O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
64-year-old O O
African-American O O
man O O
was O O
admitted O O
to O O
the O O
hospital O O
for O O
worsening O O
renal O O
failure O O
, O O
elevated O O
creatine O O
phosphokinase O O
, O O
diffuse O O
muscle O O
pain O O
, O O
and O O
severe O O
muscle O O
weakness O O
. O O

Allopurinol B-drug B-drug
: O O
Increased O O
possibility O O
of O O
skin O O
rash O O
, O O
particularly O O
in O O
hyperuricemic O O
patients O O
may O O
occur O O
. O O

Effects O O
of O O
xanthine B-group O
derivatives I-group O
in O O
a O O
light/dark O O
test O O
in O O
mice O O
and O O
the O O
contribution O O
of O O
adenosine O O
receptors O O
. O O

Therefore O O
, O O
patients O O
on O O
propranolol B-drug B-drug
should O O
be O O
observed O O
when O O
COLESTID B-brand B-brand
Tablets O O
are O O
either O O
added O O
or O O
deleted O O
from O O
a O O
therapeutic O O
regimen O O
. O O

Phenothiazines B-group B-group
and O O
butyrophenones B-group B-group
may O O
reduce O O
or O O
reverse O O
the O O
pressor O O
effect O O
of O O
epinephrine B-drug B-drug
. O O

There O O
were O O
no O O
reports O O
of O O
skeletal O O
myopathy O O
in O O
a O O
placebo-controlled O O
Phase O O
I O O
trial O O
in O O
which O O
10 O O
healthy O O
subjects O O
on O O
stable O O
simvastatin B-drug B-drug
therapy O O
were O O
treated O O
concurrently O O
with O O
daptomycin B-drug B-drug
( O O
4 O O
mg/kg O O
once O O
every O O
24 O O
hours O O
) O O
for O O
14 O O
days O O
. O O

METHODS O O
: O O
We O O
carried O O
out O O
two O O
different O O
3-way O O
crossover O O
studies O O
in O O
healthy O O
subjects O O
( O O
each O O
, O O
n O O
= O O
9 O O
) O O
. O O

In O O
addition O O
, O O
under O O
the O O
influence O O
of O O
sympatholytic O B-group
medicinal O O
products O O
such O O
as O O
beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
and O O
reserpine B-drug B-drug
, O O
the O O
signs O O
of O O
hypoglycemia O O
may O O
be O O
reduced O O
or O O
absent O O
. O O

Since O O
barbiturates B-group B-group
are O O
potentiated O O
by O O
the O O
anticholinesterases B-group B-group
, O O
they O O
should O O
be O O
used O O
cautiously O O
in O O
the O O
treatment O O
of O O
convulsions O O
. O O

Patients O O
receiving O O
medications O O
that O O
interfere O O
with O O
platelet O O
function O O
or O O
coagulation O O
should O O
have O O
more O O
frequent O O
laboratory O O
monitoring O O
for O O
thrombocytopenia O O
. O O

Pre-treatment O O
with O O
the O O
CYP3A4 O O
inducer O O
rifampicin B-drug B-drug
decreased O O
erlotinib B-drug B-drug
AUC O O
by O O
about O O
2/3 O O
. O O

These O O
doses O O
are O O
lower O O
than O O
the O O
therapeutic O O
doses O O
for O O
both O O
drugs O O
. O O

Should O O
not O O
be O O
used O O
as O O
sole O B-group
protease B-group I-group
inhibitor I-group I-group
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

In O O
vitro O O
studies O O
: O O
Studies O O
in O O
human O O
liver O O
microsomes O O
showed O O
that O O
vardenafil B-drug B-drug
is O O
metabolized O O
primarily O O
by O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
isoforms O O
3A4/5 O O
, O O
and O O
to O O
a O O
lesser O O
degree O O
by O O
CYP2C9 O B-drug
. O O

Careful O O
observation O O
is O O
required O O
when O O
amantadine B-drug B-drug
is O O
administered O O
concurrently O O
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
stimulants I-group I-group
. O O

Accutane B-brand B-brand
use O O
is O O
associated O O
with O O
depression O O
in O O
some O O
patients O O
. O O

Antiretroviral B-group B-group
regimens O O
consisted O O
of O O
two O O
reverse B-group B-group
transcriptase I-group I-group
inhibitors I-group I-group
and O O
one O O
protease B-group B-group
inhibitor I-group I-group
. O O

If O O
concomitant O O
treatment O O
with O O
AXERT B-brand B-brand
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

Fenbufen B-drug B-drug
is O O
not O O
approved O O
in O O
the O O
United O O
States O O
at O O
this O O
time O O
. O O

weaker O B-group
inhibitors O I-group
( O O
erythromycin B-drug B-drug
, O O
grapefruit O O
juice O O
) O O
have O O
not O O
been O O
studied O O
. O O

The O O
risk O O
of O O
using O O
loxapine B-drug B-drug
in O O
combination O O
with O O
CNS-active O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
. O O

In O O
practice O O
, O O
the O O
greatest O O
value O O
of O O
the O O
thioether O O
assay O O
appears O O
to O O
lie O O
in O O
its O O
signal O O
function O O
. O O

Renal O O
clearance O O
of O O
ucb O O
L057 O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
decreased O O
60 O O
% O O
, O O
probably O O
related O O
to O O
competitive O O
inhibition O O
of O O
tubular O O
secretion O O
of O O
ucb O O
L057 O O
. O O

Fat O O
redistribution O O
: O O
Redistribution/accumulation O O
of O O
body O O
fat O O
including O O
central O O
obesity O O
, O O
dorsocervical O O
fat O O
enlargement O O
( O O
buffalo O O
hump O O
) O O
, O O
peripheral O O
wasting O O
, O O
facial O O
wasting O O
, O O
breast O O
enlargement O O
, O O
and O O
cushingoid O O
appearance O O
have O O
been O O
observed O O
in O O
patients O O
receiving O O
antiretroviral B-group B-group
therapy O O
. O O

In O O
patients O O
with O O
chronic O O
hepatitis O O
C O O
treated O O
with O O
PEGASYS B-brand B-brand
in O O
combination O O
with O O
COPEGUS B-brand B-brand
, O O
PEGASYS B-brand B-brand
treatment O O
did O O
not O O
affect O O
ribavirin B-drug B-drug
distribution O O
or O O
clearance O O
. O O

In O O
addition O O
, O O
several O O
cardiovascular O O
drugs O O
directly O O
affect O O
renal O O
function O O
and O O
the O O
management O O
of O O
patients O O
with O O
renal O O
disease O O
. O O

FREQUENT O O
PROTHROMBIN O O
TIME/INR O O
DETERMINATIONS O O
ARE O O
ADVISABLE O O
UNTIL O O
IT O O
HAS O O
BEEN O O
DEFINITELY O O
DETERMINED O O
THAT O O
THE O O
PROTHROMBIN O O
TIME/INR O O
HAS O O
STABILIZED O O
. O O

PEGASYS B-brand B-brand
and O O
COPEGUS B-brand B-brand
are O O
excreted O O
by O O
the O O
kidney O O
, O O
and O O
the O O
risk O O
of O O
toxic O O
reactions O O
to O O
this O O
therapy O O
may O O
be O O
greater O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
. O O

Volatile O B-group
Anesthetic B-drug I-group
Agents O I-group
: O O
. O O

Lansoprazole B-drug B-drug
is O O
metabolized O O
through O O
the O O
cytochrome O O
P450 O O
system O O
, O O
specifically O O
through O O
the O O
CYP3A O O
and O O
CYP2C19 O O
isozymes O O
. O O

Cholinergic O O
role O O
in O O
alcohol B-drug B-drug
's O O
effects O O
on O O
evoked O O
potentials O O
in O O
visual O O
cortex O O
of O O
the O O
albino O O
rat O O
. O O

alopecia O O

Use O O
in O O
Ambulatory O O
Patients O O
The O O
effects O O
of O O
ROMAZICON B-brand B-brand
may O O
wear O O
off O O
before O O
a O O
long-acting B-group O
benzodiazepine I-group B-group
is O O
completely O O
cleared O O
from O O
the O O
body O O
. O O

Therefore O O
, O O
it O O
is O O
critically O O
important O O
for O O
women O O
of O O
childbearing O O
potential O O
to O O
select O O
and O O
commit O O
to O O
use O O
2 O O
forms O O
of O O
effective O O
contraception O O
simultaneously O O
, O O
at O O
least O O
1 O O
of O O
which O O
must O O
be O O
a O O
primary O O
form O O
, O O
unless O O
absolute O O
abstinence O O
is O O
the O O
chosen O O
method O O
, O O
or O O
the O O
patient O O
has O O
undergone O O
a O O
hysterectomy O O

Pharmacokinetics O O
were O O
assessed O O
in O O
two O O
of O O
these O O
trials O O
. O O

increased O O
serum O O
digoxin B-drug B-drug
concentrations O O
may O O
result O O
. O O

monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
; O O

There O O
does O O
not O O
appear O O
to O O
be O O
an O O
increase O O
in O O
adverse O O
events O O
in O O
subjects O O
who O O
received O O
oral O O
contraceptives B-group B-group
and O O
loratadine B-drug B-drug
. O O

However O O
, O O
numerous O O
potentiation O O
effects O O
have O O
frequently O O
been O O
reported O O
for O O
combined O O
exposure O O
to O O
substances O O
of O O
widespread O O
use O O
. O O

Because O O
of O O
its O O
lack O O
of O O
platelet O O
effects O O
, O O
VIOXX B-brand B-brand
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

Monoamine B-drug B-group
Oxidase I-drug I-group
Inhibitors I-drug I-group
: O O
Guanethidine B-drug B-drug
or O O
similarly O O
acting O O
compounds O O
; O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
taking O O
this O O
medicine O O
certain O O
antibiotics B-group B-group
, O O
such O O
as O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
or O O
azithromycin B-drug B-drug
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P450IID6 O O
( O O
CYP2D6 O O
) O O
: O O
Many O O
drugs O O
, O O
including O O
most O O
antidepressants B-group B-group
( O O
SSRIs O B-group
, O O
many O O
tricyclics B-group B-group
) O O
, O O
beta-blockers B-group B-group
, O O
antiarrhythmics B-drug B-group
, O O
and O O
antipsychotics B-group B-group
are O O
metabolized O O
by O O
the O O
CYP2D6 O O
isoenzyme O O
. O O

Moreover O O
, O O
each O O
task O O
induced O O
significant O O
alterations O O
in O O
hippocampal O O
adenylate O O
cyclase O O
activity O O
but O O
in O O
opposite O O
directions O O
. O O

Registered O O
trademark O O
of O O
Ames O O
Company O O
, O O
Division O O
of O O
Miles O O
Laboratories O O
, O O
Inc O O
. O O

Twenty O O
four O O
male O O
Wistar O O
rats O O
were O O
divided O O
into O O
four O O
groups O O
. O O

Quinidine B-drug B-drug
: O O
Immediate O O
Release O O
Capsules O O
: O O
There O O
have O O
been O O
rare O O
reports O O
of O O
an O O
interaction O O
between O O
quinidine B-drug B-drug
and O O
nifedipine B-drug B-drug
( O O
with O O
a O O
decreased O O
plasma O O
level O O
of O O
quinidine B-drug B-drug
) O O
. O O

There O O
is O O
no O O
known O O
drug O O
interference O O
with O O
standard O O
clinical O O
laboratory O O
tests O O
. O O

The O O
absorption O O
of O O
oral O O
gemifloxacin B-drug B-drug
is O O
significantly O O
reduced O O
by O O
the O O
concomitant O O
administration O O
of O O
an O O
antacid B-group B-group
containing O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
. O O

- O O
Phenytoin B-drug B-drug
( O O
e.g. O O
, O O
Dilantin B-brand B-brand
) O O
Use O O
of O O
phenytoin B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
side O O
effects O O
of O O
phenytoin B-drug B-drug

Multivalent O O
Cation-Containing O O
Products O O
: O O
Concurrent O O
administration O O
of O O
a O O
quinolone B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
with O O
multivalent O B-group
cation-containing O I-group
products O I-group
such O O
as O O
magnesium B-drug B-drug
or O O
aluminum B-drug B-drug
antacids B-group B-group
, O O
sucralfate B-drug B-drug
, O O
VIDEX B-brand B-brand
chewable/buffered O O
tablets O O
or O O
pediatric O O
powder O O
, O O
or O O
products O O
containing O O
calcium B-drug B-drug
, O O
iron B-drug B-drug
, O O
or O O
zinc B-drug B-drug
may O O
substantially O O
decrease O O
the O O
absorption O O
of O O
ciprofloxacin B-drug B-drug
, O O
resulting O O
in O O
serum O O
and O O
urine O O
levels O O
considerably O O
lower O O
than O O
desired O O
. O O

Compounds O O
that O O
have O O
been O O
tested O O
in O O
man O O
include O O
antipyrine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
and O O
no O O
clinically O O
meaningful O O
interactions O O
were O O
found O O
. O O

There O O
are O O
no O O
adequate O O
and O O
well-controlled O O
studies O O
of O O
PEGASYS B-brand B-brand
in O O
pregnant O O
women O O
. O O

cholestyramine B-drug B-drug
; O O

cases O O
of O O
rhabdomyolysis O O
have O O
been O O
reported O O
in O O
seriously O O
ill O O
patients O O
. O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side O O
effects O O
in O O
patients O O
on O O
concomitant O O
therapy O O
with O O
quinolones B-group B-group
and O O
theophylline B-drug B-drug
. O O

. O O

Use O O
with O O
Other O O
Agents O O
Affecting O O
Myelopoesis O O
: O O
Drugs O O
which O O
may O O
affect O O
leukocyte O O
production O O
, O O
including O O
co-trimoxazole B-brand B-drug
, O O
may O O
lead O O
to O O
exaggerated O O
leukopenia O O
, O O
especially O O
in O O
renal O O
transplant O O
recipients O O
. O O

Together O O
with O O
previous O O
findings O O
, O O
these O O
results O O
suggest O O
that O O
the O O
hippocampus O O
is O O
involved O O
in O O
both O O
the O O
so-called O O
" O O
hippocampal-dependent O O
" O O

A O O
clinical O O
interaction O O
study O O
was O O
also O O
conducted O O
with O O
alosetron B-drug B-drug
and O O
the O O
CYP3A4 O O
substrate O O
cisapride B-drug B-drug
. O O

In O O
addition O O
, O O
drugs O O
that O O
are O O
actively O O
secreted O O
via O O
this O O
route O O
( O O
e.g. O O
, O O
triamterene B-drug B-drug
, O O
metformin B-drug B-drug
and O O
amiloride B-drug B-drug
) O O
should O O
be O O
co-administered O O
with O O
care O O
as O O
they O O
might O O
increase O O
dofetilide B-drug B-drug
levels O O
. O O

Endothelium-intact O O
aortic O O
rings O O
from O O
high-estradiol B-drug O
rats O O
were O O
supersensitive O O
to O O
noradrenaline B-drug B-drug
when O O
compared O O
to O O
vehicle- O O
, O O
progesterone- B-drug O
and O O
progesterone B-drug B-drug
+ O O
high-estradiol-treated O O
rats O O
( O O
pD2 O O
values O O
= O O
7.77+/-0.12 O O
, O O
7.21+/-0.13 O O
, O O
6.93+/-0.04 O O
and O O
7.22+/-0.18 O O
, O O
respectively O O
) O O
. O O

A O O
potential O O
interaction O O
between O O
oral O O
miconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
leading O O
to O O
severe O O
hypoglycemia O O
has O O
been O O
reported O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
use O O
of O O
some O O
quinolones B-group B-group
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
controlled O O
clinical O O
trials O O
and O O
studies O O
involving O O
otherwise O O
healthy O O
adults O O
with O O
epilepsy O O
. O O

decreased O O
antithrombin B-drug B-drug
3 I-drug O
; O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylureas B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
both O O
the O O
( O O
R O O
) O O
and O O
( O O
S O O
) O O
isomers O O
of O O
warfarin B-drug B-drug
were O O
unaffected O O
by O O
concurrent O O
dosing O O
of O O
0.3 O O
mg O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

Clinical O O
studies O O
with O O
celecoxib B-drug B-drug
have O O
identified O O
potentially O O
significant O O
interactions O O
with O O
fluconazole B-drug B-drug
and O O
lithium B-drug B-drug
. O O

Rifabutin B-drug B-drug

Digitalis B-group B-group

Coadministration O O
of O O
digoxin B-drug B-drug
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

The O O
mechanism O O
and O O
long-term O O
consequences O O
of O O
these O O
events O O
are O O
currently O O
unknown O O
. O O

- O O
Estrogens B-group B-group
( O O
female O O
hormones O B-group
) O O
or O O

Administration O O
of O O
phenytoin B-drug B-drug
to O O
patients O O
receiving O O
dopamine B-drug B-drug
HCl I-drug I-drug
has O O
been O O
reported O O
to O O
lead O O
to O O
hypotension O O
and O O
bradycardia O O
. O O

As O O
immediate-early O O
genes O O
( O O
IEGs O O
) O O
are O O
thought O O
to O O
play O O
a O O
critical O O
role O O
in O O
mediating O O
stimulus-induced O O
neural O O
plasticity O O
, O O
IEG O O
response O O
induced O O
by O O
methamphetamine B-drug B-drug
( O O
METH B-drug B-drug
) O O
has O O
been O O
characterized O O
to O O
define O O
the O O
changes O O
in O O
gene O O
expression O O
that O O
may O O
underlie O O
its O O
long-lasting O O
behavioral O O
effects O O
. O O

In O O
seven O O
experiments O O
reactions O O
to O O
norepinephrine B-drug B-drug
and O O
oxytocin B-drug B-drug
were O O
PGF2alpha B-drug B-drug
. O O

Both O O
itraconazole B-drug B-drug
and O O
its O O
major O O
metabolite O O
, O O
hydroxyitraconazole B-drug_n B-drug_n
, O O
are O O
inhibitors O O
of O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
. O O

Prothrombin O O
times O O
were O O
measured O O
four O O
times O O
weekly O O
during O O
five O O
long-term O O
experiments O O
. O O

Caution O O
should O O
be O O
used O O
when O O
alosetron B-drug B-drug
and O O
ketoconazole B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

Caution O O
is O O
therefore O O
advised O O
when O O
administering O O
PEGANONE B-brand B-brand
to O O
patients O O
receiving O O
coumarin B-group B-group
anticoagulants I-group I-group
. O O

In O O
vitro O O
studies O O
indicate O O
CYP3A4 O O
isoform O O
and O O
CYP1A2 O O
isoform O O
mediate O O
the O O
metabolism O O
of O O
levobupivacaine B-drug B-drug
to O O
desbutyl B-drug_n O
levobupivacaine I-drug_n B-drug
and O O
3-hydroxy B-drug_n O
levobupivacaine I-drug_n B-drug
, O O
respectively O O
. O O

3 O O
. O O

Venlafaxine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
zaleplon B-drug B-drug
10 O O
mg O O
and O O
multiple O O
doses O O
of O O
venlafaxine B-drug B-drug
ER O O
( O O
extended O O
release O O
) O O
150 O O
mg O O
did O O
not O O
result O O
in O O
any O O
significant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
zaleplon B-drug B-drug
or O O
venlafaxine B-drug B-drug
. O O

Amprenavir B-drug B-drug
does O O
not O O
inhibit O O
CYP2D6 O O
, O O
CYP1A2 O O
, O O
CYP2C9 O B-drug
, O O
CYP2C19 O O
, O O
CYP2E1 O O
, O O
or O O
uridine O O
glucuronosyltransferase O O
( O O
UDPGT O O
) O O
. O O

Co-administration O O
of O O
single O O
25-mg O O
dose O O
warfarin B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
total O O
lenalidomide B-drug B-drug
. O O

Advantages O O
offered O O
by O O
this O O
class O O
of O O
antibiotics B-group B-group
include O O
optimal O O
pharmacokinetics O O
, O O
effectiveness O O
against O O
multidrug-resistant O O
organisms O O
, O O
and O O
oral O O
administration O O
even O O
when O O
parenteral O B-group
antibiotics B-drug I-group
are O O
generally O O
used O O
. O O

- O O
Amiodarone B-drug B-drug
( O O
e.g. O O
, O O
Cordarone B-brand B-brand
) O O
or O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
with O O
oral O O
midazolam B-drug B-drug
or O O
triazolam B-drug B-drug
has O O
resulted O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
the O O
latter O O
two O O
drugs O O
. O O

Ritonavir B-drug B-drug
( O O
600 O O
mg O O
b.i.d O O
. O O
) O O
co-administered O O
with O O
Vardenafil B-drug B-drug
5 O O
mg O O
resulted O O
in O O
a O O
49-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
13-fold O O
increase O O
in O O
vardenafil B-drug B-drug
Cmax O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
administration O O
of O O
ceftazidime B-drug B-drug
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
when O O
using O O
CLINITEST O O
tablets O O
, O O
Benedicts O O
solution O O
, O O
or O O
Fehlings O O
solution O O
. O O

In O O
addition O O
, O O
olanzapine B-drug B-drug
is O O
not O O
associated O O
with O O
a O O
risk O O
of O O
agranulocytosis O O
as O O
seen O O
with O O
clozapine B-drug B-drug
or O O
clinically O O
significant O O
hyperprolactinaemia O O
as O O
seen O O
with O O
risperidone B-drug B-drug
or O O
prolongation O O
of O O
the O O
QT O O
interval O O
. O O

Ethinyl I-drug B-drug
estradiol I-drug I-drug
Norethindrone I-drug I-drug

Clinical O O
trials O O
have O O
indicated O O
that O O
Pulmozyme B-brand B-brand
can O O
be O O
effectively O O
and O O
safely O O
used O O
in O O
conjunction O O
with O O
standard O B-group
cystic O I-group
fibrosis O I-group
therapies O O
including O O
oral O O
, O O
inhaled O O
and/or O O
parenteral O O
antibiotics B-group B-group
, O O
bronchodilators B-group B-group
, O O
enzyme O O
supplements O O
, O O
vitamins B-group B-group
, O O
oral O O
or O O
inhaled O O
corticosteroids B-group B-group
, O O
and O O
analgesics B-group B-group
. O O

Drug/Laboratory O O
Test O O
Interaction O O
Captopril B-drug B-drug
may O O
cause O O
a O O
false-positive O O
urine O O
test O O
for O O
acetone O B-drug
. O O

Tolbutamide B-drug B-drug
: O O
In O O
in O O
vitro O O
studies O O
, O O
M1 O O
was O O
shown O O
to O O
cause O O
increases O O
ranging O O
from O O
13 O O
- O O
50 O O
% O O
in O O
the O O
free O O
fraction O O
of O O
tolbutamide B-drug B-drug
at O O
concentrations O O
in O O
the O O
clinical O O
range O O
. O O

Interactions O O
between O O
COPAXONE B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

Therefore O O
, O O
patients O O
without O O
a O O
functioning O O
thyroid B-group O
gland O O
who O O
are O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
need O O
to O O
increase O O
their O O
thyroid O B-group
dose O O
if O O
estrogens B-group B-group
or O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
are O O
given O O
. O O

These O O
drugs O O
should O O
be O O
coadministered O O
with O O
caution O O
, O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

Serum O O
samples O O
from O O
patients O O
treated O O
with O O
cefoxitin B-drug B-drug
should O O
not O O
be O O
analyzed O O
for O O
creatinine O O
if O O
withdrawn O O
within O O
2 O O
hours O O
of O O
drug O O
administration O O
. O O

- O O
Gold B-drug B-group
salts O I-group
( O O
medicine O O
for O O
arthritis O O
) O O
or O O

Calcium B-group B-group
channel I-group I-group
blockers I-group I-group
may O O
also O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
TENORMIN B-brand B-brand
. O O

Fluvoxamine B-drug B-drug
has O O
also O O
been O O
shown O O
to O O
inhibit O O
P450 O O
1A2 O O
, O O
an O O
isoform O O
also O O
involved O O
in O O
TCAmetabolism B-group O
. O O

Coadminstration O O
with O O
agents O O
that O O
induce O O
3A4 O O
activity O O
may O O
reduce O O
the O O
efficacy O O
of O O
DURAGESIC B-brand B-brand
. O O

1 O O
. O O

Antiarrhythmics B-group B-group
: O O
amiodarone B-drug B-drug

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

Administration O O
of O O
0.1-mg/kg O O
( O O
2 O O
x O O
ED95 O O
) O O
NIMBEX B-brand B-brand
at O O
10 O O
% O O
or O O
95 O O
% O O
recovery O O
following O O
an O O
intubating O O
dose O O
of O O
succinylcholine B-drug B-drug
( O O
1 O O
mg/kg O O
) O O
produced O O
95 O O
% O O
neuromuscular O O
block O O
. O O

There O O
have O O
been O O
reports O O
of O O
interactions O O
of O O
erythromycin B-drug B-drug
with O O
carbamazepine B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
hexobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
cisapride B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
bromocriptine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
terfenadine B-drug B-drug
, O O
and O O
astemizole B-drug B-drug
. O O

( O O
SGOT O O
) O O
, O O
ALT O O
( O O
SGPT O O
) O O

However O O
, O O
10 O O
patients O O
who O O
switched O O
from O O
therapy O O
with O O
Interferon B-drug B-drug
beta I-drug I-drug
to O O
COPAXONE B-brand B-brand
did O O
not O O
report O O
any O O
serious O O
and O O
unexpected O O
adverse O O
reactions O O
thought O O
to O O
be O O
related O O
to O O
treatment O O
. O O

Therefore O O
, O O
esomeprazole B-drug B-drug
may O O
interfere O O
with O O
the O O
absorption O O
of O O
drugs O O
where O O
gastric O O
pH O O
is O O
an O O
important O O
determinant O O
of O O
bioavailability O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
iron B-drug B-drug
salts O O
and O O
digoxin B-drug B-drug
) O O
. O O

In O O
a O O
similar O O
study O O
, O O
attempting O O
to O O
replicate O O
this O O
finding O O
, O O
no O O
interactive O O
effect O O
on O O
hepatic O O
transaminases O O
was O O
identified O O
. O O

inhalation O O
anesthetics B-group B-group
; O O

Because O O
of O O
its O O
lack O O
of O O
platelet O O
effects O O
, O O
CELEBREX B-brand B-brand
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

Paroxetine B-drug B-drug
( O O
20 O O
mg O O
QD O O
) O O
increased O O
the O O
concentration O O
of O O
duloxetine B-drug B-drug
( O O
40 O O
mg O O
QD O O
) O O
by O O
about O O
60 O O
% O O
, O O
and O O
greater O O
degrees O O
of O O
inhibition O O
are O O
expected O O
with O O
higher O O
doses O O
of O O
paroxetine B-drug B-drug
. O O

Thus O O
, O O
when O O
NSAIDs B-group B-group
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

These O O
findings O O
suggest O O
that O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
release O O
by O O
cholinergic O O
stimulation O O
is O O
critical O O
for O O
determining O O
synergism O O
with O O
cAMP O O
in O O
parietal O O
cell O O
activation O O
and O O
that O O
functional O O
coupling O O
between O O
the O O
Ca O O
( O O
2+ O O
) O O
store O O
and O O
the O O
receptor O O
is O O
maintained O O
by O O
actin O O
microfilaments O O
. O O

Dose O O
adjustments O O
of O O
either O O
class O O
of O O
agents O O
may O O
be O O
necessary O O
. O O

Serum O O
concentration O O
of O O
digoxin B-drug B-drug
and O O
digitoxin B-drug B-drug
may O O
increase O O
when O O
patients O O
take O O
antithyroid B-group B-group
agents I-group I-group
. O O

The O O
administration O O
of O O
naratriptan B-drug B-drug
with O O
other O O
5-HT1 B-group B-group
agonists I-group I-group
has O O
not O O
been O O
evaluated O O
in O O
migraine O O
patients O O
. O O

Molecular O O
basis O O
for O O
the O O
selective O O
toxicity O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
for O O
yeast O O
and O O
filipin B-drug_n B-drug_n
for O O
animal O O
cells O O
. O O

Estazolam B-drug B-drug
: O O
Interaction O O
with O O
Other O O
Drugs O O
that O O
are O O
Metabolized O O
by O O
Cytochrome O O
P450 O O
( O O
CYP O O
) O O
: O O
At O O
clinically O O
relevant O O
concentrations O O
, O O
in O O
vitro O O
studies O O
indicate O O
that O O
estazolam B-drug B-drug
( O O
0.6 O O
M O O
) O O
was O O
not O O
inhibitory O O
towards O O
the O O
major O O
cytochrome O O
P450 O O
isoforms O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
and O O
CYP3A O O
. O O

However O O
, O O
when O O
the O O
thioether O O
concentration O O
ranges O O
within O O
the O O
limits O O
of O O
the O O
normal O O
value O O
, O O
one O O
must O O
not O O
conclude O O
that O O
there O O
is O O
no O O
, O O
or O O
negligible O O
, O O
exposure O O
. O O

- O O
Naltrexone B-drug B-drug
( O O
e.g. O O
, O O
Trexan B-brand B-brand
) O O
( O O
with O O
long-term O O
, O O
high-dose O O
use O O
) O O
or O O

Drugs O O
that O O
reportedly O O
may O O
increase O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
increased O O
prothrombin O O
response O O
, O O
in O O
man O O
include O O
: O O
alcohol* B-drug B-drug
; O O

Again O O
, O O
sertraline B-drug B-drug
neutralized O O
the O O
increase O O
in O O
glycemia O O
after O O
glucose B-drug O
overload O O
both O O
in O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

Coadministration O O
of O O
phenytoin B-drug B-drug
with O O
40 O O
mg O O
SULAR B-brand B-brand
tablets O O
in O O
epileptic O O
patients O O
lowered O O
the O O
nisoldipine B-drug B-drug
plasma O O
concentrations O O
to O O
undetectable O O
levels O O
. O O

The O O
effects O O
of O O
coadministration O O
of O O
BARACLUDE B-brand B-brand
with O O
other O O
drugs O O
that O O
are O O
renally O O
eliminated O O
or O O
are O O
known O O
to O O
affect O O
renal O O
function O O
have O O
not O O
been O O
evaluated O O
, O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
for O O
adverse O O
events O O
when O O
BARACLUDE B-brand B-brand
is O O
coadministered O O
with O O
such O O
drugs O O
. O O

Garlic O O
Capsules O O
Garlic O O
capsules O O
should O O
not O O
be O O
used O O
while O O
taking O O
saquinavir B-drug B-drug
( O O
FORTOVASE B-brand B-brand
) O O
as O O
the O O
sole O B-group
protease B-group I-group
inhibitor I-group I-group
due O O
to O O
the O O
risk O O
of O O
decreased O O
saquinavir B-drug B-drug
plasma O O
concentrations O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

Mylotarg B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
any O O
routine O O
diagnostic O O
tests O O
. O O

pyrazolones B-group B-group
; O O

. O O

Oral O O
Hypoglycemics B-group B-group
: O O
Bepridil B-drug B-drug
has O O
been O O
safely O O
used O O
in O O
diabetic O O
patients O O
without O O
significantly O O
lowering O O
their O O
blood O O
glucose O O
levels O O
or O O
altering O O
their O O
need O O
for O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

however O O
, O O
patients O O
with O O
moderate O O
to O O
severe O O
cardiovascular O O
disease O O
or O O
those O O
taking O O
nitrate B-group B-drug
therapy O O
are O O
at O O
increased O O
risk O O
for O O
potentially O O
serious O O
cardiovascular O O
adverse O O
effects O O
with O O
sildenafil B-drug B-drug
therapy O O
. O O

A O O
dose O O
increase O O
of O O
lopinavir/ritonavir B-drug B-drug
to O O
533/133 O O
mg O O
( O O
4 O O
capsules O O
or O O
6.5 O O
mL O O
) O O
twice O O
daily O O
taken O O
with O O
food O O
is O O
recommended O O
when O O
used O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

Systemic O B-group
antibiotic B-group I-group
agents I-group I-group
. O O

Currently O O
, O O
it O O
is O O
conceived O O
that O O
a O O
number O O
of O O
events O O
, O O
or O O
hits O O
, O O
are O O
required O O
for O O
the O O
induction O O
of O O
tumors O O
by O O
chemical O O
agents O O
. O O

In O O
contrast O O
, O O
in O O
Ontario O O
alone O O
, O O
in O O
1972 O O
and O O
1973 O O
there O O
were O O
26 O O
deaths O O
in O O
amphetamine B-drug B-drug
users O O
, O O
of O O
which O O
16 O O
were O O
due O O
to O O
accident O O
suicide O O
or O O
homicide O O
. O O

These O O
effects O O
have O O
been O O
observed O O
with O O
co-administration O O
of O O
itraconazole B-drug B-drug
( O O
a O O
potent O O
CYP3A4 B-drug O
inhibitor O O
) O O
. O O

Thus O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
and O O
Fluvoxamine B-drug B-drug
Tablets O O
should O O
have O O
their O O
prothrombin O O
time O O
monitored O O
and O O
their O O
anticoagulant B-group B-group
dose O O
adjusted O O
accordingly O O
. O O

We O O
compared O O
indinavir B-drug B-drug
pharmacokinetics O O
and O O
gastric O O
pH O O
in O O
12 O O
human O O
immunodeficiency O O
virus-positive O O
patients O O
by O O
use O O
of O O
800 O O
mg O O
of O O
indinavir B-drug B-drug
alone O O
versus O O
800 O O
mg O O
of O O
indinavir B-drug B-drug
administered O O
1 O O
h O O
after O O
didanosine B-drug B-drug
administration O O
. O O

3 O O
. O O

The O O
possible O O
adverse O O
effects O O
of O O
ZINECARD B-brand B-brand
on O O
the O O
fertility O O
of O O
humans O O
and O O
experimental O O
animals O O
, O O
male O O
or O O
female O O
, O O
have O O
not O O
been O O
adequately O O
studied O O
. O O

Terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
and O O
cisapride B-drug B-drug
are O O
all O O
metabolized O O
by O O
the O O
cytochrome O O
P450IIIA4 O O
isozyme O O
, O O
and O O
it O O
has O O
been O O
demonstrated O O
that O O
ketoconazole B-drug B-drug
, O O
a O O
potent O O
inhibitor O O
of O O
IIIA4 O O
, O O
blocks O O
the O O
metabolism O O
of O O
these O O
drugs O O
, O O
resulting O O
in O O
increased O O
plasma O O
concentrations O O
of O O
parent O O
drug O O
. O O

Loperamide B-drug B-drug
and O O
morphine B-drug B-drug
( O O
0.1 O O
and O O
1.0 O O
mg/kg O O
, O O
s.c. O O
) O O
inhibited O O
the O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
, O O
p.o O O
. O O
) O O
-induced O O
diarrhea O O
in O O
cecectomized O O
rats O O
. O O

In O O
geriatric O O
subjects O O
( O O
n=7 O O
) O O
there O O
was O O
a O O
reduction O O
in O O
the O O
rate O O
but O O
not O O
the O O
extent O O
of O O
flurbiprofen B-drug B-drug
absorption O O
. O O

Influence O O
of O O
coadministration O O
of O O
fluoxetine B-drug B-drug
on O O
cisapride B-drug B-drug
pharmacokinetics O O
and O O
QTc O O
intervals O O
in O O
healthy O O
volunteers O O
. O O

Coadministration O O
of O O
esomeprazole B-drug B-drug
30 O O
mg O O
and O O
diazepam B-drug B-drug
, O O
a O O
CYP2C19 O O
substrate O O
, O O
resulted O O
in O O
a O O
45 O O
% O O
decrease O O
in O O
clearance O O
of O O
diazepam B-drug B-drug
. O O

. O O

SIDE O O
EFFECTS O O
( O O
KEMSTRO B-brand B-brand
) O O
The O O
most O O
common O O
adverse O O
reaction O O
during O O
treatment O O
with O O
baclofen B-drug B-drug
is O O
transient O O
drowsiness O O
( O O
10-63 O O
% O O
) O O
. O O

Coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
drugs O O
primarily O O
metabolized O O
by O O
CYP3A4 O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
other O O
drug O O
, O O
which O O
could O O
increase O O
or O O
prolong O O
its O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

The O O
relevance O O
of O O
this O O
finding O O
to O O
humans O O
is O O
not O O
known O O
at O O
this O O
time O O
. O O

Effect O O
of O O
Sensipar B-brand B-brand
on O O
other O O
drugs O O
: O O
Drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
2D6 O O
( O O
CYP2D6 O O
) O O
: O O
Sensipar B-brand B-brand
is O O
a O O
strong O O
in O O
vitro O O
inhibitor O O
of O O
CYP2D6 O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
pharmacokinetic O O
basis O O
of O O
this O O
interaction O O
in O O
10 O O
normal O O
subjects O O
. O O

In O O
uninfected O O
volunteers O O
, O O
46 O O
% O O
developed O O
rash O O
while O O
receiving O O
SUSTIVA B-brand B-brand
and O O
clarithromycin B-drug B-drug
. O O

Interactions O O
for O O
Vitamin B-drug B-drug
B3 I-drug I-drug
( O O
Niacin B-drug B-drug
) O O
: O O
Antihypertensive B-group B-group
Therapy O O
: O O
Nicotinic B-drug B-drug
acid I-drug I-drug
may O O
potentiate O O
the O O
effects O O
of O O
ganglionic B-group B-group
blocking I-group I-group
agents I-group I-group
and O O
vasoactive O B-group
drugs O I-group
resulting O O
in O O
postural O O
hypotension O O
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Following O O
oral O O
administration O O
of O O
two O O
150-mg O O
sustained-release O O
tablets O O
with O O
and O O
without O O
800 O O
mg O O
of O O
cimetidine B-drug B-drug
, O O
the O O
pharmacokinetics O O
of O O
bupropion B-drug B-drug
and O O
hydroxybupropion B-drug_n B-drug_n
were O O
unaffected O O
. O O

In O O
addition O O
, O O
most O O
macrolides B-group B-group
are O O
contraindicated O O
in O O
patients O O
receiving O O
terfenadine B-drug B-drug
therapy O O
who O O
have O O
pre-existing O O
cardiac O O
abnormalities O O
( O O
arrhythmia O O
, O O
bradycardia O O
, O O
QT O O
c O O
interval O O
prolongation O O
, O O
ischemic O O
heart O O
disease O O
, O O
congestive O O
heart O O
failure O O
, O O
etc O O
. O O
) O O
or O O
electrolyte O O
disturbances O O
. O O

OBJECTIVE O O
: O O
This O O
paper O O
reviews O O
recent O O
studies O O
of O O
the O O
efficacy O O
of O O
sildenafil B-drug B-drug
, O O
its O O
adverse O O
effects O O
and O O
drug O O
interactions O O
, O O
and O O
socioeconomic O O
factors O O
involved O O
in O O
its O O
use O O
, O O
with O O
a O O
focus O O
on O O
specific O O
patient O O
populations O O
( O O
prostate O O
cancer O O
, O O
diabetes O O
mellitus O O
, O O
ischemic O O
heart O O
disease O O
, O O
spinal O O
cord O O
injuries O O
, O O
neurologic O O
disorders O O
) O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Measurement O O
of O O
serum O O
creatinine O O
levels O O
should O O
be O O
determined O O
by O O
the O O
Jaffe O O
reaction O O
, O O
since O O
Ancobon B-brand B-brand
does O O
not O O
interfere O O
with O O
the O O
determination O O
of O O
creatinine O O
values O O
by O O
this O O
method O O
. O O

Other O O
strong O O
selective O O
CYP3A4 O O
inhibitors O O
such O O
as O O
ketoconazole B-drug B-drug
can O O
also O O
be O O
expected O O
to O O
increase O O
the O O
exposure O O
of O O
zaleplon B-drug B-drug
. O O

Phenobarbital B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenobarbital B-drug B-drug
; O O

In O O
two O O
combined O O
12-week O O
placebo O O
controlled O O
trials O O
that O O
included O O
BROVANA B-brand B-brand
doses O O
of O O
15 O O
mcg O O
twice O O
daily O O
, O O
25 O O
mcg O O
twice O O
daily O O
, O O
and O O
50 O O
mcg O O
once O O
daily O O
, O O
54 O O
of O O
873 O O
BROVANA B-brand B-brand
-treated O O
subjects O O
received O O
concomitant O O
theophylline B-drug B-drug
at O O
study O O
entry O O
. O O

Limited O O
comparative O O
data O O
in O O
patients O O
with O O
high O O
viral O O
loads O O
treated O O
with O O
nevirapine- B-drug O
or O O
delavirdine-based B-drug O
regimens O O
currently O O
exist O O
. O O

Norepinephrine B-drug B-drug
: O O
Amphetamines B-group B-group
enhance O O
the O O
adrenergic O O
effect O O
of O O
norepinephrine B-drug B-drug
. O O

Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
400 O O
mg O O
daily O O
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
rofecoxib B-drug B-drug
. O O

) O O

paraldehyde B-drug B-drug
; O O

*Not O O
administered O O
, O O
but O O
an O O
active O O
metabolite O O
of O O
carbamazepine B-drug B-drug
. O O

Clinical O O
studies O O
have O O
shown O O
increased O O
sedation O O
with O O
concurrent O O
hypnotic B-group B-group
medications I-group I-group
. O O

The O O
digoxin B-drug B-drug
median O O
tmax O O
was O O
0.5 O O
hours O O
for O O
both O O
treatments O O
. O O

No O O
pharmacokinetic O O
interactions O O
between O O
dexmedetomidine B-drug B-drug
and O O
isoflurane B-drug B-drug
, O O
propofol B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
and O O
midazolam B-drug B-drug
have O O
been O O
demonstrated O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
the O O
dosage O O
are O O
required O O
when O O
nortriptyline B-drug B-drug
hydrochloride I-drug I-drug
is O O
used O O
with O O
other O O
anticholinergic B-group B-group
drugs I-group I-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Also O O
flucytosine B-drug B-drug
. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Theophylline B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
dose O O
adjustments O O
considered O O
for O O
patients O O
given O O
both O O
theophylline B-drug B-drug
and O O
PEGASYS B-brand B-brand
. O O

AXERT B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

Bosentan B-drug B-drug
is O O
also O O
expected O O
to O O
reduce O O
plasma O O
concentrations O O
of O O
other O O
statins B-group B-group
that O O
have O O
significant O O
metabolism O O
by O O
CYP3A4 O O
, O O
such O O
as O O
lovastatin B-drug B-drug
and O O
atorvastatin B-drug B-drug
. O O

No O O
clinically O O
relevant O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
these O O
CYP O O
enzymes O O
would O O
be O O
expected O O
. O O

therefore O O
, O O
nitroglycerin B-drug B-drug
or O O
other O O
nitrates B-group B-group
( O O
as O O
used O O
for O O
management O O
of O O
angina O O
) O O
or O O
other O O
drugs O O
having O O
vasodilator O O
activity O O
should O O
, O O
if O O
possible O O
, O O
be O O
discontinued O O
before O O
starting O O
captopril B-drug B-drug
. O O

( O O
Thiazide B-group B-group
drugs I-group I-group
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-drug B-drug
. O O
) O O

DISULFIRAM B-drug B-drug
SHOULD O O
BE O O
USED O O
WITH O O
CAUTION O O
IN O O
THOSE O O
PATIENTS O O
REVEIVING O B-brand
PHENYTOIN B-drug B-drug
AND O O
ITS O O
CONGENERS O O
. O O

These O O
increased O O
exposures O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
should O O
be O O
taken O O
into O O
consideration O O
when O O
selecting O O
an O O
oral O O
contraceptive B-group B-group
for O O
women O O
taking O O
valdecoxib B-drug B-drug
. O O

Patients O O
receiving O O
narrow O O
therapeutic O O
ratio O O
drugs O O
or O O
other O O
drugs O O
that O O
require O O
careful O O
titration O O
should O O
be O O
followed O O
closely O O
; O O

Evidence O O
supporting O O
the O O
conclusion O O
that O O
it O O
is O O
inadvisable O O
to O O
co-administer O O
fluvoxamine B-drug B-drug
and O O
diazepam B-drug B-drug
is O O
derived O O
from O O
a O O
study O O
in O O
which O O
healthy O O
volunteers O O
taking O O
150 O O
mg/day O O
of O O
fluvoxamine B-drug B-drug
were O O
administered O O
a O O
single O O
oral O O
dose O O
of O O
10 O O
mg O O
of O O
diazepam B-drug B-drug
. O O

Inhibition O O
of O O
these O O
isoenzymes O O
may O O
increase O O
the O O
plasma O O
concentration O O
of O O
bosentan B-drug B-drug
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
in O O
vitro O O
finding O O
that O O
neither O O
isotretinoin B-drug B-drug
nor O O
its O O
metabolites O O
induce O O
or O O
inhibit O O
the O O
activity O O
of O O
the O O
CYP O O
2C9 O O
human O O
hepatic O O
P450 O O
enzyme O O
. O O

Although O O
clinical O O
studies O O
have O O
not O O
been O O
conducted O O
, O O
in O O
vitro O O
studies O O
of O O
iloprost B-drug B-drug
indicate O O
that O O
no O O
relevant O O
inhibition O O
of O O
cytochrome O O
P450 O O
drug O O
metabolism O O
would O O
be O O
expected O O
. O O

Quinolone B-group B-group
Antibiotics O I-group
: O O
VIDEX B-brand B-brand
should O O
be O O
administered O O
at O O
least O O
2 O O
hours O O
after O O
or O O
6 O O
hours O O
before O O
dosing O O
with O O
ciprofloxacin B-drug B-drug
because O O
plasma O O
concentrations O O
of O O
ciprofloxacin B-drug B-drug
are O O
decreased O O
when O O
administered O O
with O O
antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
aluminum B-drug B-drug
. O O

Thyroid B-group B-group
administration O O
to O O
a O O
digitalized O O
, O O
hypothyroid O O
patient O O
may O O
increase O O
the O O
dose O O
requirement O O
of O O
digoxin B-drug B-drug
. O O

Similarly O O
, O O
diazepam B-drug B-drug
decreased O O
the O O
antinociceptive O O
effect O O
of O O
metamizol B-drug B-drug
( O O
only O O
in O O
the O O
tail-flick O O
test O O
) O O
and O O
indomethacin B-drug B-drug
. O O

The O O
following O O
are O O
examples O O
of O O
substances O O
that O O
may O O
increase O O
the O O
blood-glucose-lowering O O
effect O O
and O O
susceptibility O O
to O O
hypoglycemia O O
: O O
oral O O
antidiabetes O B-group
products O I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
disopyramide B-drug B-drug
, O O
fibrates B-group B-group
, O O
fluoxetine B-drug B-drug
, O O
MAO B-group B-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
salicylates B-group B-group
, O O
somatostatin B-group B-group
analog I-group I-group
( O O
e.g. O O
, O O
octreotide B-drug B-drug
) O O
, O O
sulfonamide B-group B-group
antibiotics I-group I-group
. O O

Patients O O
should O O
be O O
monitored O O
for O O
signs O O
of O O
withdrawal O O
and O O
their O O
methadone B-drug B-drug
dose O O
increased O O
as O O
required O O
to O O
alleviate O O
withdrawal O O
symptoms O O
. O O

Therefore O O
, O O
positive O O
test O O
results O O
in O O
patients O O
receiving O O
piperacillin B-drug B-drug
should O O
be O O
interpreted O O
cautiously O O
and O O
confirmed O O
by O O
other O O
diagnostic O O
methods O O
. O O

Concomitant O O
use O O
of O O
cimetidine B-drug B-drug
should O O
be O O
avoided O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
antacids B-group B-group
may O O
reduce O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

In O O
patients O O
who O O
have O O
been O O
reported O O
to O O
be O O
well O O
controlled O O
on O O
tricyclic B-group B-group
antidepressants I-group I-group
receiving O O
concurrent O O
cimetidine B-drug B-drug
therapy O O
, O O
discontinuation O O
of O O
cimetidine B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
established O O
steady-state O O
serum O O
tricyclic B-group B-group
antidepressant I-group I-group
levels O O
and O O
compromise O O
their O O
therapeutic O O
effects O O
. O O

Insulin B-drug B-drug
requirements O O
in O O
diabetic O O
patients O O
may O O
be O O
increased O O
, O O
decreased O O
, O O
or O O
unchanged O O
. O O

at O O
high O O
doses O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
decreased O O
FI O O
and O O
FR O O
responding O O
. O O

The O O
pharmacokinetics O O
of O O
terfenadine B-drug B-drug
and O O
its O O
acid O O
metabolite O O
and O O
the O O
electrocardiographic O O
QT O O
c O O
interval O O
were O O
measured O O
during O O
both O O
periods O O
: O O
with O O
terfenadine B-drug B-drug
alone O O
, O O
and O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

Thus O O
, O O
if O O
such O O
treatment O O
is O O
essential O O
, O O
the O O
possibility O O
of O O
increased O O
risk O O
relative O O
to O O
benefits O O
should O O
be O O
considered O O
. O O

In O O
10 O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
ingesting O O
phenytoin B-drug B-drug
, O O
the O O
steadystate O O
trough O O
( O O
Cmin O O
) O O
phenytoin B-drug B-drug
plasma O O
concentration O O
was O O
17 O O
5 O O
micrograms/mL O O
. O O

Antiretroviral B-group B-group
Agents I-group I-group
: O O
No O O
drug O O
interactions O O
with O O
other O O
antiretroviral B-group B-group
medications I-group I-group
have O O
been O O
identified O O
that O O
would O O
warrant O O
alteration O O
of O O
either O O
the O O
enfuvirtide B-drug B-drug
dose O O
or O O
the O O
dose O O
of O O
the O O
other O O
antiretroviral B-group B-group
medication I-group I-group
. O O

Toxicology O O
studies O O
of O O
heroin-related B-drug_n B-drug_n
deaths O O
reveal O O
frequent O O
involvement O O
of O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
, O O
including O O
alcohol B-drug B-drug
, O O
benzodiazepines B-group B-group
such O O
as O O
diazepam B-drug B-drug
( O O
Valium B-brand B-brand
) O O
, O O
and O O
, O O
to O O
a O O
rising O O
degree O O
, O O
methadone B-drug B-drug
. O O

Aprepitant B-drug B-drug
has O O
been O O
shown O O
to O O
induce O O
the O O
metabolism O O
of O O
S B-drug B-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
and O O
tolbutamide B-drug B-drug
, O O
which O O
are O O
metabolized O O
through O O
CYP2C9 O O
. O O

5 O O
. O O

Although O O
increased O O
plasma O O
concentrations O O
( O O
C O O
max O O
and O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
desloratadine B-drug B-drug
and O O
3-hydroxydesloratadine B-drug_n B-drug_n
were O O
observed O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
safety O O
profile O O
of O O
desloratadine B-drug B-drug
, O O
as O O
assessed O O
by O O
electrocardiographic O O
parameters O O
( O O
including O O
the O O
corrected O O
QT O O
interval O O
) O O
, O O
clinical O O
laboratory O O
tests O O
, O O
vital O O
signs O O
, O O
and O O
adverse O O
events O O
. O O

Plasma O O
exposure O O
of O O
diazepam B-drug B-drug
( O O
10 O O
mg O O
BID O O
) O O
was O O
increased O O
by O O
28 O O
% O O
following O O
administration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
for O O
12 O O
days O O
, O O
while O O
plasma O O
exposure O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
was O O
not O O
substantially O O
increased O O
following O O
administration O O
of O O
diazepam B-drug B-drug
( O O
10 O O
mg O O
BID O O
) O O
for O O
12 O O
days O O
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
ampicillin B-drug B-drug
. O O

Concomitant O O
treatment O O
with O O
methylxanthines B-group B-group
( O O
aminophylline B-drug B-drug
, O O
theophylline B-drug B-drug
) O O
, O O
steroids B-group B-group
, O O
or O O
diuretics B-group B-group
may O O
potentiate O O
any O O
hypokalemic O O
effect O O
of O O
adrenergic B-group B-group
agonists I-group I-group
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Drug/LaboratoryTest O O
Interactions O O
Dactinomycin B-drug B-drug
may O O
interfere O O
with O O
bioassay O O
procedures O O
for O O
the O O
determination O O
of O O
antibacterial B-group B-group
drug I-group I-group
levels O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
p.o O O
. O O

Intravenous O O
Adenocard B-brand B-brand
( O O
adenosine B-drug B-drug
) O O
has O O
been O O
effectively O O
administered O O
in O O
the O O
presence O O
of O O
other O O
cardioactive O B-group
drugs O I-group
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
agents I-group I-group
, O O
and O O
angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
without O O
any O O
change O O
in O O
the O O
adverse O O
reaction O O
profile O O
. O O

8 O O
. O O

At O O
24 O O
hours O O
postdose O O
, O O
a O O
similar O O
proportion O O
of O O
patients O O
treated O O
with O O
methotrexate B-drug B-drug
alone O O
( O O
94 O O
% O O
) O O
and O O
subsequently O O
treated O O
with O O
methotrexate B-drug B-drug
co-administered O O
with O O
75 O O
mg O O
of O O
rofecoxib B-drug B-drug
( O O
88 O O
% O O
) O O
had O O
methotrexate B-drug B-drug
plasma O O
concentrations O O
below O O
the O O
measurable O O
limit O O
( O O
5 O O
ng/mL O O
) O O
. O O

In O O
a O O
p53 O O
( O O
+/- O O
) O O
mouse O O
carcinogenicity O O
study O O
at O O
doses O O
up O O
to O O
the O O
maximum O O
tolerated O O
dose O O
of O O
100 O O
mg/kg/day O O
ribavirin B-drug B-drug
was O O
not O O
oncogenic O O
. O O

Results O O
of O O
studies O O
in O O
multiple O O
sclerosis O O
patients O O
taking O O
TYSABRI B-brand B-brand
and O O
concomitant O O
interferon B-drug B-drug
beta-1a I-drug I-drug
( O O
AVONEX B-brand B-brand
30 O O
mcg O O
IM O O
once O O
weekly O O
) O O
or O O
glatiramer B-drug O
acetate I-drug B-drug
were O O
inconclusive O O
with O O
regard O O
to O O
the O O
need O O
for O O
dose O O
adjustment O O
of O O
the O O
beta-interferon B-drug B-drug
or O O
glatiramer B-drug O
acetate I-drug B-drug
. O O

Laboratory O O
Test O O
Interactions O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
Caucasian O O
population O O
( O O
about O O
7-10 O O
% O O
of O O
Caucasians O O
are O O
so-called O O
poor O O
metabolizers O O
) O O
; O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
other O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450IID6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

In O O
general O O
, O O
any O O
added O O
antiarrhythmic B-drug B-group
drug I-drug I-group
should O O
be O O
initiated O O
at O O
a O O
lower O O
than O O
usual O O
dose O O
with O O
careful O O
monitoring O O
. O O

There O O
have O O
been O O
rare O O
postmarketing O O
reports O O
of O O
rhabdomyolysis O O
, O O
some O O
associated O O
with O O
strenuous O O
physical O O
activity O O
. O O

The O O
effects O O
of O O
concomitant O O
administration O O
of O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
on O O
the O O
PR O O
interval O O
were O O
less O O
than O O
additive O O
. O O

Influence O O
of O O
calcium-channel B-group B-group
blockers I-group I-group
on O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
. O O

Amphetamines B-group B-group
may O O
interfere O O
with O O
urinary O O
steroid O O
determinations O O
. O O

Studies O O
have O O
shown O O
that O O
lansoprazole B-drug B-drug
does O O
not O O
have O O
clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
antipyrine B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
prednisone B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
or O O
terfenadine B-drug B-drug
in O O
healthy O O
subjects O O
. O O

We O O
report O O
the O O
case O O
of O O
an O O
adolescent O O
with O O
altered O O
consciousness O O
caused O O
by O O
carbamazepine B-drug B-drug
overdose O O
with O O
a O O
positive O O
tricyclic B-group B-group
antidepressant I-group I-group
level O O
to O O
alert O O
clinicians O O
to O O
the O O
cross-reactivity O O
of O O
carbamazepine B-drug B-drug
with O O
a O O
toxicology O O
screen O O
for O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

nc1 O O
18 O O
% O O
decrease O O
[ O O
CI O O
: O O
13 O O
% O O
decrease O O
, O O
40 O O
% O O
decrease O O
] O O

Trough O O
plasma O O
enoxacin B-drug B-drug
levels O O
were O O
also O O
20 O O
% O O
higher O O
when O O
caffeine B-drug B-drug
and O O
enoxacin B-drug B-drug
were O O
administered O O
concomitantly O O
. O O

In O O
contrast O O
, O O
preliminary O O
results O O
from O O
an O O
8-week O O
controlled O O
study O O
suggested O O
risperidone B-drug B-drug
2 O O
to O O
6 O O
mg/day O O
was O O
superior O O
to O O
olanzapine B-drug B-drug
5 O O
to O O
20 O O
mg/day O O
against O O
positive O O
and O O
anxiety/depressive O O
symptoms O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
although O O
consistent O O
with O O
the O O
first O O
study O O
, O O
both O O
agents O O
demonstrated O O
similar O O
efficacy O O
on O O
measures O O
of O O
overall O O
psychopathology O O
. O O

The O O
goal O O
of O O
this O O
review O O
was O O
to O O
cite O O
primary O O
sources O O
for O O
virtually O O
all O O
research O O
specific O O
to O O
POPs O O
since O O
1975 O O
. O O

Then O O
, O O
the O O
effects O O
of O O
metabotropic O O
glutamate O O
receptor O O
( O O
mGluR O O
) O O
agonists O O
, O O
DCG-IV B-drug_n B-drug_n
and O O
L-CCG-1 B-drug_n B-drug_n
, O O
on O O
the O O
above O O
behavioral O O
changes O O
induced O O
by O O
PCP B-drug_n B-drug_n
were O O
found O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

Patients O O
treated O O
with O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
and O O
warfarin B-drug B-drug
concomitantly O O
may O O
need O O
to O O
be O O
monitored O O
for O O
increases O O
in O O
INR O O
and O O
prothrombin O O
time O O
. O O

Both O O
hypo- O O
and O O
hyperglycemic O O
effects O O
have O O
been O O
reported O O
. O O

There O O
were O O
no O O
clinically O O
significant O O
changes O O
in O O
corrected O O
QT O O
intervals O O
during O O
administration O O
of O O
cisapride B-drug B-drug
alone O O
or O O
with O O
fluoxetine B-drug B-drug
. O O

A O O
rare O O
, O O
but O O
serious O O
, O O
constellation O O
of O O
symptoms O O
, O O
termed O O
serotonin O O
syndrome O O
, O O
has O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
and O O
agents O O
for O O
migraine O O
therapy O O
, O O
such O O
as O O
Imitrex B-brand B-brand
( O O
sumatriptan B-drug B-drug
succinate I-drug I-drug
) O O
and O O
dihydroergotamine B-drug B-drug
. O O

Concomitant O O
cyclophosphamide B-drug B-drug
, O O
doxorubicin B-drug B-drug
, O O
vincristine B-drug B-drug
, O O
and O O
prednisone B-drug B-drug
chemotherapy O O
plus O O
highly B-group O
active I-group O
antiretroviral I-group B-group
therapy O O
in O O
patients O O
with O O
human O O
immunodeficiency O O
virus-related O O
, O O
non-Hodgkin O O
lymphoma O O
. O O

Most O O
automated O O
equipment O O
for O O
measurement O O
of O O
creatinine O O
makes O O
use O O
of O O
the O O
Jaffe O O
reaction O O
. O O

Some O O
quinolones B-group B-group
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

vii O O
. O O

No O O
inhibition O O
of O O
deferasirox B-drug B-drug
metabolism O O
by O O
hydroxyurea B-drug B-drug
is O O
expected O O
based O O
on O O
the O O
results O O
of O O
an O O
in O O
vitro O O
study O O
. O O

Since O O
aminotransferase O O
determinations O O
are O O
important O O
in O O
the O O
differential O O
diagnosis O O
of O O
myocardial O O
infarction O O
, O O
liver O O
disease O O
and O O
pulmonary O O
emboli O O
, O O
rises O O
that O O
might O O
be O O
caused O O
by O O
drugs O O
( O O
heparin B-drug B-drug
sodium I-drug I-drug
) O O
should O O
be O O
interpreted O O
with O O
caution O O
. O O

This O O
product O O
can O O
affect O O
the O O
results O O
of O O
certain O O
lab O O
tests O O
. O O

The O O
mean O O
QT O O
c O O
interval O O
( O O
msec O O
) O O
was O O
369 O O
with O O
terfenadine B-drug B-drug
alone O O
and O O
367 O O
with O O
terfenadine B-drug B-drug
plus O O
dirithromycin B-drug B-drug
. O O

Therefore O O
you O O
may O O
need O O
to O O
take O O
a O O
vitamin B-drug B-group
B12 I-drug I-group
supplement O O
while O O
taking O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
. O O

Beta B-group B-group
Blockers I-group I-group

Atorvastatin B-drug B-drug
: O O
Atorvastatin B-drug B-drug
increases O O
the O O
AUC O O
for O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Combinations O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
were O O
indifferent O O
for O O
29 O O
strains O O
and O O
synergistic O O
for O O
33 O O
strains O O
. O O

Agents O O
Causing O O
Renin O O
Release O O
Captopril B-drug B-drug
's O O
effect O O
will O O
be O O
augmented O O
by O O
antihypertensive B-group B-group
agents I-group I-group
that O O
cause O O
renin O O
release O O
. O O

Amprenavir B-drug B-drug
inhibits O O
the O O
ERMBT O O
, O O
and O O
rifampin B-drug B-drug
and O O
rifabutin B-drug B-drug
are O O
equipotent O O
inducers O O
of O O
the O O
ERMBT O O
. O O

Concomitant O O
use O O
of O O
zalcitabine B-drug B-drug
and O O
lamivudine B-drug B-drug
is O O
not O O
recommended O O
. O O

Although O O
activation O O
of O O
several O O
transcription O O
factor O O
IEGs O O
has O O
been O O
described O O
, O O
little O O
is O O
known O O
about O O
effector O O
IEGs O O
. O O

Clostridium B-drug_n B-drug_n
difficile I-drug_n I-drug_n
toxin I-drug_n I-drug_n
A I-drug_n I-drug_n
displays O O
both O O
cytotoxic O O
and O O
enterotoxic O O
activities O O
. O O

It O O
is O O
likely O O
that O O
experience O O
significantly O O
underestimates O O
the O O
degree O O
of O O
accumulation O O
that O O
might O O
occur O O
with O O
repealed O O
diazepam B-drug B-drug
administration O O
. O O

The O O
use O O
of O O
dexfenfluramine B-drug B-drug
with O O
other O O
CNS-active O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
; O O

NSAIDs B-group B-group
may O O
decrease O O
the O O
hemodynamic O O
effects O O
of O O
hydralazine B-drug B-drug
; O O

therefore O O
, O O
close O O
monitoring O O
of O O
prothrombin O O
time O O
is O O
recommended O O
, O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
when O O
Tagamet B-brand B-brand
is O O
administered O O
concomitantly O O
. O O

Genetic O O
variation O O
also O O
occurs O O
in O O
proteins O O
interacting O O
with O O
drugs O O
, O O
which O O
may O O
change O O
the O O
effect O O
of O O
e.g O O
. O O

Before O O
using O O
this O O
medication O O
, O O
tell O O
your O O
doctor O O
or O O
pharmacist O O
of O O
all O O
prescription O O
and O O
nonprescription O O
products O O
you O O
may O O
use O O
, O O
especially O O
of O O
: O O
aminoglycosides B-group B-group
( O O
e.g. O O
, O O
gentamicin B-drug B-drug
, O O
amikacin B-drug B-drug
) O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
cyclosporine B-drug B-drug
, O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs O I-group
( O O
e.g. O O
, O O
ibuprofen B-drug B-drug
) O O
, O O
tacrolimus B-drug B-drug
, O O
vancomycin B-drug B-drug
. O O

- O O
a O O
diuretic B-group B-group
( O O
water O O
pill O O
) O O
such O O
as O O
hydrochlorothiazide B-drug B-drug
( O O
HCTZ B-drug B-drug
, O O
Hydrodiuril B-brand B-drug
) O O
, O O
chlorothiazide B-drug B-drug
( O O
Diuril B-brand B-brand
) O O
, O O
and O O
others O O
; O O

Diuretics B-group B-group
: O O
Etodolac O B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
furosemide B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug
. O O

Interaction O O
studies O O
have O O
been O O
performed O O
with O O
fluvastatin B-drug B-drug
and O O
several O O
drugs O O
with O O
which O O
it O O
might O O
be O O
coadministered O O
. O O

As O O
with O O
other O O
antihypertensive B-group B-group
agents I-group I-group
, O O
the O O
antihypertensive O O
effect O O
of O O
losartan B-drug B-drug
may O O
be O O
blunted O O
by O O
the O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
drug I-group I-group
indomethacin B-drug B-drug

Erythromycin O B-drug
Co-administration O O
of O O
felodipine B-drug B-drug
( O O
PLENDIL B-drug B-brand
) O O
with O O
erythromycin B-drug B-drug
resulted O O
in O O
approximately O O
2.5- O O
fold O O
increase O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
and O O
about O O
2- O O
fold O O
prolongation O O
in O O
the O O
half- O O
life O O
of O O
felodipine B-drug B-drug
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
VELCADE B-brand B-brand
. O O

If O O
SPRYCEL B-brand B-brand
must O O
be O O
administered O O
with O O
a O O
CYP3A4 O O
inducer O O
, O O
a O O
dose O O
increase O O
in O O
SPRYCEL B-brand B-brand
should O O
be O O
considered O O
. O O

In O O
a O O
multiple-dose O O
study O O
, O O
enoxacin B-drug B-drug
caused O O
a O O
dose-related O O
increase O O
in O O
the O O
mean O O
elimination O O
half-life O O
of O O
caffeine B-drug B-drug
, O O
thereby O O
decreasing O O
the O O
clearance O O
of O O
caffeine B-drug B-drug
by O O
up O O
to O O
80 O O
% O O
and O O
leading O O
to O O
a O O
five-fold O O
increase O O
in O O
the O O
AUC O O
and O O
the O O
half-life O O
of O O
caffeine B-drug B-drug
. O O

Interaction O O
between O O
exogenous O O
and O O
endogenous O O
oxytocin B-drug B-drug
and O O
vasopressin O B-drug
was O O
found O O
to O O
affect O O
the O O
mechanism O O
of O O
milk O O
ejection O O
by O O
the O O
alveoli O O
of O O
the O O
mammary O O
gland O O
in O O
lactating O O
rats O O
. O O

Administration O O
of O O
ELLENCE B-brand B-brand
after O O
previous O O
radiation O O
therapy O O
may O O
induce O O
an O O
inflammatory O O
recall O O
reaction O O
at O O
the O O
site O O
of O O
the O O
irradiation O O
. O O

[ O O
The O O
effect O O
of O O
cimetidine B-drug B-drug
on O O
the O O
renal O O
excretion O O
of O O
verografin B-drug B-drug
and O O
iodamide B-drug B-drug
in O O
dogs O O
] O O
The O O
intravenous O O
injection O O
of O O
cimetidine B-drug B-drug
in O O
a O O
dose O O
of O O
20 O O
mg/kg O O
enhanced O O
verografine B-drug B-drug
and O O
iodamide B-drug B-drug
excretion O O
in O O
chronic O O
canine O O
experiments O O
. O O

An O O
adjustment O O
in O O
the O O
diltiazem B-drug B-drug
dose O O
may O O
be O O
warranted O O
. O O

The O O
concomitant O O
use O O
of O O
heparin B-drug B-drug
or O O
aspirin B-brand B-brand
during O O
the O O
first O O
24 O O
hours O O
following O O
symptom O O
onset O O
were O O
prohibited O O
in O O
The O O
NINDS O O
t-PA O O
Stroke O O
Trial O O
. O O

The O O
effects O O
of O O
concomitant O O
administration O O
of O O
cimetidine B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
bupropion B-drug B-drug
and O O
its O O
active O O
metabolites O O
were O O
studied O O
in O O
24 O O
healthy O O
young O O
male O O
volunteers O O
. O O

Gleevec B-brand B-brand
will O O
increase O O
plasmaconcentration O O
of O O
other O O
CYP3A4 O O
metabolized O O
drugs O O
( O O
e.g. O O
, O O
triazolo-benzodiazepines B-group B-group
, O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
, O O
certain O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
, O O
etc O O
. O O
) O O
. O O

Pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
were O O
also O O
not O O
affected O O
by O O
phenytoin B-drug B-drug
. O O

Fulvestrant B-drug B-drug
is O O
metabolized O O
by O O
CYP O O
3A4 O O
in O O
vitro O O
. O O

The O O
results O O
of O O
assays O O
using O O
red O O
cells O O
from O O
healthy O O
subjects O O
to O O
determine O O
whether O O
ceftibuten B-drug B-drug
would O O
cause O O
direct O O
Coombs O O
reactions O O
in O O
vitro O O
showed O O
no O O
positive O O
reaction O O
at O O
ceftibuten B-drug B-drug
concentrations O O
as O O
high O O
as O O
40 O O
g/mL O O
. O O

Theophylline B-drug B-drug
: O O
Enoxacin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
cytochrome O O
P-450 O O
isozymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
methylxanthines B-group B-group
. O O

Lithium B-drug B-drug
Reversible O O
increases O O
in O O
serum O O
lithium B-drug B-drug
concentrations O O
and O O
toxicity O O
have O O
been O O
reported O O
during O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
with O O
ACE B-group B-group
inhibitors I-group I-group
, O O
and O O
with O O
some O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
. O O

Adjustment O O
of O O
adenosine B-drug B-drug
dosage O O
may O O
be O O
necessary O O
. O O

The O O
proposed O O
mechanisms O O
of O O
analgesic O O
action O O
of O O
antihistaminics B-group B-group
are O O
reviewed O O
and O O
discussed O O
. O O

PGF2alpha B-drug B-drug
produced O O
significantly O O
increased O O
vasoconstriction O O
after O O
a O O
single O O
administration O O
of O O
oxytocin B-drug B-drug
. O O

For O O
these O O
reasons O O
, O O
it O O
is O O
felt O O
that O O
, O O
in O O
most O O
subjects O O
who O O
have O O
had O O
an O O
unsatisfactory O O
lipid O O
response O O
to O O
either O O
drug O O
alone O O
, O O
the O O
possible O O
benefits O O
of O O
combined O O
therapy O O
with O O
lovastatin B-drug B-drug
and O O
a O O
fibrate B-group B-group
do O O
not O O
outweigh O O
the O O
risks O O
of O O
severe O O
myopathy O O
, O O
rhabdomyolysis O O
, O O
and O O
acute O O
renal O O
failure O O
. O O

The O O
risk O O
of O O
hypoglycemia O O
secondary O O
to O O
this O O
mechanism O O
may O O
be O O
increased O O
if O O
allopurinol B-drug B-drug
and O O
chlorpropamide B-drug B-drug
are O O
given O O
concomitantly O O
in O O
the O O
presence O O
of O O
renal O O
insufficiency O O
. O O

When O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
reduced O O
. O O

As O O
noted O O
below O O
, O O
a O O
sub- O O
for O O
fluvoxamine B-drug B-drug
in O O
combination O O
with O O
alprazolam B-drug B-drug
, O O
a O O
drug O O
that O O
is O O
known O O
to O O
be O O
metabolized O O
by O O
the O O
IIIA4 O O
isozyme O O
. O O

In O O
a O O
clinical O O
pharmacology O O
study O O
, O O
indomethacin B-drug B-drug
or O O
sulindac B-drug B-drug
was O O
administered O O
to O O
hypertensive O O
patients O O
receiving O O
VASOTEC B-brand B-brand
. O O

Concomitant O O
administration O O
of O O
alosetron B-drug B-drug
and O O
moderate O O
CYP1A2 O B-group
inhibitors O I-group
, O O
including O O
quinolone B-group B-group
antibiotics I-group I-group
and O O
cimetidine B-drug B-drug
, O O
has O O
not O O
been O O
evaluated O O
, O O
but O O
should O O
be O O
avoided O O
unless O O
clinically O O
necessary O O
because O O
of O O
similar O O
potential O O
drug O O
interactions O O
. O O

This O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
ability O O
of O O
rifampin B-drug B-drug
to O O
induce O O
microsomal O O
enzymes O O
and O O
, O O
thus O O
, O O
the O O
catabolism O O
of O O
warfarin B-drug B-drug
. O O

NSAIDs B-group B-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
taking O O
cyclosporine B-drug B-drug
, O O
and O O
renal O O
function O O
should O O
be O O
carefully O O
monitored O O
. O O

The O O
reddish O O
color O O
is O O
due O O
to O O
the O O
formation O O
of O O
a O O
nonabsorbable O O
complex O O
between O O
cefdinir B-drug B-drug
or O O
its O O
breakdown O O
products O O
and O O
iron B-drug B-drug
in O O
the O O
gastrointestinal O O
tract O O
. O O

On O O
administration O O
of O O
oral O O
amiodarone B-drug B-drug
, O O
the O O
need O O
for O O
digitalis B-group B-group
therapy O O
should O O
be O O
reviewed O O
and O O
the O O
dose O O
reduced O O
by O O
approximately O O
50 O O
% O O
or O O
discontinued O O
. O O

Anagrelide B-drug B-drug
demonstrates O O
some O O
limited O O
inhibitory O O
activity O O
towards O O
CYP1A2 O O
which O O
may O O
present O O
a O O
theoretical O O
potential O O
for O O
interaction O O
with O O
other O O
coadministered O O
medicinal O O
products O O
sharing O O
that O O
clearance O O
mechanism O O
e.g O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
celecoxib B-drug B-drug
is O O
not O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
2C9 O O
, O O
2C19 O O
or O O
3A4 O O
. O O

The O O
metabolism O O
of O O
TAXOL B-brand B-brand
is O O
catalyzed O O
by O O
cytochrome O O
P450 O O
isoen-zymes O O
CYP2C8 O O
and O O
CYP3A4 O O
. O O

In O O
order O O
to O O
maintain O O
phenytoin B-drug B-drug
levels O O
, O O
limit O O
adverse O O
experiences O O
, O O
and O O
achieve O O
the O O
felbamate B-drug B-drug
dose O O
of O O
3600 O O
mg/day O O
, O O
a O O
phenytoin B-drug B-drug
dose O O
reduction O O
of O O
approximately O O
40 O O
% O O
was O O
necessary O O
for O O
eight O O
of O O
these O O
10 O O
subjects O O
. O O

Rare O O
cases O O
of O O
a O O
disulfiram-like O B-drug
reaction O O
to O O
alcohol B-drug B-drug
have O O
been O O
reported O O
. O O

Because O O
elderly O O
patients O O
are O O
more O O
likely O O
to O O
have O O
decreased O O
renal O O
function O O
, O O
care O O
should O O
be O O
taken O O
in O O
dose O O
selection O O
and O O
it O O
may O O
be O O
useful O O
to O O
monitor O O
renal O O
function O O
. O O

diet O O
high O O
in O O
vitamin B-group B-group
K I-group I-group
; O O

Oral O O
Contraceptives B-group B-group
: O O
Valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
) O O
did O O
not O O
induce O O
the O O
metabolism O O
of O O
the O O
combination O O
oral O O
contraceptive B-group B-group
norethindrone/ethinyl B-drug B-drug
estradiol I-drug I-drug
( O O
1 O O
mg O O
/35 O O
mcg O O
combination O O
, O O
Ortho-Novum B-brand B-brand
1/35 O O
) O O
. O O

Ketoconazole B-drug B-drug

In O O
vitro O O
studies O O
: O O
Vardenafil B-drug B-drug
and O O
its O O
metabolites O O
had O O
no O O
effect O O
on O O
CYP1A2 O O
, O O
2A6 O O
, O O
and O O
2E1 O O
( O O
Ki O O
100uM O O
) O O
. O O

MAO B-group B-group
inhibitors I-group I-group
MAOI I-group I-group
antidepressants I-group I-group
, O O
as O O
well O O
as O O
a O O
metabolite O O
of O O
furazolidone B-drug B-drug
, O O
slow O O
amphetamine B-drug B-drug
metabolism O O
. O O

Occasionally O O
TAXOL B-brand B-brand
infusions O O
must O O
be O O
interrupted O O
or O O
discontinued O O
because O O
of O O
initial O O
or O O
recurrent O O
hypertension O O
. O O

Because O O
their O O
vasospastic O O
effects O O
may O O
be O O
additive O O
, O O
coadministration O O
of O O
naratriptan B-drug B-drug
and O O
other O O
5-HT1 B-group B-group
agonists I-group I-group
within O O
24 O O
hours O O
of O O
each O O
other O O
is O O
not O O
recommended O O
. O O

Drugs O O
that O O
are O O
contraindicated O O
specifically O O
due O O
to O O
the O O
expected O O
magnitude O O
of O O
interaction O O
and O O
potential O O
for O O
serious O O
adverse O O
events O O
are O O
listed O O
CONTRAINDICATIONS O O
. O O

It O O
has O O
not O O
been O O
as O O
effective O O
in O O
women O O
with O O
sexual O O
dysfunction O O
, O O
with O O
the O O
exception O O
of O O
SSRI-associated B-group B-group
sexual O O
dysfunction O O
. O O

Corticosteroids B-group B-group
. O O

Ethopropazine B-drug B-drug
can O O
interact O O
with O O
chlorpromazine B-drug B-drug
, O O
increasing O O
the O O
metabolism O O
of O O
chlorpromazine B-drug B-drug
. O O

In O O
1992 O O
and O O
1993 O O
, O O
two O O
outbreaks O O
of O O
arsenical O O
reactive O O
encephalopathy O O
( O O
ARE O O
) O O
occurred O O
in O O
the O O
sleeping O O
sickness O O
center O O
of O O
Adjumani O B-brand
. O O

Herbal O O
products O O
: O O
St. O O
John O O
s O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O

Selegiline B-drug B-drug
: O O
Combination B-group O
hormonal I-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
serum O O
concentration O O
of O O
selegiline B-drug B-drug
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
BEXTRA B-brand B-brand
concomitantly O O
with O O
ACE-inhibitors B-group B-group
. O O

Ventricular O O
tachycardia O O
induced O O
by O O
ouabain B-drug B-drug
was O O
generally O O
converted O O
to O O
sinus O O
rhythm O O
following O O
administration O O
of O O
Innovar B-brand B-brand
, O O
ketamine B-drug B-drug
, O O
or O O
droperidol B-drug B-drug
but O O
not O O
after O O
administration O O
of O O
fentayl B-drug B-brand
alone O O
or O O
after O O
pentobarbital B-drug B-drug
. O O

The O O
most O O
common O O
adverse O O
effects O O
reported O O
with O O
olanzapine B-drug B-drug
are O O
bodyweight O O
gain O O
, O O
somnolence O O
, O O
dizziness O O
, O O
anticholinergic O O
effects O O
( O O
constipation O O
and O O
dry O O
mouth O O
) O O
and O O
transient O O
asymptomatic O O
liver O O
enzyme O O
elevations O O
. O O

Lymphocytopenia O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
CAMPTOSAR B-brand B-brand
, O O
and O O
it O O
is O O
possible O O
that O O
the O O
administration O O
of O O
dexamethasone B-drug B-drug
as O O
antiemetic O B-group
prophylaxis O I-group
may O O
have O O
enhanced O O
the O O
likelihood O O
of O O
this O O
effect O O
. O O

Because O O
alosetron B-drug B-drug
is O O
metabolized O O
by O O
a O O
variety O O
of O O
hepatic O O
CYP O O
drug-metabolizing O O
enzymes O O
, O O
inducers O O
or O O
inhibitors O O
of O O
these O O
enzymes O O
may O O
change O O
the O O
clearance O O
of O O
alosetron B-drug B-drug
. O O

Dual O O
effect O O
of O O
ouabain B-drug B-drug
on O O
the O O
palytoxin-induced B-drug_n O
contraction O O
and O O
norepinephrine O B-drug
release O O
in O O
the O O
guinea-pig O O
vas O O
deferens O O
. O O

Aspirin B-brand B-brand
should O O
be O O
used O O
cautiously O O
in O O
conjunction O O
with O O
corticosteroids B-group B-group
in O O
hypoprothrombinemia O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
and O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
does O O
not O O
interfere O O
with O O
the O O
rate O O
or O O
extent O O
of O O
the O O
absorption O O
of O O
ketoprofen B-drug B-drug
administered O O
as O O
Orudis B-brand B-brand
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
tricyclic B-drug B-group
antidepressants I-drug I-group
when O O
used O O
concomitantly O O
with O O
cimetidine B-drug B-drug
. O O

Sildenafil B-drug B-drug
citrate I-drug I-drug
: O O
a O O
therapeutic O O
update O O
. O O

Oral O O
doses O O
of O O
Antizol B-brand B-brand
( O O
10-20 O O
mg/kg O O
) O O
, O O
via O O
alcohol O B-drug
dehydrogenase O O
inhibition O O
, O O
significantly O O
reduced O O
the O O
rate O O
of O O
elimination O O
of O O
ethanol B-drug B-drug
( O O
by O O
approximately O O
40 O O
% O O
) O O
given O O
to O O
healthy O O
volunteers O O
in O O
moderate O O
doses O O
. O O

Monitor O O
salicylate B-group B-group
levels O O
or O O
the O O
therapeutic O O
effect O O
for O O
which O O
aspirin B-brand B-brand
is O O
given O O
; O O

The O O
interaction O O
was O O
pharmacodynamic O O
with O O
no O O
alteration O O
of O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Cyclosporine O B-drug
, O O
Digoxin O B-drug
, O O
Methotrexate O B-drug
Lodine B-brand B-brand
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
through O O
effects O O
on O O
renal O O
prostaglandins O O
, O O
may O O
cause O O
changes O O
in O O
the O O
elimination O O
of O O
these O O
drugs O O
leading O O
to O O
elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
and O O
increased O O
toxicity O O
. O O

Caution O O
should O O
be O O
used O O
when O O
NSAIDs B-group B-group
are O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

If O O
the O O
dose O O
of O O
lovastatin B-drug B-drug
is O O
changed O O
, O O
the O O
same O O
procedure O O
should O O
be O O
repeated O O
. O O

Although O O
no O O
clinical O O
studies O O
have O O
been O O
conducted O O
, O O
it O O
is O O
likely O O
that O O
the O O
metabolism O O
of O O
levobupivacaine B-drug B-drug
may O O
be O O
affected O O
by O O
the O O
known O O
CYP3A4 O O
inducers O O
( O O
such O O
as O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
rifampin B-drug B-drug
) O O
, O O
CYP3A4 O B-drug
inhibitors O O
( O O
azole O B-group
antimycotics O I-group
e.g. O O
, O O
ketoconazole B-drug B-drug
; O O

Salicylic B-drug B-drug
acid I-drug I-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
salicylic B-drug B-drug
acid I-drug I-drug
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
patients O O
receiving O O
Acarbose B-drug B-drug
in O O
combination O O
with O O
sulfonylureas B-group B-group
or O O
insulin B-drug B-drug
, O O
patients O O
should O O
be O O
observed O O
closely O O
for O O
any O O
evidence O O
of O O
hypoglycemia O O
. O O

Only O O
with O O
knowledge O O
of O O
the O O
interaction O O
can O O
the O O
therapeutic O O
regimen O O
be O O
altered O O
so O O
as O O
to O O
provide O O
therapeutic O O
levels O O
of O O
necessary O O
drugs O O
while O O
avoiding O O
toxicity O O
. O O

Reduced O O
efficacy O O
and O O
increased O O
incidence O O
of O O
breakthrough O O
bleeding O O
and O O
menstrual O O
irregularities O O
have O O
been O O
associated O O
with O O
concomitant O O
use O O
of O O
rifampin B-drug B-drug
. O O

Additionally O O
, O O
anti-malarial B-group B-group
drugs I-group I-group
, O O
such O O
as O O
chloroquine B-drug B-drug
and O O
mefloquine B-drug B-drug
, O O
may O O
antagonize O O
the O O
activity O O
of O O
carbamazepine B-drug B-drug
. O O

Whether O O
this O O
interaction O O
also O O
occurs O O
with O O
the O O
intravenous O O
, O O
topical O O
, O O
or O O
vaginal O O
preparations O O
of O O
miconazole B-drug B-drug
is O O
not O O
known O O
. O O

. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
Since O O
captopril B-drug B-drug
decreases O O
aldosterone O O
production O O
, O O
elevation O O
of O O
serum O O
potassium O O
may O O
occur O O
. O O

In O O
the O O
first O O
double-blind O O
comparative O O
study O O
( O O
28-week O O
) O O
of O O
olanzapine B-drug B-drug
and O O
risperidone B-drug B-drug
, O O
olanzapine B-drug B-drug
10 O O
to O O
20 O O
mg/day O O
proved O O
to O O
be O O
significantly O O
more O O
effective O O
than O O
risperidone B-drug B-drug
4 O O
to O O
12 O O
mg/day O O
in O O
the O O
treatment O O
of O O
negative O O
and O O
depressive O O
symptoms O O
but O O
not O O
on O O
overall O O
psychopathology O O
symptoms O O
. O O

Secondary O O
prevention O O
of O O
atherosclerotic O O
risk O O
factors O O
is O O
also O O
important O O
: O O
regulation O O
of O O
blood O O
pressure O O
and O O
blood O O
sugar O O
level O O
, O O
hyperlipidaemia O O
and O O
obesity O O
, O O
as O O
well O O
as O O
a O O
change O O
of O O
lifestyle O O
( O O
giving O O
up O O
smoking O O
, O O
adapting O O
of O O
diet O O
and O O
more O O
physical O O
exertion O O
) O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
FROVA B-brand B-brand
is O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

By O O
decreasing O O
the O O
gastrointestinal O O
absorption O O
of O O
primidone B-drug B-drug
, O O
DIAMOX B-brand B-brand
may O O
decrease O O
serum O O
concentrations O O
of O O
primidone B-drug B-drug
and O O
its O O
metabolites O O
, O O
with O O
a O O
consequent O O
possible O O
decrease O O
in O O
anticonvulsant O O
effect O O
. O O

Other O O
plasma O O
proteins O O
may O O
be O O
increased O O
( O O
angiotensinogen/renin O O
substrate O O
, O O
alpha-1-antitrypsin O O
, O O
ceruloplasmin O O
) O O
. O O

These O O
models O O
are O O
typically O O
nonlinear O O
in O O
the O O
parameters O O
, O O
and O O
as O O
such O O
, O O
a O O
nonlinear O O
weighted O O
least O O
squares O O
approach O O
can O O
be O O
employed O O
for O O
the O O
purpose O O
of O O
designing O O
experiments O O
. O O

Fluvoxamine B-drug B-drug
inhibits O O
the O O
CYP2C9 O O
catalyzed O O
biotransformation O O
of O O
tolbutamide B-drug B-drug
. O O

Norepinephrine B-drug B-drug

Oral O O
anticoagulants B-group B-group
decreased O O
prothrombin O O
time O O
response O O
. O O

No O O
adjustment O O
of O O
dosage O O
is O O
recommended O O
in O O
such O O
patients O O
. O O

In O O
a O O
placebo-controlled O O
trial O O
in O O
normal O O
volunteers O O
, O O
the O O
administration O O
of O O
a O O
single O O
1 O O
mg O O
dose O O
of O O
doxazosin B-drug B-drug
on O O
day O O
1 O O
of O O
a O O
four-day O O
regimen O O
of O O
oral O O
cimetidine B-drug B-drug
( O O
400 O O
mg O O
twice O O
daily O O
) O O
resulted O O
in O O
a O O
10 O O
% O O
increase O O
in O O
mean O O
AUC O O
of O O
doxazosin B-drug B-drug
( O O
p=0.006 O O
) O O
, O O
and O O
a O O
slight O O
but O O
not O O
statistically O O
significant O O
increase O O
in O O
mean O O
Cmax O O
and O O
mean O O
half-life O O
of O O
doxazosin B-drug B-drug
. O O

RESULTS O O
. O O

Similar O O
decreases O O
in O O
Cmax O O
and O O
AUC O O
were O O
seen O O
after O O
the O O
first O O
dose O O
. O O

No O O
in O O
vitro O O
metabolism O O
studies O O
were O O
performed O O
. O O

If O O
concomitant O O
treatment O O
with O O
naratriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

- O O
Other O O
anti-infectives B-group B-group
by O O
mouth O O
or O O
by O O
injection O O
( O O
medicine O O
for O O
infection O O
) O O
or O O

[ O O
Multiple O O
occupational O O
exposure O O
to O O
solvents O B-group
] O O
This O O
article O O
review O O
papers O O
published O O
over O O
the O O
last O O
20 O O
years O O
on O O
multiple O O
occupational O O
exposure O O
to O O
solvents O B-group
. O O

Drug O O
exposure O O
in O O
rodent O O
pups O O
from O O
fulvestrant-treated B-drug B-drug
lactating O O
dams O O
was O O
estimated O O
as O O
10 O O
% O O
of O O
the O O
administered O O
dose O O
. O O

If O O
rifampicin B-drug B-drug
therapy O O
is O O
required O O
, O O
isradipine B-drug B-drug
concentrations O O
and O O
therapeutic O O
effects O O
are O O
likely O O
to O O
be O O
markedly O O
reduced O O
or O O
abolished O O
as O O
a O O
consequence O O
of O O
increased O O
metabolism O O
and O O
higher O O
clearance O O
of O O
isradipine B-drug B-drug
. O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Subsequent O O
adjustment O O
of O O
doses O O
of O O
mercaptopurine B-drug B-drug
or O O
azathioprine B-drug B-drug
should O O
be O O
made O O
on O O
the O O
basis O O
of O O
therapeutic O O
response O O
and O O
the O O
appearance O O
of O O
toxic O O
effects O O
. O O

All O O
drugs O O
were O O
injected O O
intraperitoneally O O
. O O

Glyburide B-drug B-drug
: O O
Etodolac B-drug B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
glyburide B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
fenofibrate B-drug B-drug
( O O
equivalent O O
to O O
145 O O
mg O O
TRICOR B-brand B-brand
) O O
with O O
atorvastatin B-drug B-drug
( O O
20 O O
mg O O
) O O
once O O
daily O O
for O O
10 O O
days O O
resulted O O
in O O
approximately O O
17 O O
% O O
decrease O O
( O O
range O O
from O O
67 O O
% O O
decrease O O
to O O
44 O O
% O O
increase O O
) O O
in O O
atorvastatin B-drug B-drug
AUC O O
values O O
in O O
22 O O
healthy O O
males O O
. O O

Drug/Food O O
Interactions O O
The O O
bioavailability O O
( O O
AUC O O
) O O
of O O
deferasirox B-drug B-drug
was O O
variably O O
increased O O
when O O
taken O O
with O O
a O O
meal O O
. O O

Pharmacokinetic O O
data O O
from O O
these O O
patients O O
demonstrated O O
a O O
decrease O O
in O O
paclitaxel B-drug B-drug
clearance O O
of O O
approximately O O
33 O O
% O O
when O O
TAXOL B-brand B-brand
was O O
administered O O
following O O
cisplatin B-drug B-drug
. O O

In O O
secretions O O
such O O
as O O
colostrum O O
, O O
IgA O O
is O O
the O O
only O O
protein O O
precipitated O O
by O O
jacalin B-drug_n B-drug_n
. O O

Trecator B-brand B-brand
has O O
been O O
found O O
to O O
temporarily O O
raise O O
serum O O
concentrations O O
of O O
isoniazid B-drug B-drug
. O O

Therefore O O
, O O
when O O
MIDAMOR B-brand B-brand
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Omeprazole B-drug B-drug
: O O
The O O
rate O O
and O O
extent O O
of O O
absorption O O
of O O
ciprofloxacin B-drug B-drug
was O O
bioequivalent O O
when O O
Proquin B-brand B-brand
XR I-brand I-brand
was O O
given O O
alone O O
or O O
when O O
Proquin B-brand B-brand
XR I-brand I-brand
was O O
given O O
2 O O
hours O O
after O O
omeprazole B-drug B-drug
at O O
the O O
dose O O
that O O
maximally O O
suppresses O O
gastric O O
acid O O
secretion O O
. O O

Chlorotrianisene B-drug B-drug
may O O
interact O O
with O O
antidepressants B-group B-group
, O O
aspirin B-brand B-brand
, O O
barbiturates B-group B-group
, O O
bromocriptine B-drug B-drug
, O O
calcium B-drug B-drug
supplements O O
, O O
corticosteroids B-group B-group
, O O
corticotropin B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
dantrolene B-drug B-drug
, O O
nicotine B-drug B-drug
, O O
somatropin B-drug B-drug
, O O
tamoxifen B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Therefore O O
, O O
co-administration O O
of O O
clozapine B-drug B-drug
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isozyme O O
, O O
including O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
and O O
encainide B-drug B-drug
) O O
, O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
e.g. O O
, O O
quinidine B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

There O O
is O O
a O O
significant O O
increase O O
in O O
exposure O O
to O O
imatinib B-drug B-drug
when O O
Gleevec B-brand B-brand
is O O
coadministered O O
with O O
ketoconazole B-drug B-drug
( O O
CYP3A4 O O
inhibitor O O
) O O
. O O

There O O
is O O
one O O
report O O
suggesting O O
that O O
the O O
concomitant O O
use O O
of O O
trazodone B-drug B-drug
hydrochloride I-drug I-drug
( O O
Desyrel B-brand B-brand
) O O
and O O
buspirone B-drug B-drug
HCl I-drug I-drug
may O O
have O O
caused O O
3- O O
to O O
6-fold O O
elevations O O
on O O
SGPT O O
( O O
ALT O O
) O O
in O O
a O O
few O O
patients O O
. O O

An O O
alternative O O
or O O
additional O O
method O O
of O O
contraception O O
is O O
recommended O O
. O O

- O O
rifampin B-drug B-drug
( O O
Rifadin B-brand B-brand
, O O
Rifamate B-brand B-brand
) O O
; O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
Angiotensin B-group B-group
Converting I-group I-group
Enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
. O O

Cimetidine B-drug B-drug
: O O
Atorvastatin B-drug B-drug
plasma O O
concentrations O O
and O O
LDL-C O O
reduction O O
were O O
not O O
altered O O
by O O
coadministration O O
of O O
cimetidine B-drug B-drug
. O O

In O O
vivo O O
studies O O
: O O
Nitrates B-group B-group
: O O
The O O
blood O O
pressure O O
lowering O O
effects O O
of O O
sublingual O O
nitrates B-group B-group
( O O
0.4 O O
mg O O
) O O
taken O O
1 O O
and O O
4 O O
hours O O
after O O
vardenafil B-drug B-drug
and O O
increases O O
in O O
heart O O
rate O O
when O O
taken O O
at O O
1 O O
, O O
4 O O
and O O
8 O O
hours O O
were O O
potentiated O O
by O O
a O O
20 O O
mg O O
dose O O
of O O
Vardenafil B-drug B-drug
in O O
healthy O O
middle-aged O O
subjects O O
. O O

aeruginosa O O
serotype O O
O11 O O
strains O O
, O O
but O O
not O O
S O B-drug
. O O

Eprosartan B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
and O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
and O O
glyburide B-drug B-drug
. O O

Neither O O
subject O O
demonstrated O O
clinical O O
evidence O O
of O O
allergic O O
or O O
anaphylactic O O
reactions O O
and O O
repeat O O
testing O O
was O O
not O O
performed O O
. O O

No O O
specific O O
information O O
available O O

METHODS O O
: O O
Healthy O O
subjects O O
who O O
were O O
20 O O
to O O
43 O O
years O O
old O O
participated O O
in O O
an O O
open O O
, O O
three-period O O
, O O
randomized O O
, O O
crossover O O
study O O
of O O
the O O
pharmacokinetics O O
of O O
a O O
single O O
10-mg O O
oral O O
dose O O
of O O
sirolimus B-drug B-drug
, O O
a O O
single O O
oral O O
120-mg O O
dose O O
of O O
diltiazem B-drug B-drug
, O O
and O O
the O O
two O O
drugs O O
given O O
together O O
. O O

These O O
lines O O
showed O O
variable O O
degrees O O
of O O
locomotor O O
activities O O
in O O
response O O
to O O
cocaine B-drug B-drug
. O O

An O O
adequate O O
period O O
of O O
observation O O
must O O
be O O
provided O O
for O O
any O O
patient O O
in O O
whom O O
either O O
long-acting B-group O
benzodiazepines I-group B-group
( O O
such O O
as O O
diazepam B-drug B-drug
) O O
or O O
large O O
doses O O
of O O
short-acting B-group B-group
benzodiazepines I-group I-group
( O O
such O O
as O O
10 O O
mg O O
of O O
midazolam B-drug B-drug
) O O
have O O
been O O
used O O
. O O

The O O
vasodilating O O
effects O O
of O O
isosorbide B-drug B-drug
dinitrate I-drug I-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

In O O
the O O
Duloxetine B-drug B-drug
clinical O O
trials O O
database O O
, O O
three O O
Duloxetine-treated B-drug B-drug
patients O O
had O O
liver O O
injury O O
as O O
manifested O O
by O O
ALT O O
and O O
total O O
bilirubin O O
elevations O O
, O O
with O O
evidence O O
of O O
obstruction O O
. O O

Stavudine B-drug B-drug
and O O
Zidovudine B-drug B-drug
Ribavirin I-drug I-drug
can O O
antagonize O O
the O O
in O O
vitro O O
antiviral O O
activity O O
of O O
stavudine B-drug B-drug
and O O
zidovudine B-drug B-drug
against O O
HIV O O
. O O

No O O
reported O O
interactions O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
effects O O
of O O
low O O
and O O
high O O
doses O O
of O O
estradiol B-drug B-drug
, O O
and O O
of O O
progesterone B-drug B-drug
on O O
the O O
response O O
to O O
noradrenaline B-drug B-drug
in O O
rat O O
thoracic O O
aorta O O
. O O

The O O
similarity O O
of O O
the O O
TYSABRI B-brand B-brand
-associated O O
adverse O O
event O O
profile O O
between O O
Study O O
1 O O
( O O
without O O
co-administered O O
AVONEX B-brand B-brand
) O O
and O O
Study O O
2 O O
( O O
with O O
co-administered O O
AVONEX B-brand B-brand
) O O
indicates O O
that O O
this O O
alteration O O
in O O
clearance O O
does O O
not O O
necessitate O O
reduction O O
of O O
the O O
TYSABRI B-brand B-brand
dose O O
to O O
maintain O O
safety O O
, O O
General O O
) O O
. O O

Haloperidol B-drug B-drug
: O O
Haloperidol B-drug B-drug
blocks O O
dopamine O O
and O O
norepinephrine O O
reuptake O O
, O O
thus O O
inhibiting O O
the O O
central O O
stimulant O O
effects O O
of O O
amphetamines B-group B-group
. O O

Patients O O
on O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
receiving O O
VELCADE B-brand B-brand
treatment O O
may O O
require O O
close O O
monitoring O O
of O O
their O O
blood O O
glucose O O
levels O O
and O O
adjustment O O
of O O
the O O
dose O O
of O O
their O O
antidiabetic B-group B-group
medication I-group I-group
. O O

Concurrent O O
administration O O
of O O
cimetidine B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
can O O
produce O O
clinically O O
significant O O
increases O O
in O O
the O O
plasma O O
levels O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

Haemodynamic O O
effects O O
of O O
glucose B-drug B-drug
and O O
insulin B-drug B-drug
were O O
additive O O
when O O
somatostatin B-drug B-drug
was O O
co-administered O O
but O O
not O O
under O O
basal O O
conditions O O
. O O

Inhibits O O
CYP1A2 O O
( O O
weak O O
) O O
, O O
2B6 O O
( O O
weak O O
) O O
, O O
2C19 O O
( O O
weak O O
) O O
, O O
3A4 O O
( O O
weak O O
) O O
. O O

Subjects O O
who O O
do O O
not O O
metabolize O O
losartan B-drug B-drug
to O O
active O O
metabolite O O
have O O
been O O
shown O O
to O O
have O O
a O O
specific O O
, O O
rare O O
defect O O
in O O
cytochrome O O
P450 O O
2C9 O O
. O O

This O O
diminution O O
is O O
not O O
sufficient O O
to O O
preclude O O
effectiveness O O
of O O
the O O
pressor O O
agent O O
for O O
therapeutic O O
use O O
. O O

Thus O O
, O O
probenecid B-drug B-drug
should O O
not O O
be O O
administered O O
concurrently O O
with O O
bumetanide B-drug B-drug
. O O

A O O
3-fold O O
increase O O
was O O
seen O O
in O O
another O O
5 O O
patients O O
. O O

However O O
, O O
the O O
systemic O O
administration O O
of O O
some O O
quinolones B-group B-group
has O O
been O O
shown O O
to O O
elevate O O
plasma O O
concentrations O O
of O O
theophylline B-drug B-drug
, O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
, O O
and O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
and O O
its O O
derivatives O O
, O O
and O O
has O O
been O O
associated O O
with O O
transient O O
elevations O O
in O O
serum O O
creatinine O O
in O O
patients O O
receiving O O
systemic O O
cyclosporine B-drug B-drug
concomitantly O O
. O O

Other O O
Agents O O

Coumarin B-group B-group
Anticoagulants I-group I-group
: O O
There O O
have O O
been O O
rare O O
reports O O
of O O
increased O O
prothrombin O O
time O O
in O O
patients O O
taking O O
coumarin B-group B-group
anticoagulants I-group I-group
to O O
whom O O
nifedipine B-drug B-drug
was O O
administered O O
. O O

In O O
a O O
pharmacokinetic O O
study O O
, O O
40 O O
healthy O O
female O O
subjects O O
received O O
fluvoxamine B-drug B-drug
in O O
escalating O O
doses O O
from O O
50 O O
to O O
200 O O
mg O O
per O O
day O O
for O O
16 O O
days O O
, O O
with O O
coadministration O O
of O O
alosetron B-drug B-drug
1 O O
mg O O
on O O
the O O
last O O
day O O
. O O

Anakinra B-drug B-drug
: O O
Concurrent O O
administration O O
of O O
anakinra B-drug B-drug
( O O
an O O
interleukin-1 B-group B-group
antagonist I-group I-group
) O O
and O O
another O O
TNF-blocking B-group B-group
agent I-group I-group
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
, O O
an O O
increased O O
risk O O
of O O
neutropenia O O
and O O
no O O
additional O O
benefit O O
compared O O
to O O
these O O
medicinal O O
products O O
alone O O
. O O

Some O O
of O O
the O O
CNS O O
and O O
genitourinary O O
symptoms O O
may O O
be O O
related O O
to O O
the O O
underlying O O
disease O O
rather O O
than O O
to O O
drug O O
therapy O O
. O O

This O O
has O O
been O O
observed O O
with O O
Benedict O O
s O O
and O O
Fehling O O
s O O
solutions O O
but O O
not O O
with O O
the O O
glucose O O
enzymatic O O
test O O
. O O

If O O
co-administration O O
is O O
essential O O
, O O
conduct O O
close O O
clinical O O
and O O
laboratory O O
monitoring O O

Using O O
this O O
technique O O
, O O
it O O
was O O
possible O O
to O O
escalate O O
the O O
cisplatin B-drug B-drug
dose O O
to O O
225 O O
mg/m2 O O
before O O
dose-limiting O O
toxicities O O
were O O
encountered O O
. O O

Close O O
observation O O
of O O
the O O
patient O O
is O O
recommended O O
when O O
a O O
beta-blocker B-group B-group
is O O
administered O O
to O O
patients O O
receiving O O
catecholamine-depleting O O
drugs O O
such O O
as O O
reserpine B-drug B-drug
, O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
the O O
production O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
or O O
postural O O
hypotension O O
. O O

primidone B-drug B-drug
; O O

Physiological O O
oral O O
magnesium B-drug B-drug
load O O
constitutes O O
the O O
best O O
tool O O
for O O
diagnosis O O
of O O
magnesium B-drug B-drug
deficiency O O
and O O
the O O
first O O
step O O
of O O
its O O
treatment O O
. O O

sildenafil I-drug B-drug
concentration O O

Concomitant O O
administration O O
of O O
Kerlone B-brand B-brand
with O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
has O O
been O O
shown O O
not O O
to O O
potentiate O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
. O O

Free O O
hormone O O
concentrations O O
may O O
be O O
decreased O O
. O O

2 O O
. O O

Diazepam B-drug B-drug
at O O
doses O O
of O O
0.25 O O
mg/kg O O
and O O
2.5 O O
mg/kg O O
injected O O
with O O
morphine B-drug B-drug
was O O
found O O
to O O
decrease O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
. O O

Mutagenesis O O
Impairment O O
of O O
Fertility O O
PEGASYS B-brand B-brand
may O O
impair O O
fertility O O
in O O
women O O
. O O

Caution O O
should O O
be O O
used O O
if O O
ibuprofen B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

However O O
, O O
antacids B-group B-group
can O O
decrease O O
the O O
peak O O
concentration O O
reached O O
by O O
15 O O
% O O
to O O
20 O O
% O O
but O O
have O O
no O O
detectable O O
effect O O
on O O
the O O
time-to-peak O O
. O O

The O O
anesthesiologist O O
should O O
be O O
informed O O
when O O
a O O
patient O O
is O O
receiving O O
labetalol B-drug B-drug
HCl I-drug I-drug
. O O

Interactions O O
with O O
Other O O
Antiretroviral B-group B-group
Drugs I-group I-group
: O O
Significant O O
decreases O O
in O O
the O O
AUC O O
of O O
delavirdine B-drug B-drug
( O O
20 O O
% O O
) O O
and O O
indinavir B-drug B-drug
( O O
84 O O
% O O
) O O
occurred O O
following O O
simultaneous O O
administration O O
of O O
these O O
agents O O
with O O
VIDEX B-brand B-brand
. O O

Other O O
Drugs O O
: O O
Drugs O O
such O O
as O O
quinidine B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
antihistamines B-group B-group
, O O
and O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
be O O
associated O O
with O O
QT-interval O O
prolongation O O
and O O
an O O
increased O O
risk O O
of O O
ventricular O O
arrhythmia O O
. O O

Cyclophosphamide B-drug B-drug
treatment O O
, O O
which O O
causes O O
a O O
marked O O
and O O
persistent O O
inhibition O O
of O O
cholinesterase O O
activity O O
, O O
potentiates O O
the O O
effect O O
of O O
succinylcholine B-drug B-drug
chloride I-drug I-drug
. O O

Chloral B-drug B-drug
hydrate I-drug I-drug
may O O
cause O O
an O O
increased O O
prothrombin O O
response O O
by O O
displacing O O
the O O
anticoagulant B-group B-group
from O O
protein O O
binding O O
sites O O
or O O
a O O
diminished O O
prothrombin O O
response O O
through O O
increased O O
metabolism O O
of O O
the O O
unbound O O
drug O O
by O O
hepatic O O
enzyme O O
induction O O
, O O
thus O O
leading O O
to O O
inter-patient O O
variation O O
in O O
ultimate O O
prothrombin O O
effect O O
. O O

The O O
plasma O O
concentration O O
of O O
imipramine B-drug B-drug
may O O
increase O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
) O O
and O O
decrease O O
by O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
) O O
, O O
and O O
adjustment O O
of O O
the O O
dosage O O
of O O
imipramine B-drug B-drug
may O O
therefore O O
be O O
necessary O O
. O O

Lomefloxacin B-drug B-drug
is O O
unlikely O O
to O O
have O O
a O O
significant O O
effect O O
on O O
phenytoin B-drug B-drug
metabolism O O
. O O

Hemodynamic O O
and O O
electrophysiologic O O
interactions O O
have O O
also O O
been O O
observed O O
after O O
concomitant O O
administration O O
with O O
propranolol B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
and O O
verapamil B-drug B-drug
. O O

Therefore O O
, O O
appropriate O O
dose O O
adjustments O O
may O O
be O O
necessary O O
for O O
these O O
drugs O O
. O O

- O O
Perhexiline B-drug B-drug
hydrogen I-drug I-drug
maleate I-drug I-drug
or O O
MAO-inhibitors B-group B-group
( O O
with O O
hepatotoxic O O
potential O O
) O O
must O O
not O O
be O O
administered O O
together O O
with O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
. O O

These O O
data O O
suggest O O
that O O
the O O
conversion O O
of O O
losartan B-drug B-drug
to O O
its O O
active O O
metabolite O O
is O O
mediated O O
primarily O O
by O O
P450 O O
2C9 O O
and O O
not O O
P450 O O
3A4 O O
. O O

Analgesia O O
and O O
pupil O O
constriction O O
were O O
measured O O
. O O

Effects O O
on O O
in O O
vitro O O
excystment O O
rates O O
over O O
a O O
2 O O
h O O
period O O
demonstrated O O
widespread O O
effects O O
for O O
cercariae-exposed O O
P O O
. O O

In O O
a O O
single O O
subject O O
given O O
one O O
dose O O
of O O
ciprofloxacin B-drug B-drug
2 O O
hours O O
after O O
a O O
dose O O
of O O
didanosine-placebo B-drug B-drug
tablets O O
, O O
a O O
greater O O
than O O
50 O O
% O O
reduction O O
in O O
the O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
observed O O
. O O

If O O
you O O
are O O
also O O
using O O
a O O
steroid B-group B-group
inhaler O I-group
, O O
take O O
bitolterol B-drug B-drug
first O O
and O O
then O O
wait O O
about O O
15 O O
minutes O O
before O O
using O O
the O O
steroid B-group B-group
inhaler O I-group
. O O

Urinary O B-group
acidifying O I-group
agents O I-group
These O O
agents O O
( O O
ammonium B-drug B-drug
chloride I-drug I-drug
, O O
sodium B-drug B-drug
acid I-drug I-drug
phosphate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
the O O
concentration O O
of O O
the O O
ionized O O
species O O
of O O
the O O
amphetamine B-drug B-drug
molecule O O
, O O
thereby O O
increasing O O
urinary O O
excretion O O
. O O

6 O O
. O O

In O O
vitro O O
, O O
nilutamide B-drug B-drug
has O O
been O O
shown O O
to O O
inhibit O O
the O O
activity O O
of O O
liver O O
cytochrome O O
P-450 O O
isoenzymes O O
and O O
therefore O O
, O O
may O O
reduce O O
the O O
metabolism O O
of O O
compounds O O
requiring O O
these O O
systems O O
. O O

Both O O
of O O
these O O
effects O O
were O O
endothelium-dependent O B-drug_n
. O O

Although O O
clinical O O
studies O O
have O O
not O O
established O O
a O O
cause O O
and O O
effect O O
relationship O O
, O O
physicians O O
should O O
be O O
aware O O
that O O
variable O O
effects O O
an O O
blood O O
coagulation O O
have O O
been O O
reported O O
very O O
rarely O O
in O O
patients O O
receiving O O
oral O O
anticoagulants B-group B-group
and O O
chlordiazepoxide B-drug B-drug
. O O

There O O
was O O
no O O
evidence O O
in O O
clinical O O
trials O O
of O O
drug O O
interactions O O
with O O
concurrent O O
medications O O
. O O

Erythromycin B-drug B-drug
use O O
in O O
patients O O
who O O
are O O
receiving O O
high O O
doses O O
of O O
theophylline B-drug B-drug
may O O
be O O
associated O O
with O O
an O O
increase O O
in O O
serum O O
theophylline B-drug B-drug
levels O O
and O O
potential O O
theophylline B-drug B-drug
toxicity O O
. O O

If O O
concomitant O O
use O O
can O O
not O O
be O O
avoided O O
, O O
serum O O
levels O O
of O O
theophylline B-drug B-drug
should O O
be O O
monitored O O
and O O
dosage O O
adjustments O O
made O O
as O O
appropriate O O
. O O

In O O
a O O
study O O
in O O
normal O O
volunteers O O
, O O
it O O
was O O
found O O
that O O
chronic O O
concurrent O O
administration O O
of O O
3.6 O O
g O O
of O O
aspirin B-brand B-brand
per O O
day O O
decreases O O
indomethacin B-drug B-drug
blood O O
levels O O
approximately O O
20 O O
% O O
. O O

The O O
safety O O
and O O
efficacy O O
of O O
concomitant O O
use O O
of O O
REVIA B-brand B-brand
and O O
disulfiram B-drug B-drug
is O O
unknown O O
, O O
and O O
the O O
concomitant O O
use O O
of O O
two O O
potentially O O
hepatotoxic O O
medications O O
is O O
not O O
ordinarily O O
recommended O O
unless O O
the O O
probable O O
benefits O O
outweigh O O
the O O
known O O
risks O O
. O O

Propranolol B-drug B-drug
increases O O
hydralazines B-drug B-group
serum O O
concentrations O O
. O O

Uricosuric B-group B-group
Agents I-group I-group
: O O
Since O O
the O O
excretion O O
of O O
oxipurinol B-drug B-drug
is O O
similar O O
to O O
that O O
of O O
urate O B-drug
, O O
uricosuric B-group O
agents I-group O
, O O
which O O
increase O O
the O O
excretion O O
of O O
urate O O
, O O
are O O
also O O
likely O O
to O O
increase O O
the O O
excretion O O
of O O
oxipurinol B-drug B-drug
and O O
thus O O
lower O O
the O O
degree O O
of O O
inhibition O O
of O O
xanthine O O
oxidase O O
. O O

No O O
data O O
for O O
delavirdine B-drug B-drug
; O O

All O O
elevations O O
resolved O O
, O O
2 O O
with O O
continuation O O
of O O
both O O
drugs O O
and O O
3 O O
after O O
discontinuation O O
of O O
leflunomide B-drug B-drug
. O O

Reports O O
of O O
fatal O O
hepatic O O
failure O O
, O O
as O O
well O O
as O O
peripheral O O
neuropathy O O
, O O
pancreatitis O O
, O O
and O O
symptomatic O O
hyperlactatemia/lactic O O
acidosis O O
have O O
been O O
reported O O
in O O
clinical O O
trials O O
. O O

There O O
is O O
thus O O
an O O
enhancement O O
effect O O

Systemic O O
exposure O O
to O O
substrates O O
of O O
CYP2D6 O O
is O O
expected O O
to O O
be O O
increased O O
when O O
coadministered O O
with O O
Gleevec O B-brand
. O O

If O O
chlorprothixene B-drug B-drug
is O O
given O O
concomitantly O O
with O O
opioids B-group B-group
, O O
the O O
opioid B-group B-group
dose O O
should O O
be O O
reduced O O
( O O
by O O
approx O O
. O O
50 O O
% O O
) O O
, O O
because O O
chlorprothixene B-drug B-drug
amplifies O I-drug
the O O
therapeutic O O
actions O O
and O O
side-effects O O
of O O
opioids B-group B-group
massively O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
is O O
required O O
when O O
this O O
drug O O
is O O
administered O O
concomitantly O O
with O O
anticholinergic B-group B-group
drugs I-group I-group
. O O

Sucralfate B-drug B-drug
and O O
antacids B-group B-group
: O O
Quinolones B-group B-group
form O O
chelates O O
with O O
metal O O
cations O O
. O O

These O O
doses O O
correspond O O
to O O
approximately O O
1- O O
, O O
3- O O
, O O
and O O
5-fold O O
( O O
in O O
females O O
) O O
and O O
1.3- O O
, O O
1.3- O O
, O O
and O O
1.6-fold O O
( O O
in O O
males O O
) O O
the O O
systemic O O
exposure O O
[ O O
AUC0-30 O O
days O O
] O O
] O O
achieved O O
in O O
women O O
receiving O O
the O O
recommended O O
dose O O
of O O
250 O O
mg/month O O
. O O

Antibiotics B-group B-group
: O O
Macrolide B-group B-group
antibiotics I-group I-group
have O O
been O O
reported O O
to O O
cause O O
a O O
significant O O
decrease O O
in O O
corticosteroid B-group B-group
clearance O O
. O O

Digoxin O B-drug
When O O
given O O
concomitantly O O
with O O
PLENDIL B-drug B-brand
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
in O O
patients O O
with O O
heart O O
failure O O
were O O
not O O
significantly O O
altered O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
or O O
Tes-Tape O O
) O O
be O O
used O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
spironolactone B-drug B-drug
, O O
amiloride B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
and O O
others O O
) O O
or O O
potassium B-drug B-drug
supplements O O
can O O
increase O O
the O O
risk O O
of O O
hyperkalemia O O
. O O

Valproate B-drug B-drug
: O O
Available O O
data O O
suggest O O
that O O
there O O
is O O
no O O
significant O O
effect O O
of O O
valproate B-drug B-drug
on O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
at O O
steady O O
state O O
, O O
Therefore O O
, O O
the O O
addition O O
of O O
valproate B-drug B-drug
is O O
not O O
expected O O
to O O
cause O O
a O O
clinically O O
important O O
effect O O
on O O
Felbatol B-brand B-brand
( O O
felbamate B-drug B-drug
) O O
plasma O O
concentrations O O
. O O

Ascorbic B-drug B-drug
acid I-drug I-drug
and O O
the O O
common O O
cold O O
. O O

CYP3A4 O O
Interactions O O

Methotrexate B-drug B-drug
: O O
Ketoprofen B-drug B-drug
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
may O O
cause O O
changes O O
in O O
the O O
elimination O O
of O O
methotrexate B-drug B-drug
leading O O
to O O
elevated O O
serum O O
levels O O
of O O
the O O
drug O O
and O O
increased O O
toxicity O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
observations O O
is O O
unknown O O
. O O

Antacids B-group B-group
containing O O
magnesium B-drug B-drug
, O O
aluminum B-drug B-drug
, O O
or O O
calcium B-drug B-drug
; O O

Tinnitus O O
and O O
decreased O O
hearing O O
have O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-drug B-drug
and O O
quinidine B-drug B-drug
. O O

No O O
significant O O
effects O O
were O O
noted O O
with O O
other O O
drug O O
combinations O O
or O O
with O O
the O O
addition O O
of O O
ethanol B-drug B-drug
. O O

Drug/Laboratory O O
Tests O O
Interactions O O
There O O
are O O
no O O
known O O
clinically O O
significant O O
interactions O O
of O O
CLOLAR B-brand B-brand
with O O
other O O
medications O O
or O O
laboratory O O
tests O O
. O O

Dicumarol B-drug B-drug
and O O
warfarin B-drug B-drug
may O O
decrease O O
hypoprothrombinemic O O
effect O O
. O O

apomorphine B-drug B-drug
- O O
prior O O
ingestion O O
of O O
diphenidol B-drug B-drug
may O O
decrease O O
the O O
emetic B-group O
response O O
to O O
apomorphine B-drug B-drug
in O O
the O O
treatment O O
of O O
poisoning O O
. O O

Dosing O O
recommendations O O
for O O
SUSTIVA B-brand B-brand
and O O
atazanavir B-drug B-drug
in O O
treatment-experienced O O
patients O O
have O O
not O O
been O O
established O O
. O O

Toxicity O O
associated O O
with O O
concomitant O O
use O O
of O O
aerosolized O O
pentamidine B-drug B-drug
has O O
not O O
been O O
reported O O
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
: O O
The O O
stimulatory O O
effects O O
of O O
amphetamines B-group B-group
may O O
be O O
inhibited O O
by O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

The O O
treatment O O
of O O
depression O O
in O O
diabetic O O
patients O O
must O O
take O O
into O O
account O O
variations O O
of O O
glycemic O O
levels O O
at O O
different O O
times O O
and O O
a O O
comparison O O
of O O
the O O
available O O
antidepressant B-group B-group
agents I-group I-group
is O O
important O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
administering O O
ETOPOPHOS B-brand B-brand
with O O
drugs O O
that O O
are O O
known O O
to O O
inhibit O O
phosphatase O O
activities O O
( O O
e.g. O O
, O O
levamisole B-drug B-drug
hydrochloride I-drug I-drug
) O O
. O O

Because O O
there O O
is O O
a O O
theoretical O O
basis O O
that O O
these O O
effects O O
may O O
be O O
additive O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
naratriptan B-drug B-drug
within O O
24 O O
hours O O
is O O
contraindicated O O
. O O

This O O
suggests O O
that O O
interactions O O
between O O
the O O
two O O
elements O O
only O O
take O O
place O O
at O O
the O O
site O O
of O O
absorption O O
. O O

Aminoglycosides B-group B-group
: O O
The O O
mixing O O
of O O
piperacillin B-drug B-drug
with O O
an O O
aminoglycoside B-group B-group
in O O
vitro O O
can O O
result O O
in O O
substantial O O
inactivation O O
of O O
the O O
aminoglycoside B-group B-group
. O O

A O O
dose O O
adjustment O O
is O O
not O O
needed O O
when O O
zidovudine B-drug B-drug
is O O
administered O O
with O O
VIRACEPT B-brand B-brand
. O O

HIV B-group B-group
Protease I-group I-group
Inhibitors I-group I-group
: O O
Indinavir B-drug B-drug
( O O
800 O O
mg O O
t.i.d O O
. O O
) O O
co-administered O O
with O O
Vardenafil B-drug B-drug
10 O O
mg O O
resulted O O
in O O
a O O
16-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
, O O
a O O
7-fold O O
increase O O
in O O
vardenafil B-drug B-drug
Cmax O O
and O O
a O O
2-fold O O
increase O O
in O O
vardenafil B-drug B-drug
half-life O O
. O O

AED B-group B-group
Co-administered O O

Antiarrhythmic B-drug B-group
agents I-drug I-group
, I-drug O
class I-drug O
I I-drug O
( O O
such O O
as O O
flecainide B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
or O O
quinidine B-drug B-drug
) O O
: O O
concurrent O O
use O O
with O O
arbutamine B-drug B-drug
may O O
have O O
a O O
proarrhythmic O O
effect O O
. O O

Antitubercular O B-group
drugs O I-group
: O O
Serum O O
concentrations O O
of O O
isoniazid B-drug B-drug
may O O
be O O
decreased O O
. O O

No O O
information O O
available O O
. O O

Other O O
Potentially O O
Important O O
Drug O O
Interactions O O
: O O
Benzodiazepines B-group B-group
: O O
Benzodiazepines B-group B-group
metabolized O O
by O O
hepatic O O
oxidation O O
( O O
e.g. O O
, O O
alprazolam B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
triazolam B-drug B-drug
elc O O
. O O
) O O
should O O
be O O
used O O
with O O
caution O O
because O O
the O O
clearance O O
of O O
these O O
drugs O O
is O O
likely O O
to O O
be O O
reduced O O
by O O
fluvoxamine B-drug B-drug
. O O

Fluoxetine B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
clonazepam B-drug B-drug
. O O

In O O
a O O
drug O O
interaction O O
study O O
, O O
co-administration O O
of O O
orally O O
inhaled O O
ciclesonide B-drug B-drug
and O O
oral O O
erythromycin B-drug B-drug
, O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
, O O
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
des-ciclesonide B-drug B-drug
or O O
erythromycin B-drug B-drug
. O O

In O O
vitro O O
data O O
in O O
human O O
plasma O O
indicate O O
that O O
doxazosin B-drug B-drug
mesylate I-drug I-drug
has O O
no O O
effect O O
on O O
protein O O
binding O O
of O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
phenytoin B-drug B-drug
or O O
indomethacin B-drug B-drug
. O O

Herbal O O
Products O O
: O O
St. O O
John O O
s O O
wort O O
( O O
hypericum O O
perforatum O O
) O O
WARNING O O
coadministration O O
may O O
lead O O
to O O
loss O O
of O O
virologic O O
response O O
and O O
possible O O
resistance O O
to O O
INVIRASE B-brand B-brand
or O O
to O O
the O O
class O O
of O O
protease O B-group
inhibitors O I-group
. O O

The O O
action O O
of O O
nondepolarizing O B-group
relaxants O I-group
is O O
augmented O O
by O O
Enflurane B-drug B-drug
. O O

Theophylline B-drug B-drug
VIOXX B-brand B-brand
12.5 O O
, O O
25 O O
, O O
and O O
50 O O
mg O O
administered O O
once O O
daily O O
for O O
7 O O
days O O
increased O O
plasma O O
theophylline B-drug B-drug
concentrations O O
( O O
AUC O O
( O O
0- O O
) O O
) O O
by O O
38 O O
to O O
60 O O
% O O
in O O
healthy O O
subjects O O
administered O O
a O O
single O O
300-mg O O
dose O O
of O O
theophylline B-drug B-drug
. O O

If O O
bupropion B-drug B-drug
is O O
added O O
to O O
the O O
treatment O O
regimen O O
of O O
a O O
patient O O
already O O
receiving O O
a O O
drug O O
metabolized O O
by O O
CYP2D6 O O
, O O
the O O
need O O
to O O
decrease O O
the O O
dose O O
of O O
the O O
original O O
medication O O
should O O
be O O
considered O O
, O O
particularly O O
for O O
those O O
concomitant O O
medications O O
with O O
a O O
narrow O O
therapeutic O O
index O O
. O O

Consequently O O
, O O
TRACLEER B-brand B-brand
is O O
not O O
expected O O
to O O
increase O O
the O O
plasma O O
concentrations O O
of O O
drugs O O
metabolized O O
by O O
these O O
enzymes O O
. O O

Each O O
subject O O
received O O
an O O
individualized O O
fixed O O
daily O O
dose O O
of O O
warfarin B-drug B-drug
and O O
served O O
as O O
his O O
own O O
pre- O O
and O O
postsedative O O
treatment O O
control O O
. O O

Warfarin B-drug B-drug
: O O
Multiple O O
oral O O
doses O O
of O O
Sonata B-brand B-brand
( O O
20 O O
mg O O
q24h O O
for O O
13 O O
days O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-drug B-drug
( O O
R+ O O
) O O
- O O
or O O
( O O
S- O B-drug
) O O
-enantiomers O O
or O O
the O O
pharmacodynamics O O
( O O
prothrombin O O
time O O
) O O
following O O
a O O
single O O
25-mg O O
oral O O
dose O O
of O O
warfarin B-drug B-drug
. O O

The O O
hypoglycemic O O
action O O
of O O
sulfonylurea B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

Rates O O
of O O
patients O O
with O O
maximum O O
potassium O O
levels O O
5.5 O O
mEq/L O O
were O O
similar O O
regardless O O
of O O
the O O
use O O
of O O
ACEI/ARB B-group B-group
. O O

SUBSEQUENT O O
TO O O
INITIATION O O
OF O O
DISULFIRAM B-drug B-drug
THERAPY O O
. O O

Lithium B-drug B-drug
: O O
Increased O O
serum O O
lithium B-drug B-drug
levels O O
and O O
symptoms O O
of O O
lithium B-drug B-drug
toxicity O O
have O O
been O O
reported O O
in O O
patients O O
receiving O O
ACE B-group B-group
inhibitors I-group I-group
during O O
therapy O O
with O O
lithium B-drug B-drug
. O O

Phenytoin B-drug B-drug
is O O
known O O
to O O
cause O O
osteomalacia O O
. O O

The O O
beneficial O O
effects O O
on O O
arterial O O
thrombus O O
formation O O
from O O
combined O O
therapy O O
with O O
antiplatelet O B-group
and O O
anticoagulant B-group B-group
medication I-group O
must O O
be O O
weighed O O
against O O
an O O
increased O O
risk O O
of O O
inducing O O
hemorrhage O O
. O O

Sulfacetamide B-drug B-drug
preparations O O
are O O
incompatible O O
with O O
silver B-drug O
preparations O O
. O O

antibody O O

Cimetidine B-drug B-drug
: O O
Albendazole B-drug B-drug
sulfoxide I-drug I-drug
concentrations O O
in O O
bile O O
and O O
cystic O O
fluid O O
were O O
increased O O
( O O
about O O
2-fold O O
) O O
in O O
hydatid O O
cyst O O
patients O O
treated O O
with O O
cimetidine B-drug B-drug
( O O
10 O O
mg/kg/day O O
) O O
( O O
n=7 O O
) O O
compared O O
with O O
albendazole B-drug B-drug
( O O
20 O O
mg/kg/day O O
) O O
alone O O
( O O
n=12 O O
) O O
. O O

Omeprazole B-drug B-drug
: O O
Omeprazole B-drug B-drug
is O O
a O O
CYP O O
3A4 O O
substrate O O
and O O
CYP O O
2C19 O O
substrate O O
and O O
inhibitor O O
. O O

It O O
was O O
observed O O
that O O
MPTP B-drug_n B-drug_n
induced O O
long O O
lasting O O
depletions O O
of O O
striatal O O
dopamine O O
concentrations O O
and O O
this O O
neurotoxic O O
effect O O
could O O
be O O
prevented O O
by O O
pargyline B-drug B-drug
pretreatment O O
. O O

Patients O O
treated O O
concurrently O O
with O O
BREVIBLOC B-brand B-brand
( O O
esmolol B-drug B-drug
HCl I-drug I-drug
) O O
and O O
a O O
catecholamine O O
depletor O O
should O O
therefore O O
be O O
closely O O
observed O O
for O O
evidence O O
of O O
hypotension O O
or O O
marked O O
bradycardia O O
, O O
which O O
may O O
result O O
in O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

Other O O
Concomitant O O
Therapy O O
In O O
healthy O O
subjects O O
there O O
were O O
no O O
clinically O O
significant O O
interactions O O
when O O
felodipine B-drug B-drug
was O O
given O O
concomitantly O O
with O O
indomethacin B-drug B-drug
or O O
spironolactone B-drug B-drug
. O O

vasopressors B-group B-group
, O O
such O O
as O O
dopamine B-drug B-drug
and O O
isoproterenol B-drug B-drug
; O O

Decreasing O O
the O O
concentration O O
of O O
CMC-Cys B-drug_n B-drug_n
, O O
exhibiting O O
7.3 O O
% O O
( O O
m/m O O
) O O
of O O
immobilised O O
cysteine B-drug B-drug
( O O
CMC-Cys7.3 O B-brand
) O O
from O O
1 O O
% O O
( O O
m/v O O
) O O
to O O
0.5 O O
% O O
( O O
m/v O O
) O O
decreased O O
the O O
R-value O O
of O O
NaFlu B-drug B-drug
from O O
1.8 O O
to O O
1.2 O O
. O O

Antidepressants B-group B-group
, O O
tricyclic B-group B-group
Amphetamines I-group I-group
may O O
enhance O O
the O O
activity O O
of O O
tricyclic B-drug B-group
antidepressants I-drug I-group
or O O
sympathomimetic B-group B-group
agents I-group I-group
; O O

. O O

However O O
, O O
modification O O
abolished O O
the O O
'cold O O
' O O
binding O O
of O O
toxin O B-drug_n
to O O
bovine O O
thyroglobulin O O
in O O
an O O
ELISA O O
and O O
reduced O O
ligand O O
binding O O
activity O O
in O O
a O O
rabbit O O
erythrocyte O O
haemagglutination O O
assay O O
. O O

However O O
, O O
at O O
that O O
time O O
, O O
the O O
plasma O O
levels O O
of O O
diazepam B-drug B-drug
were O O
below O O
the O O
therapeutic O O
interval O O
, O O
and O O
thus O O
this O O
interaction O O
is O O
unlikely O O
to O O
be O O
of O O
clinical O O
relevance O O
. O O

In O O
simultaneous O O
treatment O O
with O O
imidazole B-group B-group
drugs I-group I-group
and O O
coumarin B-group B-group
drugs I-group I-group
, O O
the O O
anticoagulant O O
effect O O
should O O
be O O
carefully O O
titrated O O
and O O
monitored O O
. O O

There O O
was O O
no O O
evidence O O
of O O
drug O O
interactions O O
in O O
clinical O O
studies O O
in O O
which O O
dobutamine B-drug B-drug
was O O
administered O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
digitalis B-group B-group
preparations I-group I-group
, O O
furosemide B-drug B-drug
, O O
spironolactone B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
glyceryl B-drug B-drug
trinitrate I-drug I-drug
, O O
isosorbide B-drug B-drug
dinitrate I-drug I-drug
, O O
morphine B-drug B-drug
, O O
atropine B-drug B-drug
, O O
heparin B-drug B-drug
, O O
protamine B-drug B-drug
, O O
potassium B-drug B-drug
chloride I-drug I-drug
, O O
folic B-drug B-drug
acid I-drug I-drug
, O O
and O O
acetaminophen B-drug B-drug
. O O

halothane B-drug B-drug
; O O

Olanzapine B-drug B-drug
: O O
an O O
updated O O
review O O
of O O
its O O
use O O
in O O
the O O
management O O
of O O
schizophrenia O O
. O O

We O O
assessed O O
the O O
ability O O
of O O
gene O O
transfer O O
to O O
reverse O O
vancomycin B-drug O
resistance O O
in O O
class O O
A O O
( O O
VanA O O
) O O
glycopeptide-resistant O O
Enterococcus O O
faecalis O O
. O O

Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
reported O O
laboratory O O
test O O
interactions O O
. O O

Cell O O
permeable O O
caspase-3 O O
inhibitor O O
added O O
in O O
the O O
medium O O
blocked O O
the O O
decrease O O
of O O
nucleophosmin/B23 O O
and O O
apoptosis O O
induced O O
by O O
serum O O
deprivation O O
in O O
NIH-3T3 O O
cells O O
. O O

Therefore O O
, O O
co-administration O O
of O O
Duloxetine B-drug B-drug
with O O
other O O
drugs O O
that O O
are O O
extensively O O
metabolized O O
by O O
this O O
isozyme O O
and O O
which O O
have O O
a O O
narrow O O
therapeutic O O
index O O
, O O
including O O
certain O O
antidepressants B-group B-group
( O O
tricyclic B-group B-group
antidepressants I-group I-group
[ O O
TCAs B-group B-group
] O O
, O O
such O O
as O O
nortriptyline B-drug B-drug
, O O
amitriptyline B-drug B-drug
, O O
and O O
imipramine B-drug B-drug
) O O
, O O
phenothiazines B-group B-group
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

aureus O O
to O O
P O O
. O O

gestational O O
trophoblastic O O
disease O O
; O O

While O O
only O O
a O O
limited O O
number O O
of O O
in O O
vivo O O
drug-drug O O
interactions O O
with O O
amiodarone B-drug B-drug
have O O
been O O
reported O O
, O O
chiefly O O
with O O
the O O
oral O O
formulation O O
, O O
the O O
potential O O
for O O
other O O
interactions O O
should O O
be O O
anticipated O O
. O O

Discontinuing O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
could O O
pose O O
a O O
hazard O O
to O O
health O O
if O O
a O O
potentially O O
toxic O O
drug O O
that O O
is O O
significantly O O
bound O O
to O O
the O O
resin B-group B-group
has O O
been O O
titrated O O
to O O
a O O
maintenance O O
level O O
while O O
the O O
patient O O
was O O
taking O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
. O O

DEA O O
concentrations O O
were O O
not O O
affected O O
. O O

thrombocytopenia O O

Since O O
there O O
is O O
a O O
high O O
degree O O
of O O
variability O O
in O O
the O O
bioavailability O O
of O O
verapamil B-drug B-drug
, O O
the O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unclear O O
. O O

Nevirapine B-drug I-drug

Therefore O O
, O O
caffeine B-drug B-drug
has O O
the O O
potential O O
to O O
interact O O
with O O
drugs O O
that O O
are O O
substrates O O
for O O
CYP1A2 O O
, O O
inhibit O O
CYP1A2 O O
, O O
or O O
induce O O
CYP1A2 O O
. O O

Conversely O O
, O O
decreases O O
in O O
plasma O O
levels O O
of O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
upon O O
discontinuation O O
of O O
cimetidine B-drug B-drug
which O O
may O O
result O O
in O O
the O O
loss O O
of O O
the O O
therapeutic O O
efficacy O O
of O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
6 O O
. O O

Prothrombin O O
time O O
was O O
increased O O
by O O
5 O O
% O O
, O O
the O O
clinical O O
significance O O
of O O
which O O
is O O
unknown O O
. O O

Iron B-drug B-drug
salts O O
may O O
reduce O O
the O O
bioavailability O O
of O O
carbidopa B-drug B-drug
and O O
levodopa B-drug B-drug
. O O

Monoamine O B-group
Oxidase O I-group
Inhibition O O
: O O
Linezolid B-drug B-drug
is O O
a O O
reversible O O
, O O
nonselective O O
inhibitor O O
of O O
monoamine O B-group
oxidase O I-group
. O O

Patients O O
in O O
clinical O O
studies O O
were O O
prohibited O O
from O O
receiving O O
growth O O
factor O O
treatment O O
for O O
2 O O
weeks O O
prior O O
to O O
the O O
ZEVALIN B-brand B-brand
therapeutic O O
regimen O O
as O O
well O O
as O O
for O O
2 O O
weeks O O
following O O
completion O O
of O O
the O O
regimen O O
. O O

It O O
is O O
believed O O
that O O
the O O
toxicity O O
may O O
have O O
resulted O O
from O O
a O O
previously O O
unrecognized O O
interaction O O
between O O
isoniazid B-drug B-drug
and O O
acetaminophen B-drug B-drug
and O O
a O O
molecular O O
basis O O
for O O
this O O
interaction O O
has O O
been O O
proposed O O
. O O

Vesselinovitch O O
et O O
al O O
. O O

Patients O O
taking O O
these O O
drugs O O
with O O
LODOSYN B-brand B-brand
and O O
levodopa B-drug B-drug
or O O
carbidopa-levodopa B-drug B-drug
combination O O
products O O
should O O
be O O
carefully O O
observed O O
for O O
loss O O
of O O
therapeutic O O
response O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
p.o O O
. O O

Therefore O O
, O O
precaution O O
should O O
be O O
taken O O
when O O
coadministration O O
is O O
necessary O O
. O O

- O O
Drugs O O
with O O
ototoxic O O
potential O O
: O O
Especially O O
in O O
the O O
presence O O
of O O
impaired O O
renal O O
function O O
, O O
the O O
use O O
of O O
parenterally O O
administered O O
bumetanide B-drug B-drug
in O O
patients O O
to O O
whom O O
aminoglycoside B-group B-group
antibiotics I-group I-group
are O O
also O O
being O O
given O O
should O O
be O O
avoided O O
, O O
except O O
in O O
life-threatening O O
conditions O O
. O O

However O O
, O O
severe O O
reactions O O
, O O
such O O
as O O
hypotension O O
requiring O O
treatment O O
, O O
dyspnea O O
requiring O O
bronchodilators B-group B-group
, O O
angioedema O O
, O O
or O O
generalized O O
urticaria O O
require O O
immediate O O
discontinuation O O
of O O
TAXOL B-brand B-brand
and O O
aggressive O O
symptomatic O O
therapy O O
. O O

A O O
30 O O
to O O
45 O O
% O O
increase O O
in O O
AUC O O
and O O
Cmax O O
of O O
nisoldipine B-drug B-drug
was O O
observed O O
with O O
concomitant O O
administration O O
of O O
cimetidine B-drug B-drug
400 I-drug O
mg I-drug O
twice O O
daily O O
. O O

Drug O O
interaction O O
studies O O
with O O
other O O
anticonvulsants B-group B-group
have O O
not O O
been O O
conducted O O
. O O

In O O
the O O
same O O
study O O
it O O
was O O
shown O O
that O O
didanosine B-drug B-drug
and O O
stavudine B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
the O O
intracellular O O
phosphorylation O O
of O O
zalcitabine B-drug B-drug
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

A O O
study O O
of O O
interaction O O
between O O
BREVIBLOC B-brand B-brand
and O O
warfarin B-drug B-drug
showed O O
that O O
concomitant O O
administration O O
of O O
BREVIBLOC B-brand B-brand
and O O
warfarin B-drug B-drug
does O O
not O O
alter O O
warfarin B-drug B-drug
plasma O O
levels O O
. O O

In O O
a O O
study O O
involving O O
12 O O
adult O O
volunteers O O
, O O
TORADOLORAL O B-brand
was O O
coadministered O O
with O O
a O O
single O O
dose O O
of O O
25 O O
mg O O
warfarin B-drug B-drug
, O O
causing O O
no O O
significant O O
changes O O
in O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
. O O

Patients O O
receiving O O
both O O
indomethacin B-drug B-drug
and O O
furosemide B-drug B-drug
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
diuretic O B-group
and/or O O
antihypertensive O O
effect O O
of O O
furosemide B-drug B-drug
is O O
achieved O O
. O O

Nonsteroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
: O O
The O O
concomitant O O
administration O O
of O O
a O O
nonsteroidal B-group B-group
anti I-group I-group
inflammatory I-group I-group
drug I-group I-group
with O O
a O O
quinolone B-group B-group
may O O
increase O O
the O O
risks O O
of O O
CNS O O
stimulation O O
and O O
convulsions O O
. O O

The O O
effect O O
of O O
induction O O
or O O
inhibition O O
of O O
other O O
pathways O O
on O O
exposure O O
to O O
alosetron B-drug B-drug
and O O
its O O
metabolites O O
is O O
not O O
known O O
. O O

Drugs O O
such O O
as O O
troleandomycin B-drug B-drug
and O O
ketoconazole B-drug B-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
corticosteroids B-group B-group
and O O
thus O O
decrease O O
their O O
clearance O O
. O O

In O O
some O O
patients O O
, O O
this O O
may O O
lead O O
to O O
reduced O O
clearance O O
, O O
prolongation O O
of O O
plasma O O
half-life O O
, O O
and O O
enhanced O O
effects O O
of O O
caffeine B-drug B-drug
and O O
theobromine B-drug B-drug
. O O

Effect O O
of O O
aprepitant B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
other O O
agents O O

Hydrochlorothiazide B-drug B-drug
( O O
HCTZ B-drug B-drug
) O O
Alone O O
or O O
in O O
Combination O O
with O O
Triamterene B-drug B-drug
: O O
Concomitant O O
use O O
of O O
HCTZ B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
triamterene B-drug B-drug
is O O
contraindicated O O
. O O

Salicylate B-group B-group
levels O O
have O O
been O O
found O O
to O O
be O O
falsely O O
elevated O O
with O O
some O O
assay O O
methods O O
. O O

Little O O
or O O
no O O
change O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
was O O
observed O O
when O O
VIRACEPT B-brand B-brand
was O O
coadministered O O
with O O
lamivudine B-drug B-drug
or O O
stavudine B-drug B-drug
. O O

Each O O
group O O
took O O
either O O
150 O O
mg O O
or O O
75 O O
mg O O
of O O
fluvoxamine B-drug B-drug
a O O
day O O
for O O
5 O O
days O O
( O O
day O O
-3 O O
to O O
day O O
2 O O
) O O
. O O

- O O
Chloroquine B-drug B-drug
( O O
e.g. O O
, O O
Aralen B-brand B-brand
) O O
or O O

Indinavir B-drug B-drug
has O O
been O O
shown O O
to O O
increase O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
. O O

In O O
one O O
controlled O O
clinical O O
study O O
, O O
the O O
ureidopenicillins O B-group
, O O
including O O
piperacillin B-drug B-drug
, O O
were O O
reported O O
to O O
prolong O O
the O O
action O O
of O O
vecuronium B-drug B-drug
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O B-group
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

Thalidomide B-drug B-drug
: O O
Co-administration O O
with O O
thalidomide B-drug B-drug
should O O
be O O
employed O O
cautiously O O
, O O
as O O
toxic O O
epidermal O O
necrolysis O O
has O O
been O O
reported O O
with O O
concomitant O O
use O O
. O O

In O O
addition O O
, O O
studies O O
in O O
healthy O O
volunteers O O
have O O
shown O O
that O O
TIKOSYN B-brand B-brand
does O O
not O O
affect O O
the O O
pharmacokinetics O O
or O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
, O O
or O O
the O O
pharmacokinetics O O
of O O
propranolol B-drug B-drug
( O O
40 O O
mg O O
twice O O
daily O O
) O O
, O O
phenytoin B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
or O O
oral O O
contraceptives B-group B-group
. O O

- O O
Medicinal O O
or O O
dietary O O
iodine B-group B-drug
interferes O O
with O O
all O O
in O O
vivo O O
tests O O
of O O
radio-iodine O B-drug
uptake O O
producing O O
low O O
uptakes O O
which O O
may O O
not O O
be O O
reflective O O
of O O
a O O
true O O
decrease O O
in O O
hormone O O
synthesis O O

The O O
pressor O O
effects O O
of O O
diethylpropion B-drug O
and O O
those O O
of O O
other O O
drugs O O
may O O
be O O
additive O O
when O O
the O O
drugs O O
are O O
used O O
concomitantly O O
; O O

Previous O O
studies O O
have O O
demonstrated O O
a O O
significant O O
reduction O O
in O O
the O O
oral O O
bioavailability O O
of O O
trovafloxacin B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
when O O
administered O O
concomitantly O O
with O O
an O O
intravenous O O
opiate B-group B-group
such O O
as O O
morphine B-drug B-drug
. O O

Digoxin B-drug B-drug
volume O O
of O O
distribution O O
was O O
not O O
significantly O O
changed O O
. O O

free O O
T4 O O
concentration O O
is O O
unaltered O O

Serious O O
anticholinergic O O
symptoms O O
( O O
i.e. O O
, O O
severe O O
dry O O
mouth O O
, O O
urinary O O
retention O O
and O O
blurred O O
vision O O
) O O
have O O
been O O
associated O O
with O O
elevations O O
in O O
the O O
serum O O
levels O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
when O O
cimetidine B-drug B-drug
therapy O O
is O O
initiated O O
. O O

there O O
was O O
no O O
alteration O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
drug O O
. O O

Patients O O
taking O O
disopyramide B-drug B-drug
phosphate I-drug I-drug
and O O
erythromycin B-drug B-drug
concomitantly O O
may O O
develop O O
increased O O
serum O O
concentrations O O
of O O
disopyramide B-drug B-drug
resulting O O
in O O
excessive O O
widening O O
of O O
the O O
QRS O O
complex O O
and/or O O
prolongation O O
of O O
the O O
Q-T O O
interval O O
. O O

Since O O
there O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
with O O
elevated O O
digoxin B-drug B-drug
levels O O
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
nifedipine B-drug B-drug
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

Valdecoxib B-drug B-drug
did O O
not O O
have O O
a O O
statistically O O
significant O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
( O O
a O O
CYP O O
2C9 O O
and O O
CYP O O
2C19 O O
substrate O O
) O O
. O O

certain O O
protease B-group B-group
inhibitors I-group I-group
e.g. O O
, O O
ritanovir O B-drug
; O O

Three O O
clinical O O
trials O O
have O O
investigated O O
Simulect B-brand B-brand
use O O
in O O
combination O O
with O O
triple-therapy O O
regimens O O
. O O

adjust O O
dosage O O
of O O
antidiabetic B-group B-group
drug I-group I-group
accordingly O O
. O O

Potent O O
inhibitors O O
of O O
CYP3A4 O O
( O O
below O O
) O O
increase O O
the O O
risk O O
of O O
myopathy O O
by O O
reducing O O
the O O
elimination O O
of O O
lovastatin B-drug B-drug
. O O

There O O
have O O
been O O
inconsistent O O
reports O O
regarding O O
the O O
effects O O
of O O
other O O
drugs O O
( O O
e.g. O O
, O O
quinine B-drug B-drug
, O O
penicillamine B-drug B-drug
) O O
on O O
serum O O
digoxin B-drug B-drug
concentration O O
. O O

Therefore O O
, O O
cyclosporine B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
and O O
appropriate O O
cyclosporine B-drug B-drug
dosage O O
adjustments O O
made O O
when O O
these O O
drugs O O
are O O
used O O
concomitantly O O
. O O

These O O
include O O
probenecid B-drug B-drug
, O O
cholestyramine B-drug B-drug
, O O
and O O
some O O
antibiotics B-group B-group
( O O
e.g O O
. O O
erythromycin B-drug B-drug
, O O
rifamipicin O B-drug
, O O
ampicillin B-drug B-drug
and O O
chloramphenicol B-drug B-drug
) O O
. O O

Thyroid O B-group
Physiology O O
: O O
The O O
following O O
agents O O
may O O
alter O O
thyroid O O
hormone O O
or O O
TSH O O
levels O O
, O O
generally O O
by O O
effects O O
on O O
thyroid O O
hormone O O
synthesis O O
, O O
secretion O O
, O O
distribution O O
, O O
metabolism O O
, O O
hormone O O
action O O
, O O
or O O
elimination O O
, O O
or O O
altered O O
TSH O O
secretion O O
: O O
aminoglutethimide B-drug B-drug
, O O
p-aminosalicylic B-drug O
acid I-drug O
, O O
amiodarone B-drug B-drug
, O O
androgens B-group B-group
and O O
related O O
anabolic O B-group
hormones O I-group
, O O
complex O O
anions O O
( O O
thiocyanate B-drug O
, O O
perchlorate B-drug B-drug
, O O
pertechnetate B-drug B-drug
) O O
, O O
antithyroid B-group B-group
drugs I-group I-group
, O O
b-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
, O O
carbamazepine B-drug B-drug
, O O
chloral B-drug B-drug
hydrate I-drug I-drug
, O O
diazepam B-drug B-drug
, O O
dopamine B-drug B-drug
and O O
dopamine B-group B-group
agonists I-group I-group
, O O
ethionamide B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
heparin B-drug B-drug
, O O
hepatic O O
enzyme O O
inducers O O
, O O
insulin B-drug B-drug
, O O
iodinated O B-group
cholestographic O I-group
agents O I-group
, O O
iodine-containing B-group B-drug
compounds I-group I-drug
, O O
levodopa B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
lithium B-drug B-drug
, O O
6-mercaptopurine B-drug B-drug
, O O
metoclopramide B-drug B-drug
, O O
mitotane B-drug B-drug
, O O
nitroprusside B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
resorcinol B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
somatostatin B-group B-drug
analogs I-group O
, O O
sulfonamides B-group B-group
, O O
sulfonylureas B-group B-group
, O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Given O O
the O O
possibility O O
of O O
extravasation O O
, O O
it O O
is O O
advisable O O
to O O
closely O O
monitor O O
the O O
infusion O O
site O O
for O O
possible O O
infiltration O O
during O O
drug O O
administration O O
. O O

Since O O
INVIRASE B-brand B-brand
is O O
coadministered O O
with O O
ritonavir B-drug B-drug
, O O
the O O
ritonavir B-drug B-drug
label O O
should O O
be O O
reviewed O O
for O O
additional O O
drugs O O
that O O
should O O
not O O
be O O
coadministered O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

as O O
measured O O
by O O
PBI O O
, O O
T4 O O
by O O
column O O
, O O
or O O
T4 O O
by O O
radioimmunoassay O O
. O O

Sixty-two O O
( O O
94 O O
% O O
) O O
of O O
66 O O
strains O O
of O O
Enterobacteriaceae O O
and O O
Pseudomonas O O
aeruginosa O O
were O O
inhibited O O
by O O
6.2 O O
mug O O
or O O
less O O
of O O
gentamicin B-drug B-drug
per O O
ml O O
. O O

Anticonvulsants B-group B-group
: O O
carbamazepine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug

Resveratrol B-drug_n B-drug
has O O
been O O
shown O O
to O O
induce O O
vasorelaxation O O
. O O

prolonged B-group O
narcotics I-group B-group
; O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
: O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

Epinephrine B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
other O O
sympathomimetic B-group B-group
drugs I-group I-group
( O O
such O O
as O O
isoproterenol B-drug B-drug
) O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
increased O O
toxicity O O
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
INDOCIN B-brand B-brand
does O O
not O O
influence O O
the O O
hypoprothrombinemia O O
produced O O
by O O
anticoagulants B-group B-group
. O O

Effect O O
of O O
other O O
drugs O O
on O O
Sensipar B-brand B-brand
: O O
Sensipar B-brand B-brand
is O O
metabolized O O
by O O
multiple O O
cytochrome O O
P450 O O
enzymes O O
, O O
primarily O O
CYP3A4 O O
, O O
CYP2D6 O O
, O O
and O O
CYP1A2 O O
. O O

therefore O O
, O O
drug O O
interactions O O
mediated O O
by O O
inhibition O O
of O O
hepatic O O
metabolism O O
are O O
not O O
expected O O
to O O
occur O O
. O O

In O O
rheumatoid O O
arthritis O O
, O O
concomitant O O
medications O O
besides O O
MTX B-drug B-drug
were O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
folic B-drug B-drug
acid I-drug I-drug
, O O
corticosteroids B-group B-group
and/or O O
narcotics B-group B-group
. O O

Therefore O O
, O O
when O O
Hydrochlorothiazide B-drug B-drug
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

In O O
addition O O
, O O
steady O O
state O O
levels O O
of O O
racemic O O
citalopram B-drug B-drug
were O O
not O O
significantly O O
different O O
in O O
poor O O
metabolizers O O
and O O
extensive O O
CYP2D6 O O
metabolizers O O
after O O
multiple-dose O O
administration O O
of O O
citalopram B-drug B-drug
, O O
suggesting O O
that O O
coadministration O O
, O O
with O O
escitalopram B-drug B-drug
, O O
of O O
a O O
drug O O
that O O
inhibits O O
CYP2D6 O O
, O O
is O O
unlikely O O
to O O
have O O
clinically O O
significant O O
effects O O
on O O
escitalopram B-drug B-drug
metabolism O O
. O O

May O O
interact O O
anticoagulants B-group B-group
( O O
altered O O
hypo-prothrombinemic O O
effect O O
) O O
, O O
barbiturates B-group B-group
, O O
rifampin B-drug B-drug
and O O
other O O
inducers O O
of O O
hepatic O O
microsomal O O
enzyme O O
oxidation O O
system O O
( O O
decreased O O
effect O O
of O O
diethylstilbestrol B-drug B-drug
) O O
, O O
corticosteroids B-group B-group
( O O
increased O O
effect O O
of O O
corticosteroids B-group B-group
) O O
. O O

Effects O O
of O O
other O O
Antiepilepsy O O
Drugs O O
( O O
AEDs B-group B-group
) O O
on O O
GABITRIL B-brand B-brand
: O O
Carbamazepine B-drug B-drug
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
carbamazepine B-drug B-drug
with O O
or O O
without O O
other O O
enzyme- O O
inducing O O
AEDs B-group B-group
. O O

Diphenhydramine B-drug B-drug
: O O
Diphenhydramine B-drug B-drug
is O O
reported O O
to O O
be O O
a O O
weak O O
inhibitor O O
of O O
aldehyde O O
oxidase O O
in O O
rat O O
liver O O
, O O
but O O
its O O
inhibitory O O
effects O O
in O O
human O O
liver O O
are O O
not O O
known O O
. O O

Verapamil B-drug B-drug
produced O O
a O O
decrease O O
of O O
20 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
18-27 O O
] O O
of O O
the O O
plasma O O
levels O O
of O O
MHD B-drug_n B-drug_n
. O O

serum O O
magnesium O B-drug
levels O O
may O O
increase O O
in O O
uremic O O
patients O O
) O O
Serum O O
protein-bound O O
iodine O O
( O O
PBI O O
) O O
levels O O
( O O
may O O
be O O
decreased O O
) O O
Thiazides B-group B-group
should O O
be O O
discontinued O O
before O O
carrying O O
out O O
tests O O
for O O
parathyroid O O
function O O
. O O

It O O
is O O
not O O
known O O
if O O
fulvestrant B-drug B-drug
is O O
excreted O O
in O O
human O O
milk O O
. O O

Doses O O
of O O
vitamin B-drug B-drug
C I-drug I-drug
up O O
to O O
200 O O
mg O O
were O O
allowed O O
in O O
clinical O O
studies O O
without O O
negative O O
consequences O O
. O O

- O O
Drugs O O
whose O O
efficacy O O
is O O
impaired O O
by O O
phenytoin B-drug B-drug
include O O
: O O
anticoagulants B-group B-group
, O O
corticosteroids B-group B-group
, O O
coumarin B-group B-group
, O O
digitoxin B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
estrogens B-group B-group
, O O
furosemide B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
, O O
rifampin B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
vitamin B-group B-group
D I-group I-group
. O O

Here O O
we O O
show O O
that O O
a O O
combination O O
of O O
galangin B-drug B-drug
or O O
3,7-dihydroxyflavone O B-drug_n
with O O
vancomycin B-drug B-drug
may O O
be O O
used O O
to O O
sensitize O O
resistant O O
strains O O
of O O
Enterococcus O O
faecalis O O
and O O
Enterococcus O O
faecium O O
to O O
the O O
level O O
of O O
vancomycin-sensitive O O
strains O O
. O O

In O O
vitro O O
studies O O
with O O
human O O
liver O O
microsomes O O
indicate O O
that O O
bortezomib B-drug B-drug
is O O
primarily O O
a O O
substrate O O
for O O
cytochrome O O
P450 O O
3A4 O O
, O O
2C19 O O
, O O
and O O
1A2 O O
. O O

Additionally O O
, O O
there O O
is O O
no O O
evidence O O
of O O
circulating O O
active O O
metabolites O O
or O O
accumulation O O
during O O
chronic O O
dosing O O
. O O

Therefore O O
, O O
there O O
is O O
a O O
potential O O
for O O
an O O
interaction O O
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP O O
1A2 O O
( O O
e.g. O O
, O O
amitriptyline B-drug B-drug
, O O
tacrine B-drug B-drug
, O O
and O O
zileuton B-drug B-drug
) O O
. O O

In O O
vitro O O
activity O O
of O O
KRM-1648 B-drug_n B-drug_n
, O O
either O O
singly O O
or O O
in O O
combination O O
with O O
ofloxacin B-drug B-drug
, O O
against O O
Mycobacterium O O
ulcerans O O
. O O

Coadministration O O
of O O
ethoxzolamide B-drug B-drug
with O O
other O O
diuretics B-group B-group
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
and O O
corticosteroids B-group B-group
may O O
cause O O
hypokalemia O O
. O O

However O O
, O O
norepinephrine B-drug B-drug
may O O
still O O
be O O
used O O
effectively O O
. O O

haloperidol B-drug B-drug
; O O

Absorption O O
of O O
fluvastatin B-drug B-drug
is O O
virtually O O
complete O O
across O O
all O O
species O O
, O O
including O O
man O O
, O O
and O O
is O O
not O O
affected O O
by O O
the O O
presence O O
of O O
food O O
. O O

. O O

decreased O O
pregnanediol O B-drug
excretion O O
; O O

Use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

ritonavir I-drug B-drug
concentration O O

Patients O O
on O O
thyroid O O
replacement O O
therapy O O
may O O
require O O
higher O O
doses O O
of O O
thyroid B-group B-group
hormone I-group I-group
. O O

Enoxacin B-drug B-drug
interferes O O
with O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
resulting O O
in O O
a O O
42 O O
% O O
to O O
74 O O
% O O
dose-related O O
decrease O O
in O O
theophylline B-drug B-drug
clearance O O
and O O
a O O
subsequent O O
260 O O
% O O
to O O
350 O O
% O O
increase O O
in O O
serum O O
theophylline O B-drug
levels O O
. O O

Prostatic O O
epithelium O O
proliferates O O
in O O
a O O
defined O O
medium O O
consisting O O
of O O
basal O O
medium O O
RPMI1640 O O
containing O O
transferrin B-drug_n B-drug
( O O
1 O O
microgram/ml O O
) O O
, O O
EGF B-drug_n B-drug_n
( O O
10 O O
ng/ml O O
) O O
, O O
and O O
insulin B-drug B-drug
( O O
3.7 O O
micrograms/ml O O
or O O
0.1 O O
IU/ml O O
) O O
. O O

Amantadine B-drug B-drug
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
MAOIs B-group B-group
may O O
increase O O
anticholinergic O O
effect O O
of O O
clidinium B-drug B-drug
. O O

In O O
these O O
patients O O
whose O O
hypertension O O
was O O
controlled O O
with O O
nifedipine B-drug B-drug
, O O
Vardenafil B-drug B-drug
20 O O
mg O O
produced O O
mean O O
additional O O
supine O O
systolic/diastolic O O
blood O O
pressure O O
reductions O O
of O O
6/5 O O
mm O O
Hg O O
compared O O
to O O
placebo O O
. O O

- O O
Oral O O
contraceptives B-group B-group
( O O
birth O O
control O O
pills O O
) O O
containing O O
estrogen B-group B-group
or O O

meprobamate B-drug B-drug
; O O

Morphine B-drug B-drug
prolonged O O
gastrointestinal O O
transit O O
time O O
from O O
69 O O
to O O
103 O O
minutes O O
( O O
P O O
= O O
.005 O O
) O O
; O O

Hematopoietic O O

It O O
is O O
unknown O O
how O O
the O O
effect O O
seen O O
in O O
these O O
in O O
vitro O O
studies O O
translates O O
into O O
clinical O O
consequences O O
. O O

Corticosteroids B-group B-group
: O O
Dexamethasone B-drug B-drug
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
as O O
a O O
regimen O O
of O O
125mg O O
with O O
dexamethasone B-drug B-drug
coadministered O O
orally O O
as O O
20 O O
mg O O
on O O
Day O O
1 O O
, O O
and O O
Aprepitant B-drug B-drug
when O O
given O O
as O O
80 O O
mg/day O O
with O O
dexamethasone B-drug B-drug
coadministered O O
orally O O
as O O
8 O O
mg O O
on O O
Days O O
2 O O
through O O
5 O O
, O O
increased O O
the O O
AUC O O
of O O
dexamethasone B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
by O O
2.2-fold O O
, O O
on O O
Days O O
1 O O
and O O
5 O O
. O O

ii O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
following O O
drugs O O
or O O
moieties O O
are O O
known O O
to O O
interfere O O
with O O
laboratory O O
tests O O
performed O O
in O O
patients O O
on O O
thyroid B-group B-group
hormone I-group I-group
therapy O O
: O O
androgens B-group B-group
, O O
corticosteroids B-group B-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
containing O O
estrogens B-group B-group
, O O
iodine-containing B-group B-drug
preparations O O
and O O
the O O
numerous O O
preparations O O
containing O O
salicylates B-group B-group
. O O

Ketamine B-drug B-drug
: O O
Marked O O
hypertension O O
and O O
tachycardia O O
have O O
been O O
reported O O
in O O
association O O
with O O
concomitant O O
administration O O
of O O
levothyroxine B-drug B-drug
sodium I-drug I-drug
and O O
ketamine B-drug B-drug
. O O

This O O
interaction O O
should O O
be O O
given O O
consideration O O
in O O
patients O O
taking O O
NSAIDs B-group B-group
concomitantly O O
with O O
ACE B-group B-group
inhibitors I-group I-group
. O O

There O O
have O O
been O O
greater O O
than O O
2-fold O O
increases O O
in O O
previously O O
stable O O
plasma O O
levels O O
of O O
other O O
antidepressants B-group B-group
, O O
including O O
nortriptyline B-drug B-drug
, O O
when O O
fluoxetine B-drug B-drug
hydrochloride I-drug I-drug
has O O
been O O
administered O O
in O O
combination O O
with O O
these O O
agents O O
. O O

No O O
confirmed O O
interactions O O
have O O
been O O
reported O O
between O O
ZOLADEX B-brand B-brand
and O O
other O O
drugs O O

Strong O O
inducers O O
of O O
cytochrome O O
P450 O O
enzymes O O
( O O
i.e O O
. O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
phenobarbital B-drug B-drug
) O O
have O O
been O O
shown O O
to O O
decrease O O
the O O
plasma O O
levels O O
of O O
MHD B-drug_n B-drug_n
( O O
29-40 O O
% O O
) O O
. O O

Tolbutamides B-drug B-group
conversion O O
to O O
inactive O O
metabolites O O
has O O
been O O
shown O O
to O O
be O O
catalyzed O O
by O O
xanthine O O
oxidase O O
from O O
rat O O
liver O O
. O O

For O O
example O O
, O O
since O O
cholestyramine B-drug B-drug
may O O
reduce O O
the O O
gastrointestinal O O
absorption O O
of O O
both O O
the O O
oral O O
anticoagulants B-group B-group
and O O
vitamin B-group B-group
K I-group I-group
, O O
the O O
net O O
effects O O
are O O
unpredictable O O
. O O

It O O
is O O
recommended O O
that O O
if O O
CASODEX B-brand B-brand
is O O
started O O
in O O
patients O O
already O O
receiving O O
coumarin B-group B-group
anticoagulants I-group I-group
, O O
prothrombin O O
times O O
should O O
be O O
closely O O
monitored O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
. O O

Anticonvulsants B-group B-group
( O O
Phenytoin B-drug B-drug
) O O
: O O
Steady O O
state O O
plasma O O
exposure O O
( O O
AUC O O
) O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
for O O
12 O O
days O O
) O O
was O O
decreased O O
by O O
27 O O
% O O
when O O
co-administered O O
with O O
multiple O O
doses O O
( O O
300 O O
mg O O
QD O O
for O O
12 O O
days O O
) O O
of O O
phenytoin B-drug B-drug
( O O
a O O
CYP O O
3A4 O O
inducer O O
) O O
. O O

Quinolones B-group B-group
, O O
including O O
norfloxacin B-drug B-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
oral O O
anticoagulants B-group B-group
, O O
including O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
or O O
similar O O
agents O O
. O O

Felbamate B-drug B-brand
treatment O O
resulted O O
in O O
a O O
42 O O
% O O
decrease O O
in O O
the O O
gestodene B-drug B-drug
AUC O O
0-24 O O
, O O
but O O
no O O
clinically O O
relevant O O
effect O O
was O O
observed O O
on O O
the O O
pharmacokinetic O O
parameters O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
As O O
with O O
cephalothin B-drug B-drug
, O O
high O O
concentrations O O
of O O
cefoxitin B-drug B-drug
( O O
100 O O
micrograms/mL O O
) O O
may O O
interfere O O
with O O
measurement O O
of O O
serum O O
and O O
urine O O
creatinine O O
levels O O
by O O
the O O
Jaff O O
reaction O O
, O O
and O O
produce O O
false O O
increases O O
of O O
modest O O
degree O O
in O O
the O O
levels O O
of O O
creatinine O O
reported O O
. O O

aureus O O
, O O
to O O
survive O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
may O O
explain O O
in O O
part O O
a O O
shift O O
from O O
S O B-drug
. O O

In O O
addition O O
to O O
the O O
interactions O O
noted O O
above O O
, O O
chronic O O
( O O
2 O O
weeks O O
) O O
oral O O
Cordarone B-drug B-drug
administration O O
impairs O O
metabolism O O
of O O
phenytoin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
and O O
methotrexate B-drug B-drug
. O O

. O O

A O O
review O O
is O O
presented O O
of O O
some O O
of O O
the O O
problems O O
that O O
may O O
arise O O
in O O
association O O
with O O
anaesthesia O O
for O O
epileptic O O
patients O O
. O O

Special O O
care O O
is O O
required O O
if O O
this O O
drug O O
is O O
given O O
to O O
patients O O
receiving O O
ganglion B-group B-group
blocking I-group I-group
compounds I-group I-group
because O O
a O O
critical O O
fall O O
in O O
blood O O
pressure O O
may O O
occur O O
. O O

Tetracyclines B-group B-group
: O O
Concomitant O O
treatment O O
with O O
Accutane B-brand B-brand
and O O
tetracyclines B-group B-group
should O O
be O O
avoided O O
because O O
Accutane B-brand B-brand
use O O
has O O
been O O
associated O O
with O O
a O O
number O O
of O O
cases O O
of O O
pseudotumor O O
cerebri O O
( O O
benign O O
intracranial O O
hypertension O O
) O O
, O O
some O O
of O O
which O O
involved O O
concomitant O O
use O O
of O O
tetracyclines B-group B-group

No O O
drug O O
interaction O O
data O O
are O O
available O O
on O O
concomitant O O
administration O O
of O O
Panretin B-brand B-brand
gel O O
and O O
systemic O B-group
anti-KS O I-group
agents O I-group
. O O

A O O
drug-drug O O
interaction O O
study O O
with O O
rifampin B-drug B-drug
in O O
healthy O O
volunteers O O
has O O
shown O O
a O O
30 O O
% O O
decrease O O
in O O
caspofungin B-drug B-drug
trough O O
concentrations O O
. O O

To O O
find O O
out O O
whether O O
this O O
observation O O
is O O
related O O
to O O
the O O
increased O O
regional O O
perfusion O O
in O O
diabetes O O
longitudinal O O
studies O O
on O O
patients O O
with O O
Type O O
I O O
( O O
insulin-dependent O O
) O O
diabetes O O
mellitus O O
are O O
needed O O
. O O

Carbamazepine B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
14 O O
days O O
) O O
and O O
carbamazepine B-drug B-drug
( O O
titrated O O
to O O
400 O O
mg/day O O
for O O
35 O O
days O O
) O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
carbamazepine B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
. O O

Levetiracetam B-drug B-drug
circulates O O
largely O O
unbound O O
( O O
10 O O
% O O
bound O O
) O O
to O O
plasma O O
proteins O O
; O O

Therefore O O
, O O
when O O
INSPRA B-brand B-brand
and O O
NSAIDs B-group B-group
are O O
used O O
concomitantly O O
, O O
patients O O
should O O
be O O
observed O O
to O O
determine O O
whether O O
the O O
desired O O
effect O O
on O O
blood O O
pressure O O
is O O
obtained O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
treating O O
patients O O
with O O
either O O
of O O
these O O
drugs O O
or O O
other O O
highly O O
protein-bound O O
drugs O O
and O O
Atromid-S B-brand B-brand
. O O

The O O
clinical O O
relevance O O
of O O
this O O
finding O O
is O O
unclear O O
. O O

Carbamazepine B-drug B-drug
: O O
Carbamazepine B-drug B-drug
causes O O
an O O
approximate O O
50 O O
% O O
increase O O
in O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
at O O
steady O O
state O O
and O O
, O O
therefore O O
, O O
the O O
addition O O
of O O
carbamazepine B-drug B-drug
results O O
in O O
an O O
approximate O O
40 O O
% O O
decrease O O
in O O
the O O
steady-state O O
trough O O
concentrations O O
of O O
Felbatol B-brand B-brand
as O O
compared O O
to O O
the O O
same O O
dose O O
of O O
Felbatol B-brand B-brand
given O O
as O O
monotherapy O O
. O O

Saquinavir B-drug B-drug

Less O O
than O O
the O O
usual O O
amounts O O
of O O
these O O
medicines O O
should O O
be O O
used O O
. O O

In O O
clinical O O
studies O O
, O O
Tilade B-brand B-brand
has O O
been O O
co-administered O O
with O O
other O O
anti-asthma O B-group
medications O I-group
, O O
including O O
inhaled O O
and O O
oral O O
bronchodilators B-group B-group
, O O
and O O
inhaled O O
corticosteroids B-group B-group
, O O
with O O
no O O
evidence O O
of O O
increased O O
frequency O O
of O O
adverse O O
events O O
or O O
laboratory O O
abnormalities O O
. O O

- O O
Methyldopa B-drug B-drug
( O O
e.g. O O
, O O
Aldomet B-brand B-brand
) O O
Use O O
of O O
methyldopa B-drug B-drug
with O O
sulfapyridine B-drug B-drug
may O O
increase O O
the O O
chance O O
of O O
side O O
effects O O
affecting O O
the O O
liver O O
and/or O O
the O O
blood O O

Consideration O O
should O O
be O O
taken O O
in O O
patients O O
being O O
treated O O
with O O
antidiabetic B-drug B-group
agents O I-group
. O O

However O O
, O O
the O O
pharmacodynamic O O
effect O O
increased O O
by O O
197 O O
% O O
( O O
QTc O O
increase O O
over O O
time O O
) O O
and O O
by O O
95 O O
% O O
( O O
maximum O O
QTc O O
increase O O
) O O
. O O

No O O
drug/drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Insulin B-drug B-drug
or O O
Oral O O
Hypoglycemics B-group B-group
: O O
Initiating O O
thyroid O B-group
replacement O O
therapy O O
may O O
cause O O
increases O O
in O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
requirements O O
. O O

Although O O
the O O
occurrence O O
has O O
not O O
been O O
reported O O
with O O
Cefizox B-brand B-brand
, O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
other O O
cephalosporins B-group B-group
and O O
aminoglycosides B-group B-group
. O O

Serotonin O O
release O O
by O O
platelets O O
plays O O
an O O
important O O
role O O
in O O
hemostasis O O
. O O

. O O

Sumatriptan B-drug B-drug
- O O
There O O
have O O
been O O
rare O O
postmarketing O O
reports O O
describing O O
patients O O
with O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
following O O
the O O
use O O
of O O
a O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitor I-group I-group
( O O
SSRI B-group B-group
) O O
and O O
sumatriptan B-drug B-drug
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Fluoxetine B-drug B-drug
and O O
moclobemide B-drug B-drug
increased O O
blood O O
glucose B-drug O
at O O
different O O
times O O
after O O
the O O
glucose O O
overload O O
. O O

Cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
and O O
digoxin B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
at O O
the O O
initiation O O
of O O
Itraconazole B-drug B-drug
therapy O O
and O O
frequently O O
thereafter O O
, O O
and O O
the O O
dose O O
of O O
these O O
three O O
drug O O
products O O
adjusted O O
appropriately O O
. O O

Probenecid B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
TORADOL B-brand B-brand
ORAL O O
and O O
probenecid B-drug B-drug
resulted O O
in O O
decreased O O
clearance O O
of O O
ketorolac B-drug B-drug
and O O
significant O O
increases O O
in O O
ketorolac B-drug B-drug
plasma O O
levels O O
( O O
total O O
AUC O O
increased O O
approximately O O
threefold O O
from O O
5.4 O O
to O O
17.8 O O
m O O
g/h/mL O O
) O O
and O O
terminal O O
half-life O O
increased O O
approximately O O
twofold O O
from O O
6.6 O O
to O O
15.1 O O
hours O O
. O O

Therefore O O
, O O
it O O
is O O
advisable O O
to O O
be O O
particularly O O
cautious O O
in O O
patients O O
whose O O
plasma O O
digoxin B-drug B-drug
levels O O
are O O
above O O
or O O
suspected O O
to O O
be O O
above O O
the O O
usual O O
therapeutic O O
range O O
. O O

Pediatric O O
Use O O

Thus O O
, O O
the O O
interaction O O
observed O O
between O O
erythromycin B-drug B-drug
and O O
terfenadine B-drug B-drug
is O O
not O O
expected O O
for O O
dirithromycin B-drug B-drug
. O O

The O O
reported O O
dose O O
used O O
for O O
L-glutamine B-drug B-drug
was O O
21 O O
grams O O
daily O O
taken O O
in O O
divided O O
doses O O
three O O
times O O
a O O
day O O
. O O

Due O O
to O O
its O O
potential O O
to O O
cause O O
neutropenia O O
and O O
lymphopenia O O
, O O
proper O O
monitoring O O
of O O
patients O O
is O O
required O O
if O O
Rebif B-brand B-brand
is O O
given O O
in O O
combination O O
with O O
myelosuppressive O O
agents O O
. O O

Since O O
blood O O
level O O
of O O
calcitriol/ergocalcitriol B-drug B-drug
will O O
be O O
reduced O O
, O O
higher O O
doses O O
of O O
Rocaltrol B-brand B-brand
may O O
be O O
necessary O O
if O O
these O O
drugs O O
are O O
administered O O
simultaneously O O
. O O

Most O O
of O O
the O O
above O O
effects O O
concerning O O
diuretics B-group B-group
have O O
been O O
attributed O O
, O O
at O O
least O O
in O O
part O O
, O O
to O O
mechanisms O O
involving O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
by O O
INDOCIN B-brand B-brand
. O O

Warfarin B-drug B-drug
- O O
Administration O O
of O O
40 O O
mg/day O O
racemic O O
citalopram B-drug B-drug
for O O
21 O O
days O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
warfarin B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
. O O

Concomitant O O
use O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
with O O
other O O
ergot B-group B-group
alkaloids I-group I-group
is O O
not O O
recommended O O
. O O

Antifungals B-group B-group
: O O
Itraconazole B-drug B-drug
Ketoconazole I-drug I-drug

Blood O O
samples O O
were O O
drawn O O
at O O
0 O O
, O O
0.5 O O
, O O
1 O O
, O O
1.5 O O
, O O
2 O O
, O O
3 O O
, O O
4 O O
, O O
6 O O
, O O
8 O O
, O O
12 O O
, O O
18 O O
, O O
and O O
24 O O
hours O O
for O O
Cmax O O
, O O
tmax O O
, O O
and O O
AUC O O
determinations O O
. O O

In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic B-group B-group
, I-group O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

These O O
facts O O
should O O
be O O
considered O O
when O O
evaluating O O
plasma O O
renin O O
activity O O
in O O
hypertensive O O
patients O O
. O O

Onset O O
of O O
the O O
interaction O O
began O O
within O O
five O O
days O O
of O O
beginning O O
concurrent O O
therapy O O
. O O

Antacids B-group B-group
: O O
Enteric O O
Coated O O
Aspirin B-brand B-brand
should O O
not O O
be O O
given O O
concurrently O O
with O O
antacids B-group B-group
, O O
since O O
an O O
increase O O
in O O
the O O
pH O O
of O O
the O O
stomach O O
may O O
effect O O
the O O
enteric O O
coating O O
of O O
the O O
tablets O O
. O O

Naproxen B-drug B-drug
had O O
no O O
effect O O
on O O
plasma O O
levels O O
of O O
diflunisal B-drug B-drug
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
coadministered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

To O O
study O O
the O O
pancreatic O O
effects O O
of O O
other O O
agents O O
, O O
dynamic O O
insulin O B-drug
and O O
glucagon O O
release O O
was O O
measured O O
from O O
the O O
in O O
vitro O O
perfused O O
pancreases O O
of O O
normal O O
and O O
diabetic O O
Chinese O O
hamsters O O
in O O
response O O
to O O
various O O
combinations O O
of O O
arginine B-drug B-drug
( O O
20mM O O
) O O
, O O
glucose B-drug B-drug
( O O
100 O O
or O O
150 O O
mg. O O
per O O
100 O O
ml O O
. O O
) O O
, O O
and O O
theophylline B-drug B-drug
( O O
10 O O
mM O O
) O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
Studies O O
in O O
animals O O
demonstrate O O
that O O
the O O
acute O O
toxicity O O
of O O
bupropion B-drug B-drug
is O O
enhanced O O
by O O
the O O
MAO B-group B-group
inhibitor I-group I-group
phenelzine B-drug B-drug
. O O

Ethopropazine B-drug B-drug
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
causing O O
increased O O
sedative O O
effects O O
. O O

The O O
blood O O
pressure O O
effect O O
of O O
SULAR B-brand B-brand
tended O O
to O O
be O O
greater O O
in O O
patients O O
on O O
atenolol B-drug B-drug
than O O
in O O
patients O O
on O O
no O O
other O O
antihypertensive B-group B-group
therapy O O
. O O

Digoxin B-drug B-drug
: O O
In O O
controlled O O
studies O O
in O O
healthy O O
volunteers O O
, O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
either O O
had O O
no O O
effect O O
( O O
one O O
study O O
) O O
or O O
was O O
associated O O
with O O
modest O O
increases O O
, O O
about O O
30 O O
% O O
( O O
two O O
studies O O
) O O
in O O
steady-state O O
serum O O
digoxin B-drug B-drug
concentrations O O
. O O

Four O O
educational O O
messages O O
advise O O
on O O
over O O
60 O O
% O O
of O O
the O O
PICR O O
detected O O
. O O

Racemic O O
citalopram B-drug B-drug
did O O
not O O
alter O O
the O O
mean O O
AUC O O
or O O
Cmax O O
of O O
pimozide B-drug B-drug
. O O

Antigout B-group B-group
medications I-group I-group

Because O O
warfarin B-drug B-drug
is O O
metabolized O O
by O O
CYP2C9 O B-drug
and O O
CYP3A4 O O
, O O
patients O O
who O O
require O O
anticoagulation O O
should O O
receive O O
low-molecular O O
weight O O
or O O
standard O O
heparin B-drug B-drug
. O O

Lupus-like O O
syndrome O O

Other O O
binding O O
proteins O O
may O O
be O O
elevated O O
in O O
serum O O
, O O
i.e. O O
, O O
corticosteroid O O
binding O O
globulin O O
( O O
CBG O O
) O O
, O O
sex O O
hormone-binding O O
globulin O O
( O O
SHBG O O
) O O
, O O
leading O O
to O O
increased O O
total O O
circulating O O
corticosteroids B-group B-group
and O O
sex B-group B-group
steroids I-group I-group
, O O
respectively O O
. O O

Toxicity O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
to O O
encystment O O
and O O
in O O
vitro O O
excystment O O
of O O
Parorchis O O
acanthus O O
( O O
Digenea O O
: O O
Philophthalmidae O O
) O O
. O O

Although O O
clinical O O
evidence O O
to O O
date O O
has O O
not O O
demonstrated O O
renal O O
precipitation O O
of O O
oxypurines O B-drug
in O O
patients O O
either O O
on O O
allopurinol B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
uricosuric B-group O
agents I-group O
, O O
the O O
possibility O O
should O O
be O O
kept O O
in O O
mind O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
may O O
intensify O O
electrolyte O O
imbalance O O
, O O
particularly O O
hypokalemia O O
. O O
) O O

Diphenoxylate B-drug B-drug
HCl I-drug I-drug
and O O
atropine B-drug B-drug
sulfate I-drug I-drug
may O O
interact O O
with O O
MAO B-group B-group
inhibitors I-group I-group
In O O
studies O O
with O O
male O O
rats O O
, O O
diphenoxylate B-drug B-drug
hydrochloride I-drug I-drug
was O O
found O O
to O O
inhibit O O
the O O
hepatic O O
microsomal O O
enzyme O O
system O O
at O O
a O O
dose O O
of O O
2 O O
mg/kg/day O O
. O O

The O O
following O O
similar O O
changes O O
may O O
be O O
expected O O
with O O
larger O O
doses O O
of O O
estrogen B-group B-group
: O O
- O O
Increased O O
sulfobromophthalein O O
retention O O

Corticosteroids B-group B-group
, O O
ACTH B-drug B-drug
: O O
intensified O O
electrolyte O O
depletion O O
, O O
particularly O O
hypokalemia O O
. O O

Flucytosine B-drug B-drug
: O O
while O O
a O O
synergistic O O
relationship O O
with O O
amphotericin B-drug B-drug
B I-drug I-drug
has O O
been O O
reported O O
, O O
concomitant O O
use O O
may O O
increase O O
the O O
toxicity O O
of O O
flucytosine B-drug B-drug
by O O
possibly O O
increasing O O
its O O
cellular O O
uptake O O
and/or O O
impairing O O
its O O
renal O O
excretion O O
. O O

reduced O O
response O O
to O O
metyrapone O O
test O O
; O O

Quinidine B-drug B-drug
, O O
verapamil B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
propafenone B-drug B-drug
, O O
indomethacin B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
and O O
spironolactone B-drug B-drug
raise O O
the O O
serum O O
digoxin B-drug B-drug
concentration O O
due O O
to O O
a O O
reduction O O
in O O
clearance O O
and/or O O
in O O
volume O O
of O O
distribution O O
of O O
the O O
drug O O
, O O
with O O
the O O
implication O O
that O O
digitalis B-group B-group
intoxication O O
may O O
result O O
. O O

Aminoglutethimide B-drug B-drug
: O O
May O O
increase O O
CYP O O
metabolism O O
of O O
progestins B-group B-group
leading O O
to O O
possible O O
decrease O O
in O O
contraceptive O O
effectiveness O O
. O O

There O O
are O O
case O O
reports O O
of O O
patients O O
who O O
developed O O
increased O O
BUN O O
, O O
serum O O
creatinine O O
and O O
serum O O
potassium O O
levels O O
, O O
and O O
weight O O
gain O O
when O O
furosemide B-drug B-drug
was O O
used O O
in O O
conjunction O O
with O O
NSAIDs B-group B-group
. O O

A O O
drug O O
interaction O O
study O O
was O O
performed O O
in O O
which O O
ERBITUX B-brand B-brand
was O O
administered O O
in O O
combination O O
with O O
irinotecan B-drug B-drug
. O O

Clinically O O
significant O O
effects O O
have O O
been O O
reported O O
with O O
the O O
warfarin B-group B-group
anticoagulants I-group I-group
; O O

Phenobarbital B-drug B-drug
or O O
Primidone B-drug B-drug
: O O
No O O
formal O O
pharmacokinetic O O
studies O O
have O O
been O O
performed O O
examining O O
the O O
addition O O
of O O
tiagabine B-drug B-drug
to O O
regimens O O
containing O O
phenobarbital B-drug B-drug
or O O
primidone B-drug B-drug
. O O

. O O

Interconversion O O
between O O
caffeine B-drug B-drug
and O O
theophylline B-drug B-drug
has O O
been O O
reported O O
in O O
preterm O O
neonates O O
. O O

therefore O O
, O O
the O O
use O O
of O O
dofetilide B-drug B-drug
does O O
not O O
necessitate O O
an O O
adjustment O O
in O O
digoxin B-drug B-drug
dose O O
to O O
maintain O O
therapeutic O O
digoxin O B-drug
levels O O
. O O

Spermine B-drug B-drug
promotes O O
the O O
translocation O O
of O O
phosphatidate O O
phosphohydrolase O O
from O O
the O O
cytosol O O
to O O
the O O
microsomal O O
fraction O O
of O O
rat O O
liver O O
and O O
it O O
enhances O O
the O O
effects O O
of O O
oleate O O
in O O
this O O
respect O O
. O O

The O O
steady O O
state O O
plasma O O
concentrations O O
of O O
imipramine B-drug B-drug
and O O
desipramine B-drug B-drug
have O O
been O O
reported O O
to O O
be O O
increased O O
an O O
average O O
of O O
31 O O
% O O
and O O
20 O O
% O O
, O O
respectively O O
, O O
by O O
the O O
concomitant O O
administration O O
of O O
alprazolam B-drug B-drug
tablets O O
in O O
doses O O
up O O
to O O
4 O O
mg/day O O
. O O

There O O
is O O
insufficient O O
experience O O
to O O
assess O O
the O O
safety O O
and O O
efficacy O O
of O O
ORENCIA B-brand B-brand
administered O O
concurrently O O
with O O
anakinra B-drug B-drug
, O O
and O O
therefore O O
such O O
use O O
is O O
not O O
recommended O O
. O O

however O O
, O O
it O O
adversely O O
affected O O
response O O
duration O O
suggesting O O
that O O
pyridoxine B-drug B-drug
should O O
not O O
be O O
administered O O
with O O
HEXALEN B-brand B-brand
and/or O O
cisplatin.1 B-drug B-drug

Nursing O O
Mothers O O
It O O
is O O
not O O
known O O
whether O O
peginterferon B-drug B-drug
or O O
ribavirin B-drug B-drug
or O O
its O O
components O O
are O O
excreted O O
in O O
human O O
milk O O
. O O

Antiretroviral B-group B-drug
plasma O O
and O O
urine O O
sampling O O
were O O
conducted O O
on O O
Days O O
1 O O
, O O
7 O O
, O O
and O O
21 O O
for O O
zidovudine B-drug B-drug
and O O
on O O
Days O O
7 O O
and O O
21 O O
for O O
dideoxyinosine B-drug B-drug
. O O

. O O

In O O
order O O
to O O
provide O O
information O O
for O O
the O O
appropriate O O
package O O
insert O O
labeling O O
of O O
progestin-only B-group B-group
oral I-group O
contraceptives I-group B-group
( O O
POC B-group B-group
) O O
in O O
the O O
US O O
, O O
a O O
comprehensive O O
review O O
was O O
made O O
of O O
norgestrel B-drug B-drug
( O O
0.075 O O
mg O O
) O O
and O O
norethindrone B-drug B-drug
( O O
0.35 O O
mg O O
) O O
, O O
with O O
the O O
clinical O O
differences O O
indicated O O
where O O
applicable O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
ELLENCE B-brand B-brand
and O O
laboratory O O
tests O O
. O O

None O O
known O O
. O O

Valproate B-drug B-drug
: O O
The O O
addition O O
of O O
tiagabine B-drug B-drug
to O O
patients O O
taking O O
valproate B-drug B-drug
chronically O O
had O O
no O O
effect O O
on O O
tiagabine B-drug B-drug
pharmacokinetics O O
, O O
but O O
valproate B-drug B-drug
significantly O O
decreased O O
tiagabine B-drug B-drug
binding O O
in O O
vitro O O
from O O
96.3 O O
to O O
94.8 O O
% O O
, O O
which O O
resulted O O
in O O
an O O
increase O O
of O O
approximately O O
40 O O
% O O
in O O
the O O
free O O
tiagabine O B-drug
concentration O O
. O O

The O O
successive O O
application O O
of O O
glycine B-drug B-drug
( O O
5 O O
or O O
10 O O
mg/kg O O
egg O O
weight O O
( O O
e.w O O
. O O
) O O
and O O
glutamate B-drug B-drug
( O O
15 O O
mg/kg O O
e.w O O
. O O
) O O
in O O
a O O
10 O O
min O O
interval O O
significantly O O
increased O O
the O O
activation O O
of O O
spontaneous O O
motility O O
of O O
17-day-old O O
chick O O
embryos O O
in O O
comparison O O
with O O
the O O
effect O O
of O O
glutamate B-drug B-drug
alone O O
. O O

Propranolol B-drug B-drug
: O O
May O O
decrease O O
aspirins B-brand B-group
anti-inflammatory O I-group
action O O
by O O
competing O O
for O O
the O O
same O O
receptors O O
. O O

with O O
sucralfate B-drug B-drug
; O O

Some O O
quinolones B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
have O O
been O O
associated O O
with O O
transient O O
elevations O O
in O O
serum O O
creatinine O O
in O O
patients O O
receiving O O
cyclosporine B-drug B-drug
concomitantly O O
. O O

twice O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
and O O
non-ossification O O
of O O
the O O
odontoid O O
and O O
ventral O O
tubercle O O
of O O
the O O
first O O
cervical O O
vertebra O O
at O O
doses O O
0.1 O O
mg/kg/day O O
IM O O
( O O
approximately O O
one-tenth O O
of O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
when O O
administered O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

Thus O O
there O O
was O O
a O O
tendency O O
toward O O
a O O
more O O
pronounced O O
inhibition O O
of O O
the O O
4-hydroxylation O O
during O O
treatment O O
with O O
150 O O
mg/d O O
of O O
fluvoxamine B-drug B-drug
compared O O
with O O
75 O O
mg/d O O
, O O
but O O
the O O
difference O O
was O O
not O O
statistically O O
significant O O
. O O

Amiodarone B-drug B-drug
is O O
also O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Concomitant O O
administration O O
of O O
Mefloquine B-drug B-drug
and O O
other O O
related O O
compounds O O
( O O
eg O O
, O O
quinine B-drug B-drug
, O O
quinidine B-drug B-drug
and O O
chloroquine B-drug B-drug
) O O
may O O
produce O O
electrocardiographic O O
abnormalities O O
and O O
increase O O
the O O
risk O O
of O O
convulsions O O
. O O

Clinical O O
studies O O
of O O
the O O
effect O O
of O O
strong O O
CYP O O
3A4 O O
inhibitors O O
on O O
the O O
pharmacokinetics O O
of O O
fulvestrant B-drug B-drug
have O O
not O O
been O O
performed O O
. O O

The O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
has O O
been O O
reported O O
to O O
be O O
inhibited O O
by O O
some O O
drugs O O
of O O
this O O
class O O
. O O

Interference O O
of O O
biocytin O O
with O O
opioid-evoked B-group B-drug_n
hyperpolarization O O
and O O
membrane O O
properties O O
of O O
rat O O
spinal O O
substantia O O
gelatinosa O O
neurons O O
. O O

tricyclic B-group B-group
antidepressants I-group I-group
. O O

Coadministration O O
of O O
digoxin B-drug B-drug
did O O
not O O
have O O
effects O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

In O O
an O O
effort O O
to O O
screen O O
compounds O O
for O O
antipsychotic O O
activity O O
, O O
preclinical O O
researchers O O
have O O
investigated O O
whether O O
these O O
compounds O O
block O O
PCP-induced B-drug_n B-drug_n
behaviors O O
in O O
animals O O
. O O

Other O O
compounds O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
may O O
have O O
decreased O O
plasma O O
concentrations O O
when O O
coadministered O O
with O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
. O O

Only O O
at O O
the O O
highest O O
concentration O O
tested O O
( O O
171 O O

No O O
carcinogenicity O O
or O O
fertility O O
studies O O
were O O
conducted O O
. O O

Estazolam B-drug B-drug
: O O
Interaction O O
with O O
Drugs O O
that O O
Inhibit O O
Metabolism O O
via O O
Cytochrome O O
P450 O O
3A O O
( O O
CYP3A O O
) O O
: O O
The O O
metabolism O O
of O O
estazolam B-drug B-drug
to O O
the O O
major O O
circulating O O
metabolite O O
4-hydroxy-estazolam B-drug_n B-drug_n
and O O
the O O
metabolism O O
of O O
other O O
triazolobenzodiazepines B-group B-group
is O O
catalyzed O O
by O O
CYP3A O O
. O O

A O O
daily O O
dose O O
of O O
2 O O
mg O O
of O O
coumaphos/kg B-drug_n B-drug_n
of O O
body O O
weight O O
for O O
6 O O
days O O
did O O
not O O
affect O O
the O O
plasma O O
enzymes O O
or O O
the O O
antiprothrombinemic O O
effect O O
of O O
bishydroxy-coumarin B-drug B-drug
in O O
wethers O O
. O O

The O O
incidence O O
of O O
cardiovascular O O
morbidity O O
and O O
mortality O O
is O O
not O O
higher O O
among O O
users O O
of O O
sildenafil B-drug B-drug
. O O

- O O
Primaquine B-drug B-drug
or O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side O O
effects O O
in O O
patients O O
on O O
concomitant O O
therapy O O
with O O
norfloxacin B-drug B-drug
and O O
theophylline B-drug B-drug
. O O

Since O O
entecavir B-drug B-drug
is O O
primarily O O
eliminated O O
by O O
the O O
kidneys O O
, O O
coadministration O O
of O O
BARACLUDE B-brand B-brand
with O O
drugs O O
that O O
reduce O O
renal O O
function O O
or O O
compete O O
for O O
active O O
tubular O O
secretion O O
may O O
increase O O
serum O O
concentrations O O
of O O
either O O
entecavir B-drug B-drug
or O O
the O O
coadministered O O
drug O O
. O O

Naproxen B-drug B-drug
: O O
Coadministration O O
( O O
N=18 O O
) O O
of O O
naproxen B-drug B-drug
sodium I-drug I-drug
capsules O O
( O O
250 O O
mg O O
) O O
with O O
Neurontin B-brand B-brand
( O O
125 O O
mg O O
) O O
appears O O
to O O
increase O O
the O O
amount O O
of O O
gabapentin B-drug B-drug
absorbed O O
by O O
12 O O
% O O
to O O
15 O O
% O O
. O O

Therefore O O
, O O
COLESTlD B-brand B-brand
Tablets O O
may O O
delay O O
or O O
reduce O O
the O O
absorption O O
of O O
concomitant O O
oral O O
medication O O
. O O

PEGANONE B-brand B-brand
used O O
in O O
combination O O
with O O
other O O
drugs O O
known O O
to O O
adversely O O
affect O O
the O O
hematopoietic O O
system O O
should O O
be O O
avoided O O
if O O
possible O O
. O O

Drug O O
Interactions O O
with O O
Antacids B-group B-group
Administration O O
of O O
120 O O
mg O O
of O O
fexofenadine B-drug B-drug
hydrochloride I-drug I-drug
( O O
2 O O
x O O
60 O O
mg O O
capsule O O
) O O
within O O
15 O O
minutes O O
of O O
an O O
aluminum B-drug B-drug
and O O
magnesium B-drug B-drug
containing O O
antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
decreased O O
fexofenadine B-drug B-drug
AUC O O
by O O
41 O O
% O O
and O O
cmax O O
by O O
43 O O
% O O
. O O

Somatrem/Somatropin B-drug B-drug
: O O
Excessive O O
concurrent O O
use O O
of O O
thyroid B-group B-group
hormone I-group I-group
may O O
accelerate O O
epiphyseal O O
closure O O
. O O

Drugs O O
whose O O
absorption O O
is O O
sensitive O O
to O O
pH O O
may O O
be O O
negatively O O
impacted O O
by O O
concomitant O O
administration O O
of O O
omeprazole B-drug B-drug
and O O
valdecoxib B-drug B-drug
. O O

No O O
information O O
available O O
. O O

Arginine B-drug B-drug
, O O
in O O
the O O
absence O O
of O O
glucose B-drug B-drug
or O O
theophylline B-drug B-drug
, O O
caused O O
excessive O O
glucagon O O
release O O
in O O
the O O
diabetics O O
and O O
undetectable O O
insulin O O
release O O
in O O
either O O
diabetics O O
or O O
normals O O
. O O

These O O
agents O O
should O O
not O O
be O O
taken O O
for O O
8 O O
hours O O
before O O
or O O
for O O
2 O O
hours O O
after O O
enoxacin B-drug B-drug
administration O O
. O O

During O O
amiodarone B-drug B-drug
administration O O
, O O
systemic O O
clearance O O
of O O
digoxin B-drug B-drug
was O O
reduced O O
from O O
234 O O
+/- O O
72 O O
ml/min O O
( O O
mean O O
+/- O O
standard O O
deviation O O
) O O
to O O
172 O O
+/- O O
33 O O
ml/min O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

Drug O O
interactions O O
: O O
How O O
to O O
identify O O
them O O
. O O

. O O

injection O O
of O O
vehicle O O
( O O
corn O O
oil O B-drug
, O O
0.1 O O
mL/day O O
) O O
, O O
estradiol B-drug B-drug
( O O
10 O O
microg/kg/day O O
or O O
4 O O
mg/kg/day O O
) O O
and/or O O
progesterone B-drug B-drug
( O O
20 O O
mg/kg/day O O
) O O
, O O
for O O
eight O O
days O O
. O O

This O O
may O O
indicate O O
that O O
they O O
could O O
enhance O O
the O O
toxicity O O
of O O
methotrexate B-drug B-drug
. O O

Inhibitors O O
of O O
CYP3A4 O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
) O O
or O O
CYP2D6 O B-drug
( O O
eg O O
, O O
quinidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
or O O
paroxetine B-drug B-drug
) O O
can O O
inhibit O O
aripiprazole B-drug B-drug
elimination O O
and O O
cause O O
increased O O
blood O O
levels O O
. O O

The O O
mechanism O O
underlying O O
many O O
of O O
these O O
events O O
is O O
unknown O O
, O O
but O O
may O O
represent O O
increased O O
hypotension O O
. O O

It O O
is O O
therefore O O
necessary O O
to O O
be O O
well O O
acquainted O O
with O O
the O O
clinical O O
and O O
paraclinical O O
pattern O O
of O O
magnesium B-drug B-drug
deficit O O
and O O
to O O
discriminate O O
between O O
magnesium B-drug B-drug
deficiency O O
due O O
to O O
an O O
insufficient O O
magnesium B-drug B-drug
intake O O
which O O
only O O
requires O O
oral O O
physiological O O
supplementation O O
and O O
magnesium B-drug B-drug
depletion O O
related O O
to O O
a O O
dysregulation O O
of O O
the O O
control O O
mechanisms O O
of O O
magnesium B-drug B-drug
status O O
which O O
requires O O
more O O
or O O
less O O
specific O O
regulation O O
of O O
its O O
causal O O
dysregulation O O
. O O

Therefore O O
, O O
the O O
concomitant O O
administration O O
of O O
TRACLEER B-brand B-brand
and O O
glyburide B-drug B-drug
is O O
contraindicated O O
, O O
and O O
alternative O O
hypoglycemic B-group B-group
agents I-group I-group
should O O
be O O
considered O O
. O O

